Document:

EX-10.3

 Exhibit 10.3 

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 

AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 9, 2018, by and among Endologix, Inc., a Delaware
corporation (the “Company”), and Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P. (each individually, a “Lender” and together, the “Lenders”). 

WHEREAS: 
 A. In connection with the Facility Agreement,
dated as of April 3, 2017, by and among the Company, the Lenders, Deerfield International Master Fund, L.P. (the “Prior Lender”), the other Loan Parties (as defined therein) and Deerfield Private Design Fund IV, L.P., as agent for
itself and the other Lenders (as the same has heretofore been amended, modified, restated or otherwise supplemented, the “Existing Facility Agreement”), (i) the Company issued the Initial Warrants (as defined in the Amended Facility
Agreement (as defined below)) to the Lenders in the amounts described in the Existing Facility Agreement, each of which Initial Warrants is exercisable into shares of the Company’s common stock, $0.001 par value per share (the “Common
Stock”); and 
 B. In connection with the Facility Agreement, the Company, the Lenders and the Prior Lender executed and delivered that certain
Registration Rights Agreement, dated as of April 3, 2017 (the “Existing Registration Rights Agreement”). 
 C. Pursuant to the Existing
Registration Rights Agreement, the Company filed with the United States Securities and Exchange Commission (“SEC”) a Registration Statement (File No. 333-217602) on Form S-3, which registered the resale of an aggregate of 6,470,000 Common Shares issuable upon exercise of the Initial Warrants and was declared effective by the SEC as of May 22, 2017 (the “Existing
Registration Statement”). On May 22, 2017, pursuant to Rule 424(b)(3) under the Securities Act (as defined below), the Company filed a final prospectus as part of the Existing Registration Statement (the “Initial Prospectus”).
For the avoidance of doubt, the Existing Registration Statements and the Initial Prospectus constitute a Registration Statement and Prospectus (each as defined in this Agreement), respectively, under this Agreement. 

D. Effective as of January 1, 2018, the Prior Lender transferred and assigned its Initial Warrants and its rights under the Existing Registration Rights
Agreement to Deerfield Partners, L.P. (the “Warrant Transfer”). 
 F. Contemporaneously with the execution of this Agreement, the Company, the
Lenders, the other Loan Parties (as defined therein) and Deerfield Private Design Fund IV, L.P., as agent for itself and the other Lenders, are entering into an Amended and Restated Facility Agreement, dated as of the date hereof (as the same may
hereafter be amended, modified, restated or otherwise supplemented from time to time, the “Amended Facility Agreement”), which amends and restates the Existing Facility Agreement in its entirety. All capitalized terms used and not
otherwise defined herein shall have the respective meanings set forth in the Amended Facility Agreement. 
 G. The Amended Facility Agreement, among other
things, provides for the issuance of the Additional Warrants (as defined in the Amended Facility Agreement). 
 H. The parties hereto desire to amend and
restate the Existing Registration Rights Agreement to provide for certain changes relating to the issuance of the Additional Warrants. 

 I. To induce the Lenders to execute and deliver the Amended Facility Agreement, the Company has agreed to
provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the “Securities Act”), and applicable state securities laws. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company and each of the Lenders hereby agree as follows: 
 1. DEFINITIONS. 

a. As used in this Agreement, the following terms shall have the following meanings: 

(i) “Additional Filing Deadline” means, with respect to any Registration Statements that may be required pursuant to Section 2(a)(ii), (A) the
first date or time that such Registrable Securities may then be included in a Registration Statement if such Registration Statement is required because the SEC shall have notified the Company in writing that certain Registrable Securities were not
eligible for inclusion on a previously filed Registration Statement, or (B) if such additional Registration Statement is required for a reason other than as described in (A) above, the twentieth (20th) day following the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is required. 

(ii) “Additional Registration Deadline” means, with respect to any additional Registration Statement(s) required pursuant to Section 2(a)(ii),
the thirtieth (30th) day following (A) the first date or time that such Registrable Securities may then be included in a Registration Statement if such Registration Statement is required
because the SEC shall have notified the Company in writing that certain Registrable Securities were not eligible for inclusion on a previously filed Registration Statement, or (B) if such additional Registration Statement is required for a
reason other than as described in (A) above, the fortieth (40th) day following the date on which the Company first knows, or reasonably should have known, that such additional Registration
Statement(s) is required. 
 (iii) “Investor” means any Lender and any transferee or assignee who agrees to become bound by the provisions of this
Agreement in accordance with Section 10 hereof. 
 (iv) “Exchange Act” means the Securities Exchange Act of 1934, as amended, together with
the rules and regulations promulgated thereunder, and any successor statute. 
 (v) “FINRA” means the Financial Industry Regulatory Authority (or
successor thereto). 
 (vi) “Filing Deadline,” for the Registration Statement required pursuant to Section 2(a)(i), shall mean
September 6, 2018, and for each Registration Statement required pursuant to Section 2(a)(ii) shall mean the Additional Filing Deadline. 
 (vii)
“Person” means and includes any natural person, partnership, joint venture, corporation, trust, limited liability company, limited company, joint stock company, unincorporated organization, government entity or any political subdivision or
agency thereof, or any other entity. 
 (viii) “Prospectus” means (i) any prospectus (preliminary or final) included in any Registration
Statement (including the Initial Prospectus), as may be amended or supplemented by any prospectus supplement with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all
other amendments and supplements to such prospectus, including post-

  
 2 

 
effective amendments, and all material incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the Securities Act relating
to any offering of Registrable Securities pursuant to a Registration Statement. 
 (ix) “Register,” “Registered,” and
“Registration” refer to a registration effected by preparing and filing a Registration Statement or Statements in compliance with the Securities Act and pursuant to Rule 415, and the declaration or ordering of effectiveness of such
Registration Statement by the United States Securities and Exchange Commission (the “SEC”). 
 (x) “Registrable Securities,” for a given
Registration, means (a) any shares of Common Stock (the “Warrant Shares”) issued or issuable upon exercise of, or otherwise pursuant to, the Warrants (without giving effect to any limitations on exercise set forth in the Warrants),
(b) any shares of capital stock issued or issuable as a dividend on or in exchange for or otherwise with respect to any of the foregoing, (c) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the
Warrants, (d) any other shares of Common Stock issuable pursuant to the terms of the Warrants or this Agreement, and (e) any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar
event with respect to any of the foregoing. 
 (xi) “Registration Deadline” shall mean, for purposes of the Registration Statement required
pursuant to Section 2(a)(i), the earlier of (i) the date that is seventy-five (75) days after the date that the applicable Registration Statement is actually filed or (ii) the date that is seventy-five (75) days after the
applicable Filing Deadline and, with respect to any Registration Statement required pursuant to Section 2(a)(ii), the Additional Registration Deadline. 

(xii) “Registration Statement(s)” means any registration statement(s) of the Company filed under the Securities Act that covers the resale of any of
the Registrable Securities pursuant to the provisions of this Agreement (including the Existing Registration Statement), all amendments and supplements to such Registration Statement, including post-effective amendments, and all exhibits to, and all
material incorporated by reference in, such Registration Statement. 
 (xiii) “Rule 415” means Rule 415 under the Securities Act or any successor
rule providing for the offering of securities on a continuous basis 
 (xiv) “Warrants” means the Warrants (including, for the avoidance of doubt,
both the Initial Warrants and the Additional Warrants) issued by the Company pursuant to the Existing Facility Agreement and the Amended Facility Agreement. 

2. REGISTRATION. 
 a. MANDATORY REGISTRATION.
(i) Following the Agreement Date, the Company shall prepare, and, on or prior to the applicable Filing Deadline, file with the SEC a Registration Statement (the “Mandatory Registration Statement”) on Form S-3 (or, if Form S-3 is not then available, on such form of Registration Statement as is then available to effect a registration of the Registrable Securities, subject to the
consent of the Investors, which consent shall not be unreasonably withheld), covering the resale of all of the Registrable Securities that are not at that time covered by the Existing Registration Statement (as then in effect and available for
resale of the Registrable Securities covered thereby), which Registration Statement, to the extent allowable under the Securities Act and the rules and regulations promulgated thereunder (including Rule 416), shall state that such Registration
Statement also covers such indeterminate number of additional shares of Common Stock as may become issuable upon exercise of or otherwise pursuant to the Warrants or the Warrant Shares to prevent dilution resulting from stock splits, stock
dividends, stock issuances or similar transactions. The number of shares of Common Stock initially 

  
 3 

 
included in such Registration Statement shall be no less than the aggregate number of Warrant Shares that are then issuable upon exercise of or otherwise pursuant to the Warrants, without regard
to any limitations on the Investors’ ability to exercise the Warrants. Each Registration Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided to (and shall be subject
to the approval, which shall not be unreasonably withheld or delayed, of) the Investors and their counsel prior to its filing or other submission. 
 (ii) If
for any reason, despite the Company’s use of its best efforts to include all of the Registrable Securities in the Registration Statement filed pursuant to Section 2 (a)(i) above (and subject to Section 3(q) below), the SEC does not
permit all such Registrable Securities to be included in such Registration Statement, or for any other reason any Registrable Securities are not then included in a Registration Statement (including the Existing Registration Statement), then the
Company shall prepare, and, as soon as practicable but in no event later than the Additional Filing Deadline, file with the SEC an additional Registration Statement covering the resale of all Registrable Securities not already covered by an existing
and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. 
 (iii) Unless the SEC does not so permit or
otherwise directed by the Buyers, each Registration Statement filed pursuant to this Section 2(a) or Section 3(b) shall include a combined prospectus for the resale of the Registrable Securities registered by such Registration Statement,
the Existing Registration Statement and any other Registration Statement previously filed hereunder, and shall be deemed a post-effective amendment to the Existing Registration Statement or, other previously filed Registration Statement in
accordance with Rule 429 under the Securities Act. 
 b. PIGGY-BACK REGISTRATIONS. If at any time prior to the expiration of the Registration Period
(as hereinafter defined) the Company shall determine (i) to file with the SEC a registration statement under the Securities Act relating to an offering for its own account or for the account of any other holder of its equity securities (other
than securities being registered on Form S-4 or Form S-8 or their then equivalents relating to equity securities to be issued solely in connection with any acquisition
of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans), and/or (ii) otherwise to effect an underwritten offering of any securities of the Company of a type included in a then
effective Registration Statement, the Company shall send to each Investor written notice of such determination and, if within fifteen (15) days after the effective date of such notice, the Investor shall so request in writing, the Company shall
include in such Registration Statement and/or include in such underwritten offering, as applicable, all or any part of such Investor’s Registrable Securities that the Investor requests to be registered and/or included in the underwritten
offering, as applicable, except that if, in connection with any underwritten offering for the account of the Company, the managing underwriter(s) thereof shall impose a limitation on the number of Registrable Securities which may be included in such
offering because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such underwritten offering only such
limited portion of the Registrable Securities with respect to which the Investor has requested inclusion hereunder as the underwriter(s) shall permit; 

provided, however, that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding
securities to be sold for the accounts of any holders of the Company’s equity securities which are not entitled by contract to inclusion of such securities in an underwritten offering or are not entitled to pro rata inclusion with the
Registrable Securities; and 
 provided, further, however, that, after giving effect to the immediately preceding proviso, any exclusion of
Registrable Securities shall be made pro rata with holders of other securities having the contractual right to include such securities in such underwritten offering other than holders of securities entitled to

  
 4 

 
inclusion of their securities in such underwritten offering by reason of demand registration rights. No right to registration of Registrable Securities under this Section 2(b) shall be
construed to limit any registration required under Section 2(a) hereof. If an Investor’s Registrable Securities are included in an underwritten offering pursuant to this Section 2(b), then such Investor shall, unless otherwise agreed
by the Company, offer and sell such Registrable Securities in such underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other shares of Common Stock
included in such underwritten offering. Notwithstanding anything to the contrary set forth herein, the rights of the Investors pursuant to this Section 2(b) shall only be available in the case of an underwritten offering or in the event the
Company fails to timely file, obtain effectiveness or maintain effectiveness of any Registration Statement to be filed pursuant to Section 2(a) or Section 3(b) in accordance with the terms of this Agreement. 

3. OBLIGATIONS OF THE COMPANY. In connection with any registration of the Registrable Securities hereunder, the Company shall have the following
obligations: 
 a. The Company shall prepare promptly, and file with the SEC as soon as practicable after such registration obligation arises hereunder (but
in no event later than the applicable Filing Deadline), a Registration Statement with respect to the Registrable Securities as provided in Section 2(a), and thereafter use its reasonable best efforts to cause each such Registration Statement
relating to Registrable Securities to become effective as soon as possible after such filing, but in any event shall use its reasonable best efforts to cause each such Registration Statement relating to Registrable Securities to become effective no
later than the Registration Deadline, and shall use its reasonable best efforts to keep each of such Registration Statement and the Existing Registration Statement current and effective pursuant to Rule 415 at all times after its effective date
until such date as is the earlier of (i) the date on which all of the Registrable Securities included in such Registration Statement have been sold and (ii) assuming all of the Warrants will be exercised pursuant to Cash Exercises (as
defined in the Warrants), the date on which all of the Registrable Securities included in such Registration Statement (in the opinion of counsel to the Investors) may be immediately sold to the public without registration or restriction (including
without limitation as to volume by each holder thereof), and without compliance with any “current public information” requirement, pursuant to Rule 144 under the Securities Act (the “Registration Period”), which Registration
Statement (including any amendments or supplements thereto and prospectuses contained therein), except for information provided in writing by an Investor pursuant to Section 4(a), shall not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading. In the event that Form S-3 is not available for the registration of the resale of any
Registrable Securities hereunder (but, for the avoidance of doubt, without in any way affecting the Company’s obligation to register the resale of the Registrable Securities on such other form as is available, as provided in Section 2(a)),
(i) the Company shall undertake to file, within twenty (20) days of such time as such form is available for such registration, a post-effective amendment to the Registration Statement then in effect, or otherwise file a Registration Statement
on Form S-3, registering such Registrable Securities on Form S-3; provided that the Company shall maintain the effectiveness of the Registration Statement then in effect
until such time as a Registration Statement (or post-effective amendment) on Form S-3 covering such Registrable Securities has been declared effective by the SEC, and (ii) the Company shall provide that
any Registration Statement on Form S-1 filed hereunder shall incorporate documents by reference (including by way of forward incorporation by reference) to the maximum extent possible. 

b. The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to each Registration Statement and the
prospectus used in connection with each Registration Statement as may be necessary to keep each Registration Statement current and effective at all times during the Registration Period, and, during the Registration Period, shall comply with the
provisions of the Securities Act with respect to the disposition of all Registrable Securities of the 

  
 5 

 
Company covered by each Registration Statement until such time as all of such Registrable Securities have been disposed of in accordance with the intended methods of disposition by the seller or
sellers thereof as set forth in such Registration Statement. Without limiting the foregoing, no later than August 17, 2018, the Company shall file with the SEC a prospectus supplement that supplements the Initial Prospectus with such
information as shall be necessary to reflect the Warrant Transfer (including to provide that Deerfield Partners, L.P. may resell the Registrable Securities underlying the Initial Warrants pursuant to the Existing Registration Statement and the
Initial Prospectus) and the transactions contemplated by the Amended Facility Agreement, to include updated information with respect to the Lenders to the extent provided by the Lenders in accordance with this Agreement and to include such other
information as may be necessary to enable the Existing Registration Statement to be used for resales of all of the Registrable Securities covered thereby. In the event that on any Trading Day (as defined below) (the “Registration Trigger
Date”) the number of shares available under the Registration Statements filed pursuant to this Agreement is insufficient to cover all of the Registrable Securities issued or issuable upon exercise of or otherwise pursuant to the Warrants,
including any additional shares of Common Stock issued in connection with any anti-dilution provisions contained in the Warrants, without giving effect to any limitations on the Investors’ ability to exercise the Warrants, the Company shall
amend the Registration Statements, or file a new Registration Statement (on the short form available therefor, if applicable), or both, so as to cover the total number of Registrable Securities so issued or issuable (without giving effect to any
limitations on exercise contained in the Warrants) as of the Registration Trigger Date as soon as practicable, but in any event within twenty (20) days after the Registration Trigger Date. The Company shall use its best efforts to cause such
amendment and/or new Registration Statement to become effective as soon as practicable following the filing thereof, but in any event the Company shall cause such amendment and/or new Registration Statement to become effective within sixty
(60) days of the Registration Trigger Date or as promptly as practicable in the event the Company is required to increase its authorized shares. “Trading Day” shall mean any day on which the Common Stock is traded for any period on
the NASDAQ Global Select Market (the “NasdaqGS”), or if not the NasdaqGS, the principal securities exchange or other securities market on which the Common Stock is then being traded. 

c. The Company shall furnish to each Investor and its legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC
or received by the Company, one copy of each Registration Statement and any amendment thereto, each preliminary prospectus and prospectus and each amendment or supplement thereto, and, each letter written by or on behalf of the Company to the SEC or
the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion of any thereof which contains information for which the Company has sought or
intends to seek confidential treatment, which contains or reflects any material non-public information with respect to the Company or its securities or which relates to Company matters that are in the
reasonable judgment of the Company not relevant to the Investor’s interests with respect to the Registrable Securities), and (ii) such number of copies of a prospectus, including a preliminary prospectus, and all amendments and supplements
thereto and such other documents as an Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor; provided that the Company may determine in its reasonable judgment to provide any
such copies in electronic form only. The Company will promptly notify each of the Investors by electronic mail of the effectiveness of each Registration Statement or any post-effective amendment. The Company will promptly respond to any and all
comments received from the SEC, with a view towards causing each Registration Statement or any amendment thereto (including any post-effective amendment to the Existing Registration Statement) to be declared effective by the SEC as soon as
practicable and, as soon as practicable, but in no event later than three (3) business days, following the resolution or clearance of all SEC comments or, if applicable, following notification by the SEC that any such Registration Statement or
any amendment thereto will not be subject to review, shall file a request for acceleration of effectiveness of such Registration Statement to a time and date not later than two (2) business days after

  
 6 

 
the submission of such request. No later than the first business day after such Registration Statement becomes effective, the Company will file with the SEC the final prospectus included therein
pursuant to Rule 424 (or successor thereto) under the Securities Act. 
 d. The Company shall use its reasonable best efforts to (i) register and
qualify, in any jurisdiction where registration and/or qualification is required, the Registrable Securities covered by the Registration Statements under such other securities or “blue sky” laws of such jurisdictions in the United States
as the Investors shall reasonably request, (ii) prepare and file in those jurisdictions such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be reasonably necessary to maintain
the effectiveness thereof during the Registration Period, (iii) take such other actions as may be reasonably necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take
all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify
to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(d), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in
any such jurisdiction. 
 e. As promptly as practicable after becoming aware of such event, the Company shall notify each Investor that holds Registrable
Securities of the happening of any event, of which the Company has knowledge, as a result of which the prospectus included in any Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material
fact required to be stated therein or necessary to make the statements therein not misleading, and promptly prepare a supplement or amendment to any Registration Statement to correct such untrue statement or omission, and deliver such number of
copies of such supplement or amendment to each Investor as such Investor may reasonably request. 
 f. The Company shall use its reasonable best efforts to
prevent the issuance of any stop order or other suspension of effectiveness of any Registration Statement, and, if such an order is issued, to obtain the withdrawal of such order at the earliest possible moment and to notify each Investor that holds
Registrable Securities (and, in the event of an underwritten offering, the managing underwriters) of the issuance of such order and the resolution thereof. 

g. The Company shall permit a single firm of counsel designated by the Investors (“Legal Counsel”) to review such Registration Statement and all
amendments and supplements thereto (as well as all requests for acceleration or effectiveness thereof), a reasonable period of time prior to their filing with the SEC (not less than five (5) business days but not more than eight
(8) business days) and not file any documents in a form to which Legal Counsel reasonably objects and will not request acceleration of such Registration Statement without prior notice to Legal Counsel. 

h. The Company shall hold in confidence and not make any disclosure of information concerning an Investor provided to the Company unless (i) disclosure of
such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such
information is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation of this or
any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning any Investor is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to
such Investor prior to making such disclosure, and allow such Investor, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information. 

  
 7 

 i. The Company shall use its reasonable best efforts to cause all the Registrable Securities covered by each
Registration Statement to be listed on each securities exchange on which securities of the same class or series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such
exchange, and, to arrange for at least two market makers to register with the Financial Industry Regulatory Authority, Inc. (“FINRA”) as such with respect to such Registrable Securities. 

j. The Company shall provide a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of
the initial Registration Statement. 
 k. The Company shall cooperate with each Investor that holds Registrable Securities being offered and the managing
underwriter or underwriters with respect to an applicable Registration Statement, if any, to facilitate the timely (i) preparation and delivery of certificates (not bearing any restrictive legends) representing Registrable Securities to be
offered pursuant to such Registration Statement, and enable such certificates to be registered in such names and in such denominations or amounts, as the case may be, or (ii) crediting of the Registrable Securities to be offered pursuant to a
Registration Statement to the applicable account (or accounts) with The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) system, in any such case as such Investor or the managing underwriter or underwriters, if any, may
reasonably request. Within three (3) business days after a Registration Statement which includes Registrable Securities becomes effective, the Company shall deliver, and shall cause legal counsel selected by the Company to deliver, to the
transfer agent for the Registrable Securities (with copies to each Investor) an appropriate instruction and an opinion of such counsel in the form required by the transfer agent in order to issue the Registrable Securities free of restrictive
legends. 
 l. At the reasonable request of an Investor, the Company shall prepare and file with the SEC such amendments (including post-effective
amendments) and supplements to a Registration Statement and any prospectus used in connection with the Registration Statement as may be necessary in order to change the plan of distribution set forth in such Registration Statement. 

m. The Company shall not, and shall not agree to, allow the holders of any securities of the Company to include any of their securities (other than Registrable
Securities) in any Registration Statement filed pursuant to Section 2(a) or Section 3(b) hereof or any amendment or supplement thereto under Section 3(b) hereof without the consent of Investors holding a
majority-in-interest of the then outstanding Registrable Securities. In addition, the Company shall not include any securities for its own account or the account of
others in any Registration Statement filed pursuant to Section 2(a) or Section 3(b) hereof or any amendment or supplement thereto filed pursuant to Section 3(b) hereof without the consent of Investors holding a majority-in-interest of the then outstanding Registrable Securities. 
 n.
Reserved. 
 o. The Company shall comply with all applicable laws related to a Registration Statement and offering and sale of securities and all applicable
rules and regulations of governmental authorities in connection therewith (including the Securities Act and the Exchange Act and the rules and regulations promulgated by the SEC). 

p. If required by the FINRA Corporate Financing Department, the Company shall promptly effect a filing with FINRA pursuant to FINRA Rule 5110 (or successor
thereto) with respect to the public offering contemplated by resales of securities under the Registration Statement (an “Issuer Filing”), and pay the filing fee required by such Issuer Filing. The Company shall use its reasonable best
efforts to pursue the Issuer Filing until FINRA issues a letter confirming that it does not object to the terms of the offering 

  
 8 

 
contemplated by the Registration Statement. 
 q. If at any time the SEC advises the Company in writing
that the offering of some or all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act, the Company shall use its reasonable
best efforts to persuade the SEC that the offering contemplated by a Registration Statement is a bona fide secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that none of the Investors is an
“underwriter.” The Investors shall have the right to participate or have their respective counsel participate in any meetings or discussions with the SEC regarding the SEC’s position and to comment or have their respective counsel
comment on any written submission made to the SEC with respect thereto. No such written submission shall be made to the SEC to which any Investor’s counsel reasonably objects. In the event that, despite the Company’s reasonable best
efforts and compliance with the terms of this Section 3(q), the SEC refuses to alter its position, the Company shall remove from the Registration Statement such portion of the Registrable Securities as the SEC requires in writing be removed
therefrom. Any such cut-back imposed by the SEC as contemplated by this Section 3(q) shall be imposed on a pro rata basis (based upon the Registrable Securities held by each of the Investors). 

r. Notwithstanding anything to the contrary in Section 3(e), at any time after the effective date of the applicable Registration
Statement, the Company may delay the disclosure of material non-public information concerning the Company the disclosure of which at the time is not, in the good faith opinion of the Board of Directors of the
Company and its counsel, in the best interest of the Company and not, in the opinion of counsel to the Company, otherwise required (a “Grace Period”); provided, that the Company shall (i) promptly notify the Investors in
writing of the existence of material non-public information giving rise to a Grace Period (provided that in each notice the Company shall not disclose the content of such material non-public information to any Investor unless otherwise requested in writing by such Investor) and the date on which the Grace Period will begin, and (ii) as soon as such date may be determined, promptly notify
the Investors in writing of the date on which the Grace Period ends; and, provided, further, that (A) no Grace Period shall exceed forty-five (45) consecutive days, (B) during any three hundred sixty five (365) day
period, such Grace Periods shall not exceed an aggregate of seventy-five (75) days, and (C) the first day of any Grace Period must be at least ten (10) business days after the last day of any prior Grace Period (each Grace Period that
satisfies all of the requirements of this Section 3(r) being referred to as an “Allowable Grace Period”). For purposes of determining the length of a Grace Period above, the Grace Period shall begin on and
include the date the Investors receive the notice referred to in clause (i) and shall end on and include the later of the date the Investors receive the notice referred to in clause (ii) and the date referred to in such notice. The
provisions of Section 3(e) hereof shall not be applicable during the period of any Allowable Grace Period, Failure Payments (as defined in the Warrants) shall not accrue on any day during an Allowable Grace Period, and the
unavailability of a Registration Statement for resales of the Registrable Securities on any day during an Allowable Grace Period shall not constitute a “Registration Failure” (as defined in the Warrants). Upon expiration of the Grace
Period, the Company shall again be bound by the first sentence of Section 3(e) with respect to the information giving rise thereto unless such material non-public information is no
longer applicable. 
 4. OBLIGATIONS OF THE INVESTOR. In connection with the registration of the Registrable Securities, each Investor shall have the
following obligations: 
 a. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with
respect to the Registrable Securities of an Investor that such Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held
by it as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such 

  
 9 

 
registration as the Company may reasonably request. At least five (5) business days prior to the first anticipated filing date of a Registration Statement, the Company shall notify each
Investor of the information the Company requires from such Investor. Any such information shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements
therein not misleading. An Investor must provide such information to the Company at least two (2) business days prior to the first anticipated filing date of such Registration Statement if such Investor elects to have any Registrable Securities
included in the Registration Statement. 
 b. Each Investor, by such Investor’s acceptance of the Registrable Securities, agrees to cooperate with the
Company as reasonably requested by the Company in connection with the preparation and filing of a Registration Statement hereunder, unless such Investor has notified the Company in writing of such Investor’s election to exclude all of the
Investor’s Registrable Securities from such Registration Statement. 
 c. In the event of an underwritten offering pursuant to Section 2(b) in
which any Registrable Securities of any Investor are to be included, such Investor agrees to enter into and perform the Investor’s obligations under an underwriting agreement, in usual and customary form, including customary indemnification and
contribution obligations (as applicable to selling security holders generally), with the managing underwriter of such offering and take such other actions as are reasonably required in order to expedite or facilitate the disposition of such Investor
Registrable Securities. 
 d. Each Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in
Section 3(e) or 3(f), such Investor will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Investor’s receipt of the copies of the
supplemented or amended prospectus contemplated by Section 3(e) or 3(f). 
 e. Each Investor agrees that it will promptly notify the Company of any
material changes in the information set forth in a Registration Statement furnished by or regarding such Investor, other than changes in the number of shares beneficially owned. 

5. REGISTRATION FAILURE. In the event of a Registration Failure (as defined in the Warrants), the Investors shall be entitled to Failure
Payments (as defined in the Warrants) and such other rights as set forth in the Warrants. 
 6. EXPENSES OF REGISTRATION. All reasonable expenses,
other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualification fees, printers and
accounting fees, and the fees and disbursements of counsel for the Company shall be borne by the Company. The Company shall also reimburse the Investors for the reasonable fees and disbursements of Legal Counsel in the aggregate amount up to $25,000
per registration in connection with registrations pursuant to Section 2 or 3 of this Agreement. 
 7. INDEMNIFICATION. In the event any
Registrable Securities are included in a Registration Statement under this Agreement: 
 a. The Company will indemnify, hold harmless and defend
(i) each Investor, (ii) the directors, officers, partners, managers, members, employees and agents of each Investor, and each Person who controls any Investor within the meaning of the Securities Act or the Exchange Act, if any,
(iii) any underwriter (as defined in the Securities Act) for each Investor in connection with an underwritten offering pursuant to Section 2(b) hereof, and (iv) the directors, officers, partners and employees of, and each Person who

  
 10 

 
controls, any such underwriter within the meaning of the Securities Act or the Exchange Act, if any (each, an “Indemnified Person”), against any joint or several losses, claims,
damages, liabilities or expenses (collectively, together with actions, proceedings or inquiries by any regulatory or self-regulatory organization, whether commenced or threatened, in respect thereof, “Claims”) to which any of them may
become subject insofar as such Claims arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in any Registration Statement, or any amendment as supplement thereto, or any filing made under state
securities laws as required hereby, or the omission or alleged omission to state therein a material fact required to be stated or necessary to make the statements therein not misleading; (ii) any untrue statement or alleged untrue statement of
a material fact contained in any Prospectus, or any amendment or supplement thereto, or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in the light of the circumstances under which
the statements therein were made, not misleading; or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including any state securities law, or any rule or regulation thereunder
relating to the offer or sale of the Registrable Securities (the matters in the foregoing clauses (i) through (iii) being, collectively, “Violations”). The Company shall reimburse the Indemnified Person, promptly as such expenses are
incurred and are due and payable, for any reasonable legal fees and other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the
indemnification agreement contained in this Section 7(a) shall not apply to a Claim arising out of or based upon a Violation to the extent that such Violation occurs in reliance upon and in conformity with information furnished in writing to
the Company by or on behalf of any Indemnified Person expressly for use in connection with the preparation of such Registration Statement or any such amendment thereof or supplement thereto, or (B) to any amounts paid in settlement of any Claim
effected without the prior written consent of the Company, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified
Person and shall survive the transfer of the Registrable Securities by any of the Investors pursuant to Section 10. 
 b. Promptly after receipt by an
Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Indemnified Person shall, if a Claim in respect thereof is to be made against the Company under this Section 7,
deliver to the Company a written notice of the commencement thereof, and the Company shall have the right to participate in, and, to the extent the Company so desires, to assume control of the defense thereof with counsel mutually satisfactory to
the Company and the Indemnified Person, as the case may be; 
 provided, however, that an Indemnified Person shall have the right to retain
its own counsel with the reasonable fees and expenses to be paid by the Company, if, in the reasonable opinion of counsel for such Indemnified Person, the representation by such counsel of the Indemnified Person and the Company would be
inappropriate due to actual or potential differing interests between such Indemnified Person and any other party represented by such counsel in such proceeding. The Company shall pay for only one separate legal counsel for the Indemnified Persons,
and such legal counsel shall be selected by the Investors. The failure to deliver written notice to the Company within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnified Person
under this Section 7, except to the extent that the Company is actually prejudiced in its ability to defend such action, and shall not relieve the Company of any liability to the Indemnified Person otherwise than pursuant to this
Section 7. The Company shall not, without the prior written consent of the Indemnified Persons, consent to entry of any judgment or enter into any settlement or other compromise with respect to any Claim in respect of which indemnification or
contribution may be or has been sought hereunder (whether or not any such Indemnified Party is an actual or potential party to such action or claim) which does not include as an unconditional term thereof the giving by the claimant or plaintiff to
the Indemnified Persons of a full release from all liability with respect to such Claim or which 

  
 11 

 
includes any admission as to fault or culpability on the part of any Indemnified Person. The indemnification required by this Section 7 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as any expense, loss, damage or liability is incurred. 
 c. Each Investor will indemnify, hold
harmless and defend (i) the Company, and (ii) the directors, officers, partners, managers, members, employees or agents of the Company, if any (each, a “Company Indemnified Person”), against any Claims to which any of them may
become subject insofar as such Claims arise out of or are based upon any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including any state securities law, or any rule or regulation thereunder
relating to the offer or sale of the Registrable Securities, which occurs due to the inclusion by the Company in a Registration Statement of false or misleading information about an Investor, where such information was furnished in writing to the
Company by or on behalf of such Investor expressly for the purpose of inclusion in such Registration Statement. Notwithstanding anything herein to the contrary, the indemnity agreement contained in this Section 7(c) shall not apply to amounts
paid in settlement of any Claim if such settlement is effected without the prior written consent of the Investors, which consent shall not be unreasonably withheld or delayed; and provided, further, however, that an Investor shall be liable
under this Section 7(c) for only that amount of a Claim as does not exceed the net amount of proceeds received by such Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement. 

d. Promptly after receipt by a Company Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental
action), such Company Indemnified Person shall, if a Claim in respect thereof is to be made against any Investor under this Section 7, deliver to such Investor a written notice of the commencement thereof, and such Investor shall have the right
to participate in, and, to the extent such Investor so desires, to assume control of the defense thereof with counsel mutually satisfactory to such Investor and such Company Indemnified Person. 

8. CONTRIBUTION. If for any reason the indemnification provided for in Section 7(a) or 7(c) (as applicable) is unavailable to an Indemnified
Person or Company Indemnified Person (as applicable) or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the Indemnified Person or Company
Indemnified Person (as applicable) as a result of the Claim in such proportion as is appropriate to reflect the relative fault of the Indemnified Person or Company Indemnified Person (as applicable) and the indemnifying party (provided that the
relative fault of any Company Indemnified Person shall be deemed to include the fault of all other Company Indemnified Persons), as well as any other relevant equitable considerations. No Person guilty of fraudulent misrepresentation within the
meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of an Investor be greater in amount than the net
amount of proceeds received by such Investor as a result of the sale of Registrable Securities giving rise to such contribution obligation pursuant to the applicable Registration Statement (net of the aggregate amount of any damages or other amounts
such Investor has otherwise been required to pay (pursuant to Section 7(c) or otherwise) by reason of such Investor’s untrue or alleged untrue statement or omission or alleged omission). 

9. REPORTS UNDER THE 1934 ACT. With a view to making available to the Investors the benefits of Rule 144 promulgated under the Securities Act or
any other similar rule or regulation of the SEC that may at any time permit the Investors to sell securities of the Company to the public without registration, the Company agrees to: 

a. make and keep public information available, as those terms are understood and defined in Rule 144; 

  
 12 

 b. file with the SEC in a timely manner all reports and other documents required of the Company under the
Exchange Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144; and 

c. so long as any of the Investors owns Registrable Securities, promptly upon request, furnish to such Investor (i) a written statement by the Company
that it has complied with the reporting requirements of the Exchange Act as required for applicable provisions of Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed
by the Company and (iii) such other information as may be reasonably requested to permit such Investor to sell such Registrable Securities pursuant to Rule 144 without registration. 

10. ASSIGNMENT OF REGISTRATION RIGHTS. The rights under this Agreement shall be automatically assignable by each Investor to any transferee of all or
any portion of the Registrable Securities if: (i) such Investor agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment,
(ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of (a) the name and address of such transferee or assignee, and (b) the securities with respect to which such registration
rights are being transferred or assigned, and (iii) at or before the time the Company receives the written notice contemplated in clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company to be bound
by all of the provisions contained herein as applicable to the Investors. In the event that the Company receives written notice from an Investor that it has transferred all or any portion of its Registrable Securities pursuant to this Section, the
Company shall have up to ten (10) days to file any amendments or supplements necessary to keep a Registration Statement current and effective pursuant to Rule 415, and the commencement date of any Event of Failure (as defined in the
Warrants) or Event of Default (as defined in the Warrants) under the Warrants caused thereby will be extended by ten (10) days. Each Investor shall at all times comply with the restrictions on transfer set forth in Section 8 of the Warrant
(to the extent applicable to such Investor), which provisions are hereby incorporated by reference and made a part hereof. 
 11. AMENDMENT OF
REGISTRATION RIGHTS. Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with written consent of the Company and the
holders of a majority in interest of then-outstanding Registrable Securities. Any amendment or waiver effected in accordance with this Section 11 shall be binding upon each of the Investors and the Company. 

12. MISCELLANEOUS. 
 a. A Person is deemed to hold, and be
a holder of, shares of Common Stock or other Registrable Securities whenever such Person owns of record or beneficially through a “street name” holder such shares of Common Stock or other Registrable Securities (or the Warrants or other
securities upon exercise, conversion or exchange of which such Registrable Securities are directly or indirectly issuable, without giving effect to any limitations on exercise, conversion or exchange of the Warrants or other securities), and solely
for purposes hereof, Registrable Securities shall be deemed outstanding to the extent they are directly or indirectly issuable upon exercise, conversion or exchange of the Warrants or other outstanding securities, Registrable Securities, without
giving effect to any limits on exercise, conversion or exchange of the Warrants or other securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the
Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable Securities (or the Warrants or other securities upon exercise, conversion or exchange of which such Registrable Securities
are directly or indirectly issuable). 

  
 13 

 b. Any notices required or permitted to be given under the terms hereof shall be sent by certified or
registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by electronic mail and shall be effective five days after being placed in the mail, if mailed by regular United
States mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by electronic mail, in each case addressed to a party. The addresses for such communications shall be: 

If to the Company: 
 Endologix, Inc. 

2 Musick 
 Irvine, CA 92618 

E-mail: jtejedor@endologix.com 

Attn: Vaseem Mahboob, CFO 
 Attn: James Tejedor, Treasury Manager

 With copy to: 
 DLA Piper LLP (US) 

4365 Executive Drive, Suite 1100 
 San Diego, CA 92101 

E-mail: michael.kagnoff@dlapiper.com 

Attn: Michael Kagnoff 
 If to an Investor: 

c/o Deerfield Mgmt, L.P. 
 780 Third Avenue, 37th Floor 
 New York, NY 10017 

Fax: (212) 599-1248 

Email: 
 Attn: David J. Clark, Esq. 

With a copy to: 
 Katten Muchin Rosenman LLP 

575 Madison Avenue 
 New York, NY 10022 

Fax: (212) 940-8776 

Email: mark.fisher@kattenlaw.com and mark.wood@kattenlaw.com 

Attn: Mark I. Fisher, Esq. 

         Mark D. Wood, Esq. 

Each party shall provide notice to the other party of any change in address. 

c. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not
operate as a waiver thereof. 
 d. Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that 

  
 14 

 
all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, borough of Manhattan. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any other manner permitted by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provision of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. 

e. This Agreement and the Warrants constitute the entire agreement among the parties hereto with respect to the subject matter hereof. This Agreement and the
Warrants (including all schedules and exhibits thereto) supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof. 

f. Subject to the requirements of Section 10 hereof, this Agreement shall inure to the benefit of and be binding upon the successors and assigns of each
of the parties hereto, and the provisions of Sections 7 and 8 hereof shall inure to the benefit of, and be enforceable by, each Indemnified Person and Company Indemnified Person (as applicable). 

g. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. 

h. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same
agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by electronic transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement. 

i. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as the other parties may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. 

j. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Investors by vitiating the intent and purpose
of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for breach of its obligations hereunder will be inadequate and agrees, in the event of a breach or threatened breach by the Company of any of the
provisions hereunder, that the Investors shall be entitled, in addition to all other available remedies in law or in equity, to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically
the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required. 

  
 15 

 k. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party. 
 l. In the event that any provision of this Agreement is
invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any
provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof. 
 m.
In the event an Investor shall sell or otherwise transfer any of such holder’s Registrable Securities, each transferee shall be allocated a pro rata portion of the number of Registrable Securities included in a Registration Statement for such
transferor. 
 n. There shall be no oral modifications or amendments to this Agreement. This Agreement may be modified or amended only in writing. 

o. The Company shall not grant any Person any registration rights with respect to shares of Common Stock or any other securities of the Company other than
registration rights that will not adversely affect the rights of the Investors hereunder (including by limiting in any way the number of Registrable Securities that could be included in any Registration Statement pursuant to Rule 415) and shall not
otherwise enter into any agreement that is inconsistent with the rights granted to the Investors hereunder. 
 p. The obligations of each Investor hereunder
are several and not joint with the obligations of any other Investor, and no provision of this Agreement is intended to confer any obligations on any Investor
vis-à-vis any other Investor. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as a
partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated herein. 

q. Unless the context otherwise requires, (i) all references to Sections, Schedules or Exhibits are to Sections, Schedules or Exhibits contained in or
attached to this Agreement, (ii) words in the singular or plural include the singular and plural, and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter, and (ii) the use
of the word “including” in this Agreement shall be by way of example rather than limitation. 
 [Remainder of page left
intentionally blank] 
 [Signature page follows] 

  
 16 

 IN WITNESS WHEREOF, the undersigned Investors and the Company have caused this Amended and
Restated Registration Rights Agreement to be duly executed as of the date first written above. 
  

			
	COMPANY:
	
	ENDOLOGIX, INC., a Delaware corporation
		
	By:	 	 /s/ Vaseem Mahboob

	Name:	 	Vaseem Mahboob
	Title:	 	Chief Financial Officer

 [Signature Page to Registration Rights Agreement] 

 IN WITNESS WHEREOF, the undersigned Investors and the Company have caused this Amended and
Restated Registration Rights Agreement to be duly executed as of the date first written above. 
  

			
	INVESTORS:
	
	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
	
	By: Deerfield Mgmt IV, L.P., General Partner
	
	By: J.E. Flynn Capital IV, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory
	
	DEERFIELD PRIVATE DESIGN FUND III, L.P.
	
	By: Deerfield Mgmt III, L.P., General Partner
	
	By: J.E. Flynn Capital III, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory
	
	DEERFIELD PARTNERS, L.P.
	
	By: Deerfield Mgmt, L.P., General Partner
	
	By: J.E. Flynn Capital, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

  
 18EX-10.4

 Exhibit 10.4 

AMENDED AND RESTATED 

GUARANTY AND SECURITY AGREEMENT 

dated as of August 9, 2018 

by and among 

Endologix, Inc., 
 as
Borrower, 
 the other Grantors and Guarantors party hereto from time to time 

and 
 Deerfield Private
Design Fund IV, L.P., 
 as agent for itself and the other Secured Parties 

 AMENDED AND RESTATED 

GUARANTY AND SECURITY AGREEMENT 

This AMENDED AND RESTATED GUARANTY AND SECURITY AGREEMENT (this “Agreement”), dated as of August 9, 2018, by and among
Endologix, Inc., a Delaware corporation (“Borrower”), CVD/RMS Acquisition Corp., a Delaware corporation (“CVD”), Nellix, Inc., a Delaware corporation (“Nellix”), TriVascular Technologies, Inc., a
Delaware corporation (“TriVascular Technologies”), TriVascular, Inc., a California corporation (“TriVascular California”), Endologix Canada, LLC, a Delaware limited liability company (f/k/a TriVascular Canada, LLC)
(“Endologix Canada”), TriVascular Sales LLC, a Texas limited liability company (“Sales”), RMS/Endologix Sideways Merger Corp., a Delaware corporation (“Sideways”), each other Person who becomes a
party hereto pursuant to Section 8.15 (together with the Borrower, CVD, Nellix, TriVascular Technologies, TriVascular California, Endologix Canada, Sales and Sideways, the “Grantors” and each, a
“Grantor”), each other Person signatory hereto as a “Guarantor” (as defined below) and Deerfield Private Design Fund IV, L.P., as Agent. 

RECITALS 
 A.
Borrower, CVD, Nellix, TriVascular Technologies, TriVascular California and Sales previously entered into a certain Guaranty and Security Agreement dated April 3, 2017 (as amended, restated, supplemented and otherwise modified from time to time
prior to the effectiveness of the Facility Agreement (defined below) (including by that certain Joinder to Guaranty and Security Agreement, Facility Agreement and Intercreditor Agreement, dated as of May 18, 2017, by and among Sales, Sideways
and Agent (the “Joinder”)), the “Existing Guaranty and Security Agreement”). Pursuant to the Existing Guaranty and Security Agreement and the Joinder, Borrower, the other Grantors and the other Guarantors, among
other things, previously (i) agreed to jointly and severally guaranty the Guaranteed Obligations (as defined therein) and (ii) pledged and granted unto Agent, for the benefit of the Secured Parties, security interests and liens in the
collateral described therein, in order to secure the Secured Obligations (as defined therein). 
 B. The Existing Guaranty and Security
Agreement and the Joinder were entered into in connection with the Prior Facility Agreement (as defined in the Facility Agreement). The Prior Facility Agreement, among other things and in addition to the other Loan Documents (as defined in the Prior
Facility Agreement, such documents are referred to herein as the “Existing Loan Documents”), prior to the time of the effectiveness of the Facility Agreement, evidences and governs certain Loans and Obligations (as both such terms
are defined in the Prior Facility Agreement). 
 C. Borrower, the other Loan Parties, the Agent and the Lenders have agreed to certain
amendments, restatements, amendments and restatements, supplements and other modifications to the terms of the Existing Loan Documents, and in connection therewith such Persons have amended and restated the Prior Facility Agreement in its entirety
pursuant to the terms of the Facility Agreement. 
 D. Each Grantor will (a) derive substantial direct and indirect benefits from
(i) the making of the extensions of credit under the Facility Agreement, (ii) the Agent and the Lenders permitting the Grantors party thereto to enter into the ABL Credit Facility and ABL Debt Documents on the terms and conditions set
forth in the Facility Agreement and other Loan Documents and (iii) the amendments, restatements, amendments and restatements, supplements and modifications to the Existing Loan Documents and (b) continue to derive substantial direct and
indirect benefits from any prior making of extensions of credit under the Prior Facility Agreement (which continue as Loans and Obligations under the Facility Agreement and the other Loan Documents). 

 E. As a further condition to the Agent and the Lenders agreeing to the amendments,
restatements, amendments and restatements, supplements and modifications to the Existing Loan Documents, and continuing to extend the Loans and other Obligations under the Existing Loan Documents, as amended, restated, amended and restated,
supplemented and otherwise modified pursuant to the Loan Documents, the Agent and Lenders are requiring that the parties hereto enter into this Agreement, and thereby amend and restate the Existing Guaranty and Security Agreement in its entirety as
set forth herein. 
 F. In consideration of the premises and to induce the Lenders and Agent to enter into the Facility Agreement and the
Loan Documents (including the amendment, restatements, amendments and restatements, supplements and modifications to the Existing Loan Documents) and to permit the Grantors party thereto to enter into the ABL Credit Facility and ABL Debt Documents
on the terms and conditions set forth in the Facility Agreement and other Loan Documents and to induce the Lenders to continue to allow their respective extensions of credit and Loans to Borrower under the Facility Agreement to remain outstanding
and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto do hereby amend and restate the Existing Guaranty and Security Agreement in its entirety as set forth herein, and hereby
covenant and agree, as follows: 
 SECTION 1 DEFINITIONS. 

1.1 Unless otherwise defined herein, terms defined in the Facility Agreement and used herein shall have the meanings given to them in the
Facility Agreement, and the following terms are used herein as defined in the UCC (such meanings to be equally applicable to both the singular and plural forms of the terms defined): “accounts”, “certificated security”,
“chattel paper”, “commercial tort claims”, “commodity contract”, “deposit accounts”, “documents”, “electronic chattel paper”, “equipment”, “farm products”,
“fixture”, “general intangibles”, “goods”, “health care insurance receivables”, “instruments”, “inventory”, “leases”, “letter-of-credit rights”, “money”, “payment intangibles”, “product”, “record”, “securities account”, “security”, “supporting
obligations”, and “tangible chattel paper”. It is hereby agreed that the term “instrument” shall not include checks received in the ordinary course of business. 

1.2 Whenever used in this Agreement, the Exhibits or the Schedules attached hereto, unless the context otherwise requires, the following terms
have the following meanings: 
 “Agreement” has the meaning set forth in the preamble of this Agreement. 

“Collateral” means all of Grantors’ assets, whether now owned or hereafter created, acquired or arising, including
without limitation, all of Grantors’ right, title and interest in and to the following: 
 (a) all goods, accounts
(including health care insurance receivables), equipment, inventory, contract rights or rights to payment of money, leases, license agreements and other licenses, franchise agreements, general intangibles, commercial tort claims (including any
Identified Claims), documents, instruments (including any promissory notes) (and any distribution of property made on, in respect of or in exchange for such instruments from time to time), chattel paper (whether tangible chattel paper or
electronic), cash, Cash Equivalents, deposit accounts, Intellectual Property, Intellectual Property Licenses, securities accounts, fixtures, letter-of-credit rights
(whether or not the letter of credit is evidenced by a writing), securities, all other Pledged Collateral and Pledged Investment Property (including any distribution of property made on, in respect of or in exchange for such Pledged Collateral
and/or Pledged Investment Property from time to time) and all supporting obligations related to any of the foregoing, and financial assets, wherever located; 

  
 2 

 (b) all books and records relating to any of the foregoing; 

(c) all property of any Grantor held by any Secured Party, including all property of every description, in the custody of or in
transit to such Secured Party for any purpose, including safekeeping, collection or pledge, for the account of such Grantor or as to which such Grantor may have any right or power, including but not limited to cash; and 

(d) any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments,
accessories, accessions and improvements to and replacements, products, Proceeds and insurance Proceeds of any or all of the foregoing. 
 Where the context
requires, terms relating to the Collateral or any part thereof, when used in relation to a Grantor, shall refer to such Grantor’s Collateral or the relevant part thereof. Notwithstanding the foregoing, “Collateral” shall not include
Excluded Property; provided, however, that if and when any assets cease to be Excluded Property, the term “Collateral” shall include such assets and a Lien on and security interest in such assets shall be deemed granted
therein pursuant to Section 3.1 hereof. 
 “Copyrights” means any and all rights in any works of
authorship, including (A) copyrights and moral rights, (B) copyright registrations and recordings thereof and all applications in connection therewith including those listed on Schedule 8, (C) income, license fees, royalties,
damages, and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past, present, or future infringements thereof,
(D) the right to sue for past, present, and future infringements thereof, and (E) all of each Grantor’s rights corresponding thereto throughout the world. 

“Facility Agreement” means the Amended and Restated Facility Agreement of even date herewith by and among Borrower, the other
Loan Parties party thereto from time to time, Agent and Lenders, as amended, supplemented, restated or otherwise modified from time to time. 

“Fraudulent Transfer Laws” has the meaning set forth in Section 2.6 hereof. 

“Grantor” has the meaning set forth in the preamble of this Agreement. 

“Guaranteed Obligations” means all obligations of each Guarantor under the Loan Documents and all other Obligations
(including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment). 

“Guarantors” means Borrower, CVD, Nellix, TriVascular Technologies, TriVascular, Endologix Canada, Sales, Sideways and any
other Person who becomes a party to this Agreement pursuant to Section 8.15. 
 “Identified
Claims” means the commercial tort claims described on Schedule 5, as such schedule shall be supplemented from time to time in accordance with the terms and conditions of this Agreement. 

“Intellectual Property License” means, with respect to any Grantor (the “Specified Party”), (A) any licenses
or other similar rights provided to the Specified Party in or with respect to Intellectual Property owned or controlled by any other Person, and (B) any licenses or other similar rights provided to any other Person in or with respect to
Intellectual Property owned or controlled by the Specified Party, in each case, including (1) any software license agreements, (2) the license agreements listed on Schedule 9, and (3) the right to use any of the licenses or
other similar rights described in this definition in connection with the enforcement of any Secured Party’s rights under the Loan Documents. 

  
 3 

 “Issuers” means the collective reference to each issuer of Pledged
Collateral and Pledged Investment Property. 
 “Paid in Full” and “Payment in Full” each means
(a) with respect to Guaranteed Obligations, all Guaranteed Obligations have been repaid in full in cash (other than (i) any unasserted contingent indemnification obligations and (ii) any Obligations under any Warrant and the
Registration Rights Agreement that are not due or payable at the time when all such other Guaranteed Obligations are repaid in full in cash) and (b) with respect to Secured Obligations, all Secured Obligations have been repaid in full in cash
(other than (i) any unasserted contingent indemnification obligations and (ii) any Obligations under any Warrant and the Registration Rights Agreement that are not due or payable at the time when all such other Secured Obligations are
repaid in full in cash); provided that the foregoing shall be subject to any reinstatement pursuant to (and the other provisions set forth in) Section 8.18 hereof. 

“Patents” means patents and patent applications, including (A) the patents and patent applications listed on Schedule
10, (B) all continuations, divisionals, continuations-in-part, re-examinations, reissues, and renewals thereof and
improvements thereon, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past,
present, or future infringements thereof, (D) the right to sue for past, present, and future infringements thereof, and (E) all of each Grantor’s rights corresponding thereto throughout the world. 

“Pledged Collateral” means, collectively, the Pledged Equity and the Pledged Debt Instruments. 

“Pledged Debt Instruments” means all right, title and interest of any Grantor in instruments evidencing any Indebtedness owed
to such Grantor or other obligations owed to such Grantor, including all Indebtedness described on Schedule 1, issued by the obligors named therein. Pledged Debt Instruments excludes any Excluded Property. 

“Pledged Equity” means collectively, all Pledged Interests and Pledged Stock. 

“Pledged Interests” shall mean, with respect to each limited liability company, partnership or other organization listed on
Schedule 1, (i) the Stock in such limited liability company, partnership or other organization owned by a Grantor and listed on Schedule 1, and the certificates, if any, representing such interests and any interest of such Grantor, as
applicable, on the books and records of such limited liability company, partnership or other organization or on the books and records of any securities intermediary pertaining to such interests, (ii) the Stock of any other Person whose Stock is
at any time hereafter issued or granted to, or held by any Grantor, and (iii) all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or Proceeds from time to time received, receivable or
otherwise distributed in respect of or in exchange for any or all interests set forth in the preceding clauses (i) and (ii). Pledged Interests excludes any Excluded Property. 

“Pledged Investment Property” means the collective reference to (i) all “investment property” as such term is
defined in Section 9-102(a)(49) of the UCC and (ii) all “financial assets” as such term is defined in Section 8-102(a)(9) of the UCC, other than
any Pledged Equity or Pledged Debt Instruments. Pledged Investment Property excludes any Excluded Property. 
 “Pledged
Stock” shall mean, with respect to each corporation listed on Schedule 1, the Stock of such corporation owned by a Grantor and listed on Schedule 1, and the certificates, if any, representing such shares and any interest of
such Grantor, as applicable, in the entries on the books of the issuer of such shares or on the books of any securities intermediary pertaining to such shares and the Stock of any other Person whose Stock is at any time hereafter issued to or
granted to or held by any Grantor, and all dividends, 

  
 4 

 
distributions, cash, warrants, rights, options, instruments, securities and other property or Proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange
for any or all of such shares. Pledged Stock excludes any Excluded Property. 
 “Proceeds” means all “proceeds”
as such term is defined in Section 9-102(a)(64) of the UCC and, in any event, shall include all dividends or other income from the Pledged Investment Property, collections thereon or distributions or
payments with respect thereto. 
 “Receivable” means any right to payment for goods sold or leased or for services
rendered, whether or not such right is evidenced by an instrument or chattel paper and whether or not it has been earned by performance (including any accounts). 

“Secured Obligations” means the Obligations (including any Non-Callable Make Whole
Amount, any CoC Fee and the Exit Payment). 
 “Trademarks” means any and all trademarks, trade names, registered
trademarks, trademark applications, service marks, registered service marks and service mark applications, including (A) the trade names, registered trademarks, trademark applications, registered service marks and service mark applications
listed on Schedule 11, (B) all renewals thereof, (C) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including payments under all licenses entered into in connection therewith
and damages and payments for past or future infringements or dilutions thereof, (D) the right to sue for past, present and future infringements and dilutions thereof, (E) the goodwill of each Grantor’s business symbolized by the
foregoing or connected therewith, and (F) all of each Grantor’s rights corresponding thereto throughout the world. 

“Transferred Guarantor” has the meaning set forth in Section 8.16(c). 

SECTION 2 GUARANTY. 
 2.1 Guaranty.

 (a) To induce Lenders to make the Loans and each other Secured Party to make credit available to or for the benefit of one or more
Grantors and for the applicable Secured Parties to enter into the Loan Documents, each of the Guarantors hereby, jointly and severally, absolutely, unconditionally and irrevocably, as a primary obligor and not only a surety, guarantees to Agent and
the other Secured Parties and their respective successors and permitted assigns, the prompt and complete payment and performance by Borrower and each other Grantor, as applicable, of the Guaranteed Obligations when due (whether at the stated
maturity or earlier, by reason of acceleration, any mandatory prepayment required pursuant to the terms of the Financing Agreement or otherwise). 

(b) This guaranty includes all present and future Guaranteed Obligations including any under transactions continuing, compromising, extending,
increasing, modifying, releasing, or renewing the Guaranteed Obligations, changing the interest rate, payment terms, or other terms and conditions thereof, or creating new or additional Guaranteed Obligations after prior Guaranteed Obligations have
been satisfied in whole or in part. To the maximum extent permitted by law, each Guarantor hereby waives any right to revoke this guaranty as to future Guaranteed Obligations. If such a revocation is effective notwithstanding the foregoing waiver,
each Guarantor acknowledges and agrees that (i) no such revocation shall be effective until written notice thereof has been received by Agent, (ii) no such revocation shall apply to any Guaranteed Obligations in existence on the date of
receipt by Agent of such written notice (including any subsequent continuation, extension, or renewal thereof, or change in the interest rate, payment terms, or other terms and conditions thereof), (iii) no such revocation shall apply to any
Guaranteed Obligations 

  
 5 

 
made or created after such date to the extent made or created pursuant to a legally binding commitment of any Lender in existence on the date of such revocation, (iv) no payment by any
Guarantor, Borrower, or from any other source, prior to the date of Agent’s receipt of written notice of such revocation shall reduce the maximum obligation of such Guarantor hereunder, and (v) any payment by Borrower or from any source
other than such Guarantor subsequent to the date of such revocation shall first be applied to that portion of the Guaranteed Obligations as to which the revocation is effective and which are not, therefore, Guaranteed hereunder, and to the extent so
applied shall not reduce the maximum obligation of such Guarantor hereunder. This guaranty shall be binding upon each Guarantor, its successors and assigns and inure to the benefit of and be enforceable by Agent (for the benefit of the Secured
Parties) and its successors, transferees, or assigns. 
 (c) The guaranty contained in this Section 2 is a guaranty
of payment and not of collection and shall remain in full force and effect until all of the Guaranteed Obligations shall have been Paid in Full. 

(d) No payment made by Borrower, any of the Guarantors, any other guarantor or any other Person, or received or collected by Agent or the other
Secured Parties from Borrower, any of the Guarantors, any other guarantor or any other Person, as applicable, by virtue of any action or proceeding or any set-off or appropriation or application at any time or
from time to time in reduction of or in payment of the Guaranteed Obligations shall be deemed to modify, reduce, release or otherwise affect the Liability of any Guarantor hereunder which Guarantor shall, notwithstanding any such payment (other than
any payment received or collected from such Guarantor in respect of the Guaranteed Obligations), remain liable for the Guaranteed Obligations until the Guaranteed Obligations are Paid in Full. 

2.2 No Subrogation. Notwithstanding any payment made by any Guarantor hereunder or any set-off
or application of funds of any Guarantor by Agent or any other Secured Party, no Guarantor shall be entitled to be subrogated to any of the rights of Agent or any other Secured Party against Borrower or any Guarantor or any collateral security or
guaranty or right of offset held by Agent or any other Secured Party for the payment of the Guaranteed Obligations, nor shall any Guarantor seek or be entitled to seek any contribution or reimbursement from Borrower or any Guarantor in respect of
payments made by such Guarantor hereunder, until all of the Guaranteed Obligations are Paid in Full. If any amount shall be paid to any Guarantor on account of such subrogation rights at any time when all of the Guaranteed Obligations shall not have
been Paid in Full, such amount shall be held by such Guarantor in trust for Agent and the other Secured Parties, segregated from other funds of such Guarantor, and shall, forthwith upon receipt by such Guarantor, be turned over to Agent (for the
benefit of the Secured Parties) in the exact form received by such Guarantor (duly indorsed by such Guarantor to Agent), to be applied against the Guaranteed Obligations, whether matured or unmatured, as set forth in
Section 6.5 hereof. 
 2.3 Amendments, etc. with respect to the Guaranteed Obligations. 

(a) Each Guarantor shall remain obligated hereunder, without any reservation of rights against any Guarantor and without notice to or further
assent by any Guarantor, notwithstanding the fact that: (i) any demand for payment of any of the Guaranteed Obligations made by Agent or the other Secured Parties may be rescinded by Agent or the other Secured Parties and any of the Guaranteed
Obligations continued, (ii) the Guaranteed Obligations, or the Liability of any other Person upon or for any part thereof, or any collateral security or guaranty therefor or right of offset with respect thereto, may, from time to time, in whole
or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by Agent or any other Secured Party, or (iii) any of the Facility Agreement or the other Loan Documents or any other documents
executed and delivered in connection therewith may be amended, modified, supplemented or terminated, in whole or in part, as Agent or any other Secured Party may deem advisable from time to time. Agent and the other Secured Parties shall have no
obligation 

  
 6 

 
to protect, secure, perfect or insure any Lien at any time held by them as security for the Guaranteed Obligations or for the guaranty contained in this Section 2 or any
property subject thereto. 
 (b) Agent or any other Secured Party may, from time to time, in their reasonable discretion and without notice
to or demand upon the Guarantors (or any of them), take any or all of the following actions, without discharging or otherwise affecting the Obligations (including any Non-Callable Make Whole Amount, any CoC
Fee and the Exit Payment) of any Guarantor hereunder and without incurring any Liability hereunder: (i) receive, take and hold additional Collateral to secure any of the Guaranteed Obligations or any obligation hereunder, (ii) retain or
obtain the primary or secondary obligation of any obligor or obligors, in addition to the undersigned, with respect to any of the Guaranteed Obligations, (iii) extend or renew any of the Guaranteed Obligations for one or more periods (whether
or not longer than the original period), alter or exchange any of the Guaranteed Obligations or otherwise modify, amend, supplement or otherwise change any Guaranteed Obligation or any Loan Document (including accelerating or otherwise changing the
time of payment), or release or compromise any obligation of any of the undersigned hereunder or any obligation of any nature of any other obligor with respect to any of the Guaranteed Obligations or otherwise in connection with the Loan Documents,
(iv) release any guaranty or right of offset or their security interest in, or surrender, release or permit any substitution or exchange for, all or any part of any personal property securing any of the Guaranteed Obligations or any obligation
hereunder, or extend or renew for one or more periods (whether or not longer than the original period) or release, compromise, alter or exchange any obligations of any nature of any obligor with respect to any such personal property, (v) resort
to the undersigned (or any of them) for payment of any of the Guaranteed Obligations when due, whether or not Agent or any other Secured Party shall have resorted to any personal property securing any of the Guaranteed Obligations or any obligation
hereunder or shall have proceeded against any other of the undersigned or any other obligor primarily or secondarily obligated with respect to any of the Guaranteed Obligations, (vi) apply to the Guaranteed Obligations any sums by whomever paid
or however realized to any Guaranteed Obligation as set forth in Section 6.5 hereof, (vii) refund at any time any payment received by any Secured Party in respect of any Guaranteed Obligation, (viii) sell,
exchange, enforce, waive, substitute, liquidate, terminate, release, abandon, fail to perfect, subordinate, accept, substitute, surrender, exchange, affect, impair or otherwise alter or release any Collateral for any Guaranteed Obligation or any
other guaranty therefor in any manner, (ix) otherwise deal in any manner with Borrower or any other Guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and/or (x) settle, release, compromise, collect or otherwise
liquidate the Guaranteed Obligations. 
 2.4 Waivers. To the extent permitted by Applicable Law, each Guarantor hereby unconditionally
and irrevocably waives any and all notice of the creation, renewal, extension or accrual of any of the Guaranteed Obligations and notice of or proof of reliance by Agent or any other Secured Party upon the guaranty contained in this
Section 2 or acceptance of the guaranty contained in this Section 2. The Guaranteed Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or
renewed, extended, amended or waived, in reliance upon the guaranty contained in this Section 2, and all dealings between Borrower and any of the Guarantors, on the one hand, and Agent and the other Secured Parties, on the
other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon the guaranty contained in this Section 2. To the extent permitted by Applicable Law, each Guarantor hereby unconditionally
and irrevocably waives and agrees not to assert any claim, defense, setoff or counterclaim based on (i) diligence, promptness, presentment, protest, requirements for any demand for payment or performance and protest and notice of protest,
requirements for any notice of default, dishonor or nonpayment and all other notices whatsoever to or upon Borrower or any of the Guarantors with respect to the Guaranteed Obligations or any part thereof, (ii) notice of the existence or
creation or non-payment of all or any of the Guaranteed Obligations, (iii) all diligence in collection or protection of or realization upon any Guaranteed Obligations or any security for or guaranty of
any Guaranteed Obligations, (iv) any presentment, demand, protest or further notice or other formality or 

  
 7 

 
requirements of any kind with respect to any Guaranteed Obligation (including any accrued but unpaid interest thereon) becoming immediately due and payable, and (v) any defense arising by
reason of a disability or other defense of Borrower or any Guarantor. No obligation of any Guarantor hereunder shall be discharged other than by Payment in Full in cash of the Guaranteed Obligations. Each Guarantor further waives any right such
Guarantor may have under any Applicable Law to require any Secured Party to seek recourse first against Borrower or any other Person, or to realize upon any Collateral for any of the Obligations (including any
Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment), as a condition precedent to enforcing such Guarantor’s Liability and obligations under this Guaranty. 

2.5 Payments. Each Guarantor hereby guaranties that payments hereunder will be paid to Agent and the other Secured Parties without set-off or counterclaim in Dollars in accordance with Section 2.4 of the Facility Agreement. 

2.6 Limitation of Guaranty. Any term or provision of this Agreement or any other Loan Document to the contrary notwithstanding, the
maximum aggregate amount for which any Guarantor shall be liable hereunder shall not exceed the maximum amount for which such Guarantor can be liable without rendering this Agreement or any other Loan Document, as it relates to such Guarantor,
subject to avoidance under Applicable Laws relating to fraudulent conveyance or fraudulent transfer (including the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act and Section 548 of title 11 of the United States Code or
any applicable provisions of comparable Applicable Laws) (collectively, “Fraudulent Transfer Laws”). Any analysis of the provisions of this Agreement for purposes of Fraudulent Transfer Laws shall take into account the right of
contribution established in Section 2.7 hereof and, for purposes of such analysis, give effect to any discharge of intercompany debt as a result of any payment made under this Agreement. 

2.7 Contribution. To the extent that any Guarantor shall be required hereunder to pay any portion of any Guaranteed Obligation exceeding
the greater of (i) the amount of the value actually received by such Guarantor and its Subsidiaries from the Loans and other Obligations and (ii) the amount such Guarantor would otherwise have paid if such Guarantor had paid the aggregate
amount of the Guaranteed Obligations (excluding the amount thereof repaid by the Borrower and any other Guarantor that is a direct or indirect parent entity of the Borrower) in the same proportion as such Guarantor’s net worth on the date
enforcement is sought hereunder bears to the aggregate net worth of all the Guarantors on such date, then such Guarantor shall be reimbursed by such other Guarantors for the amount of such excess, pro rata, based on the respective net worth of such
other Guarantors on such date. 
 2.8 Guaranty Absolute and Unconditional. Each Guarantor hereby waives and agrees not to assert any
defense, whether arising in connection with or in respect of any of the following or otherwise, and hereby agrees that its obligations under this Agreement are irrevocable, absolute and unconditional and shall not be discharged as a result of or
otherwise affected by any of the following (which may not be pleaded and evidence of which may not be introduced in any proceeding with respect to this Agreement) to the fullest extent not prohibited by Applicable Law: 

(a) the invalidity or unenforceability of any obligation of Borrower or any Guarantor under any Loan Document or any other agreement or
instrument relating thereto (including any amendment, consent or waiver thereto), or any security for, or other guaranty of, any Guaranteed Obligation or any part thereof, or the lack of perfection or continuing perfection or failure of priority of
any security for the Guaranteed Obligations or any part thereof; 
 (b) the absence of (i) any attempt to collect any Guaranteed
Obligation or any part thereof from Borrower or any Guarantor or other action to enforce the same or (ii) any action to enforce any Loan Document or any Lien thereunder; 

  
 8 

 (c) the failure by any Person to take any steps to perfect and maintain any Lien on, or to
preserve any rights with respect to, any Collateral; 
 (d) any workout, insolvency, bankruptcy proceeding, reorganization, arrangement,
liquidation or dissolution by or against Borrower, any Guarantor or any of Borrower’s Subsidiaries or any procedure, agreement, order, stipulation, election, action or omission thereunder, including any discharge or disallowance of, or bar or
stay against collecting, any Guaranteed Obligation (or any interest thereon) in or as a result of any such proceeding; 
 (e) any
foreclosure, whether or not through judicial sale, and any other sale or other disposition of any Collateral or any election following the occurrence of an Event of Default by any Secured Party to proceed separately against any Collateral in
accordance with such Secured Party’s rights under any Applicable Law; or 
 (f) any other defense, setoff, counterclaim or any other
circumstance that might otherwise constitute a legal or equitable discharge of Borrower, any Guarantor or any Subsidiary of Borrower, in each case other than the Payment in Full in cash of the Guaranteed Obligations. 

2.9 Reliance. Each Guarantor hereby assumes responsibility for keeping itself informed of the financial condition of Borrower, each
Guarantor and any other guarantor, maker or endorser of any Guaranteed Obligation or any part thereof, and of all other circumstances bearing upon the risk of nonpayment of any Guaranteed Obligation or any part thereof that diligent inquiry would
reveal, and each Guarantor hereby agrees that no Secured Party shall have any duty to advise any Guarantor of information known to it regarding such condition or any such circumstances. In the event any Secured Party, in its sole discretion,
undertakes at any time or from time to time to provide any such information to any Guarantor, such Secured Party shall be under no obligation to (i) undertake any investigation not a part of its regular business routine, (ii) disclose any
information that such Secured Party, pursuant to accepted or reasonable commercial finance or banking practices, wishes to maintain confidential, or (iii) make any future disclosures of such information or any other information to any
Guarantor. 
 SECTION 3 GRANT OF SECURITY INTEREST. 

3.1 Grant. Each Grantor hereby collaterally assigns and grants to Agent, for the benefit of the Secured Parties, a Lien on and security
interest in all of its Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations. Notwithstanding the foregoing, no Lien
or security interest is hereby granted on any Excluded Property. Each Grantor hereby represents and warrants as of (i) the Agreement Date, (ii) the date of each amendment, consent or waiver of this Agreement or the Facility Agreement
executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement after the Agreement Date, on the date such new Grantor joins this Agreement, that the Excluded Property, when taken as a whole, is not material
to the business operations or financial condition of the Grantors, taken as a whole. 
 SECTION 4 REPRESENTATIONS AND WARRANTIES. 

To induce Agent and Lenders to enter into the Facility Agreement and to induce Lenders to make extensions of credit to Borrower thereunder,
each Grantor jointly and severally hereby represents and warrants to Agent and the other Secured Parties that the following are true, correct and complete, in each case to the extent and in the manner set forth herein, on the Agreement Date and as
of (i) the Agreement Date, (ii) the date of each amendment, consent or waiver of this Agreement or the Facility Agreement 

  
 9 

 
executed by any Grantor and (iii) solely with respect to any new Grantor that joins this Agreement after the Agreement Date, on the date such new Grantor joins this Agreement: 

4.1 Title; No Other Liens. Except for the Lien granted to Agent pursuant to this Agreement and other Permitted Liens, such Grantor owns,
or has rights or the power to transfer rights in, each item of the Collateral free and clear of any and all Liens of others. Such Grantor (i) is the record and beneficial owner of the Collateral pledged by it hereunder constituting instruments
or certificates and (ii) has rights in or the power to transfer each other item of Collateral in which a Lien is granted by it hereunder, free and clear of any other Lien (other than Permitted Liens). No effective financing statement or other
public notice with respect to all or any part of the Collateral is on file or of record in any public office, except filings evidencing Permitted Liens. 

4.2 Perfected Liens. The security interests granted in the Collateral pursuant to this Agreement (i) will constitute valid and
continuing perfected security interests in all of the Grantors’ rights in the Collateral in favor of Agent as collateral security for the Secured Obligations, enforceable in accordance with the terms hereof, except as such enforceability may be
limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally, upon (A) in the case of all Collateral in which a security interest may be perfected by filing a
financing statement under the UCC, completion of the filings and other actions specified on Schedule 2 (which filings and other documents referred to on Schedule 2 have been delivered to Agent in completed form), (B) with respect to
any deposit account or securities account, the execution of Control Agreements, (C) in the case of all Copyrights, Trademarks and Patents for which UCC filings are insufficient, all appropriate filings having been made with the applicable
Intellectual Property registries, including but not limited to the United States Copyright Office or the United States Patent and Trademark Office, as applicable, (D) in the case of letter-of-credit rights that are not supporting obligations of Collateral, the execution of a contractual obligation granting control to Agent over such letter-of-credit rights and (E) in the case of electronic chattel paper with payment or amounts owing thereon in excess of $250,000 in the aggregate, the completion of all steps necessary to grant
control to Agent over such electronic chattel paper; and (ii) shall be prior to all other Liens on the Collateral except for Permitted Priority Liens, upon (A) in the case of all Pledged Collateral and Pledged Investment Property, the
delivery thereof to Agent (for the benefit of the Secured Parties) of such Pledged Collateral and Pledged Investment Property consisting of instruments and certificates, in each case properly endorsed for transfer to Agent (for the benefit of the
Secured Parties) or in blank, (B) in the case of all Pledged Investment Property not in certificated form and deposit accounts, the execution of Control Agreements with respect to such Pledged Investment Property and deposit accounts and
(C) in the case of all other instruments and tangible chattel paper that has aggregate payments or amounts owing thereunder in excess of $250,000 in the aggregate that are not Pledged Collateral or Pledged Investment Property, the delivery
thereof to Agent (for the benefit of the Secured Parties) of such instruments and tangible chattel paper. Except as set forth in this Section 4.2 or as otherwise provided in the Facility Agreement, all actions by each
Grantor necessary or otherwise requested by Agent to perfect the Liens granted hereunder on the Collateral have been duly taken. 
 4.3
Grantor Information. On the Agreement Date, Schedule 3 sets forth (i) each Grantor’s and each Guarantor’s jurisdiction of organization, (ii) the location of each Grantor’s and each Guarantor’s chief
executive office, (iii) each Grantor’s and each Guarantor’s exact legal name as it appears on its organizational documents and (iv) each Grantor’s organizational identification number (to the extent a Grantor or Guarantor is
organized in a jurisdiction which assigns such numbers) and federal employer identification number. 
 4.4 Collateral Locations. On
the Agreement Date, Schedule 4 sets forth (i) each place of business of each Grantor and each Guarantor (including its chief executive office), (ii) all locations where any material portion of inventory and equipment owned by each
Grantor is kept (other than 

  
 10 

 
(A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts of inventory with sales
personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Facility Agreement), (iii) all locations where each Grantor’s books and records concerning the Collateral are kept and (iv) whether
each such Collateral location and place of business (including each Grantor’s chief executive office) is owned or leased (and if leased, specifies the complete name and notice address of each lessor) or otherwise occupied (and if otherwise
occupied, describes the nature of such occupation). On the Agreement Date, no Collateral (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business,
(B) de minimis amounts of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Facility Agreement) is located outside the United States or in the possession of any lessor,
bailee, warehouseman or consignee, except as indicated on Schedule 4. 
 4.5 Certain Property. None of the Collateral
constitutes, or is the Proceeds of, (i) farm products, (ii) as-extracted collateral, (iii) timber to be cut or (iv) vessels, aircraft or any other personal property subject to any
certificate of title or other registration statute of the United States, any State or other jurisdiction, except for motor vehicles owned by the Grantors and used by employees of the Grantors in the Ordinary Course of Business. 

4.6 Pledged Collateral and Pledged Investment Property. 

(a) The Pledged Collateral pledged by each Grantor hereunder is listed on Schedule 1 and, with respect to the Pledged
Equity, constitutes all the issued and outstanding equity interests of each Issuer owned by such Grantor as set forth on Schedule 1. None of the Pledged Equity is a certificated security or otherwise represented or evidenced by any
certificate other than the Pledged Equity in Nellix, Inc., CVD/RMS Acquisition Corp., RMS/Endologix Sideways Merger Corp., TriVascular, Inc. and TriVascular Technologies, Inc, and no foreign Issuer has certificated its Stock nor is any Grantor (or
any representative, agent or any other Related Party of any Grantor) holding any certificate of Stock of any foreign Issuer. 
 (b) All of
the Pledged Equity has been duly authorized and validly issued and, in the case of shares of capital stock and membership interests, is fully paid and nonassessable. 

(c) Each of the Pledged Equity, Pledged Debt Instruments and Pledged Investment Property constitutes the legal, valid and binding obligation of
the obligor with respect thereto, enforceable in accordance with its terms, except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights
generally. 
 (d) Schedule 1A lists all Pledged Investment Property owned by each Grantor. Each Grantor is the record and beneficial
owner of, and has good and valid title to, the Pledged Investment Property pledged by it hereunder, free of any and all Liens or options in favor of, or claims of, any other Person, except Permitted Liens. 

(e) All Pledged Collateral (other than uncertificated Pledged Equity) and all Pledged Investment Property consisting of instruments and
certificates has been delivered to Agent (for the benefit of the Secured Parties) in accordance with Section 5.1 hereof to the extent required thereby. 

(f) Upon the occurrence and during the continuance of an Event of Default, Agent shall be entitled to exercise all of the rights of the Grantor
granting the security interest in any Pledged Equity, and a transferee or assignee of such Pledged Equity shall become a holder of such Pledged Equity to the same extent as such Grantor and be entitled to participate in the management of the Issuer
of such 

  
 11 

 
Pledged Equity, and, subject to Agent’s exercise of remedies pursuant to Section 6 hereof, upon the transfer of the entire interest of such Grantor, such Grantor
shall, by operation of law, cease to be a holder of such Pledged Equity. 
 4.7 Receivables. 

(a) No amount over $250,000 in the aggregate payable to a Grantor under or in connection with any account is evidenced by any instrument or
chattel paper which, to the extent required hereunder, has not been delivered to Agent (for the benefit of the Secured Parties), properly endorsed for transfer. 

(b) No obligor on any Receivable in excess of $250,000 in the aggregate is a Governmental Authority, unless any assignment of claims act or law
has been complied with for the benefit of Agent. 
 4.8 Facility Agreement. Each Grantor and each Guarantor makes each of the
representations and warranties made by Borrower in Section 3.1 of the Facility Agreement to the extent applicable to it on the date such Grantor or Guarantor becomes a party hereto (which representations and warranties
shall be deemed to be re-made (i) as of the date of each amendment, consent or waiver of this Agreement or the Facility Agreement executed by any Grantor and (iii) solely with respect to any new
Grantor that joins this Agreement after the Agreement Date, on the date such new Grantor joins this Agreement). Such representations and warranties shall be incorporated herein by this reference as if fully set forth herein. 

4.9 Commercial Tort Claims. The only commercial tort claims that any Grantor is asserting or intends to assert in which the potential
recovery exceeds $250,000 in the aggregate are those listed on Schedule 5, as may be supplemented from time to time by delivery thereof to Agent, which sets forth such information separately for each Grantor. 

4.10 Enforcement. No material permit, notice to or filing with any Governmental Authority or any other Person or any material consent
from any Person is required for the exercise by Agent of its rights (including voting rights) provided for in this Agreement or the enforcement of remedies in respect of the Collateral pursuant to this Agreement, including the transfer of any
Collateral, except (i) as may be required in connection with the disposition of any portion of the Pledged Collateral by laws affecting the offering and sale of securities generally, (ii) any approvals that may be required to be obtained
from any bailees or landlords to collect the Collateral, (iii) permits or consents which have been obtained and notices or filings which have been made, and (iv) any requirements set forth in any assignment of claims act and laws. 

4.11 Accounts. Set forth on Schedule 6 (as such Schedule may be expressly updated from time to time to reflect changes resulting
from transactions permitted under the Loan Documents) is a listing of all of Grantors’ and their Subsidiaries’ deposit accounts and securities accounts, including, with respect to each bank or securities intermediary (a) the name and
address of such Person, and (b) the account numbers of the deposit accounts or securities accounts maintained with such Person. 
 4.12
Real Estate. Schedule 7 sets forth all Real Estate owned by any of the Grantors as of the Agreement Date. 
 4.13
Intellectual Property. As of the Agreement Date: (i) Schedule 8 provides a complete and correct list of all registered Copyrights owned by any Grantor and all other Copyrights owned by any Grantor and material to the conduct of
the business of any Grantor; (ii) Schedule 9 provides a 

  
 12 

 
complete and correct list of all Intellectual Property Licenses (other than license agreements for commercially available
off-the-shelf software that is generally available to the public which have been licensed to a Grantor pursuant to end-user
licenses) entered into by any Grantor that are material to the business of such Grantor, including any Intellectual Property Licenses that relate to Intellectual Property that is incorporated in any Inventory, software, or other product marketed,
sold, licensed, or distributed by such Grantor; (iii) Schedule 10 provides a complete and correct list of all Patents owned by any Grantor; and (iv) Schedule 11 provides a complete and correct list of all registered
Trademarks owned by any Grantor and all other Trademarks owned by any Grantor and material to the conduct of the business of any Grantor. 
 SECTION 5
COVENANTS. 
 Each Grantor covenants and agrees with Agent that, from and after the date of this Agreement until the Secured
Obligations and the Guaranteed Obligations, as applicable, shall have been Paid in Full: 
 5.1 Delivery of Instruments, Certificated
Securities and Chattel Paper. 
 (a) Such Grantor shall (i) deliver to Agent (for the benefit of the Secured Parties), in suitable
form for transfer and in form and substance reasonably satisfactory to Agent, (A) all certificated Pledged Equity, together with stock powers or other suitable instruments for transfer, executed in blank, (B) all Pledged Debt Instruments
and (C) all certificates and instruments evidencing Pledged Investment Property and (ii) to the extent required by Section 5.1(k) of the Facility Agreement, maintain all other Pledged Investment Property in an
account that is subject to a Control Agreement. No foreign Issuer shall issue certificates of its Stock unless the foregoing provisions of this paragraph are complied with. 

(b) If any amount in excess of $250,000 in the aggregate payable under or in connection with any Collateral owned by such Grantor shall be or
become evidenced by an instrument or tangible chattel paper other than such instrument delivered in accordance with this Section 5.1 and in the possession of Agent, such Grantor shall notify Agent, and upon the written
request of Agent, mark all such instruments and tangible chattel paper with the following legend: “This writing and the obligations evidenced or secured hereby are subject to the security interest of Deerfield Private Design Fund IV, L.P., as
Agent” and, at the written request of Agent, shall promptly deliver such instrument or tangible chattel paper to Agent (for the benefit of the Secured Parties), duly indorsed in a manner reasonably satisfactory to Agent. 

(c) Such Grantor shall not grant “control” (within the meaning of such term under Article
9-106 of the UCC) over any Pledged Collateral or Pledged Investment Property to any Person other than Agent (for the benefit of the Secured Parties) or, to the extent permitted under (and subject to the terms
of) the Intercreditor Agreement and subject to the terms of Section 8.21, the ABL Agent. 
 (d) If such Grantor is
or becomes the beneficiary of a letter of credit that is (i) not a supporting obligation of any Collateral and (ii) in excess of $250,000 in the aggregate, such Grantor shall promptly, and in any event within five (5) Business Days
after becoming a beneficiary, notify Agent thereof and shall use commercially reasonable efforts to enter into a contractual arrangement reasonably requested by the Agent with respect to the letter-of-credit rights under such letter of credit. Such contractual arrangement shall assign such letter-of-credit rights to
Agent and such assignment shall be sufficient to grant control for the purposes of Section 9-107 of the UCC (or any similar section under any equivalent UCC). Such contractual arrangement shall also
direct all payments thereunder to an account subject to a Control Agreement. The provisions of the contractual arrangement shall be in form and substance reasonably satisfactory to Agent. 

  
 13 

 (e) If any amount in excess of $250,000 in the aggregate payable under or in connection with
any Collateral owned by such Grantor shall be or become evidenced by electronic chattel paper, such Grantor shall take all commercially reasonable steps necessary to grant Agent control of all such electronic chattel paper for the purposes of Section 9-105 of the UCC (or any similar section under any equivalent UCC) and all “transferable records” as defined in each of the Uniform Electronic Transactions Act and the Electronic Signatures in
Global and National Commerce Act. 
 (f) In the event that an Event of Default shall have occurred and be continuing, upon the request of
Agent, any instrument, certificated security or chattel paper not theretofore delivered to Agent and at such time being held by such Grantor shall be promptly (and, in any event, within five (5) Business Days) delivered to Agent (for the
benefit of the Secured Parties), duly indorsed in a manner satisfactory to Agent, to be held as Collateral pursuant to this Agreement and in the case of electronic chattel paper, such Grantor shall cause Agent to have control thereof within the
meaning set forth in Section 9-105 of the UCC. In the event that an Event of Default shall have occurred and be continuing, Agent shall have the right, at any time in its discretion and without notice to
any Grantor, to (i) transfer to or to register in its name or in the name of its nominees any Pledged Collateral or any Pledged Investment Property and (ii) exchange any certificate or instrument representing or evidencing any Pledged
Collateral or any Pledged Investment Property for certificates or instruments of smaller or larger denominations. 
 5.2 Maintenance of
Perfected Security Interest; Further Documentation. 
 (a) Such Grantor shall maintain the security interests created by this Agreement
as perfected security interests (to the extent such security interests can be perfected by the filing of UCC financing statements (and, with respect to commercial tort claims, to the extent any commercial tort claims are sufficiently identified
herein)) having at least the priority described in Section 4.2 hereof, and shall defend such security interests against the claims and demands of all Persons whomsoever (other than holders of Permitted Liens). 

(b) Subject to Section 5.1(q) of the Facility Agreement, such Grantor will furnish to Agent from time to time
statements and schedules further identifying and describing the assets and property of such Grantor and such other reports in connection therewith as Agent may reasonably request, all in reasonable detail in form and substance reasonably
satisfactory to Agent. 
 (c) At any time and from time to time, upon the written request of Agent, and at Grantor’s sole expense, such
Grantor will, for the purpose of obtaining or preserving the full benefits of this Agreement and of the rights and powers herein granted, promptly and duly execute and deliver, and have recorded, such further instruments and documents and take such
further actions as Agent may reasonably request, including (i) filing or authorizing the filing of any financing or continuation statements under the UCC (or other similar laws) in effect in any jurisdiction with respect to the security
interests created hereby; (ii) in the case of Pledged Collateral, Pledged Investment Property and any other relevant Collateral, taking any such reasonably requested actions necessary to enable Agent (on behalf of the Secured Parties) to obtain
“control” (within the meaning of the applicable UCC) with respect to such Pledged Collateral, Pledged Investment Property and other Collateral to the extent required to be pledged hereunder; (iii) if requested by Agent, delivering, to
the extent permitted by Applicable Law, any original motor vehicle certificates of title for vehicles in the aggregate with a fair market value in excess of $250,000 received by such Grantor from the applicable secretary of state or other
Governmental Authority after information reflecting Agent’s security interest has been recorded in such motor vehicles to the extent required to be pledged thereunder; (iv) use of commercially reasonable efforts to secure all approvals
necessary or appropriate for the assignment to or the benefit of Agent of any contractual obligation held by such Grantor and to enforce the security interests hereunder; and (v) subject to Section 5.1(k) of the
Facility Agreement, executing and delivering any Control Agreements with respect to deposit, securities, commodity and 

  
 14 

 
similar accounts. 
 (d) Such Grantor shall not use or permit any Collateral to be used
unlawfully or in violation of any provision of any Loan Document or any policy of insurance covering the Collateral. 
 5.3 Changes in
Locations, Name, etc. Such Grantor shall not, except upon 10 Business Days’ prior written notice to Agent (or such lesser notice as Agent may agree to in writing in its sole discretion) and delivery to Agent of (i) all additional
financing statements and other documents reasonably requested by Agent as to the validity, perfection and priority of the security interests provided for herein and (ii) if applicable, a written supplement to Schedule 4 showing any
additional location at which inventory or equipment shall be kept (other than (A) inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing in the Ordinary Course of Business, (B) de minimis amounts
of inventory with sales personnel and at medical facilities or (C) otherwise disposed of in a transaction permitted by the Facility Agreement): 

(a) permit any of the inventory or equipment comprising Collateral to be kept at a location subject to the possession or control of any
warehouse, consignee, bailee, or any of the Grantors’ agents or processors other than those listed on Schedule 4, other than (i) the inventory or equipment that is otherwise in transit or out for repair, refurbishment or processing
in the Ordinary Course of Business, (ii) de minimis amounts of inventory with sales personnel and at medical facilities or (iii) otherwise disposed of in a transaction permitted by the Facility Agreement; 

(b) change its jurisdiction of organization or the location of its chief executive office from that specified on Schedule 3 or in any
subsequent notice delivered pursuant to this Section 5.3; or 
 (c) change its name, organizational identification
number (if any), identity or corporate structure, except as permitted by Section 5.2(i) of the Facility Agreement upon prior written notice thereof to the Agent. 

5.4 Notices. Such Grantor will advise Agent in writing promptly, in reasonable detail, of: 

(a) any Lien (other than Permitted Liens) on any of the Collateral; and 

(b) the occurrence of any other event which would reasonably be expected to have a Material Adverse Effect on the Collateral or on the Liens
created hereby. 
 5.5 Pledged Investment Property and Pledged Collateral. 

(a) If such Grantor shall become entitled to receive or shall receive any certificate, option or rights in respect of the Stock of any Issuer,
whether in addition to, in substitution of, as a conversion of, or in exchange for, any of the Pledged Equity, or otherwise in respect thereof, such Stock shall be Pledged Equity (to the extent consistent with the percentage of such Grantor’s
Stock in such Issuer pledged hereunder, as set forth on Schedule 1) and such Grantor shall accept the same as the agent of Agent, hold the same in trust for Agent (for the benefit of the Secured Parties) and deliver the same forthwith to
Agent (for the benefit of the Secured Parties) in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties), if required by Agent, together with an undated instrument of transfer covering such
certificate duly executed in blank by such Grantor and with, if Agent so request, signature guarantied, to be held by Agent (for the benefit of the Secured Parties), subject to the terms hereof, as additional Collateral for the Secured Obligations.

  
 15 

 (b) Upon the occurrence and during the continuance of an Event of Default and the request of
Agent, (i) any sums paid upon or in respect of the Pledged Collateral or Pledged Investment Property upon the liquidation or dissolution of any Issuer shall be paid over to Agent (for the benefit of the Secured Parties) to be held by it
hereunder as additional Collateral for the Secured Obligations, and (ii) in case any distribution of capital shall be made on or in respect of the Pledged Collateral, or any property shall be distributed upon or with respect to the Pledged
Collateral, pursuant to the recapitalization or reclassification of the capital of any Issuer or pursuant to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected Lien in favor of Agent, be delivered
to Agent (for the benefit of the Secured Parties) to be held by it hereunder as additional Collateral for the Secured Obligations. Upon the occurrence and during the continuance of an Event of Default, if any sums of money or property so paid or
distributed in respect of the Pledged Investment Property shall be received by a Grantor, such Grantor shall, at the request of Agent and until such money or property is paid or delivered to the applicable Secured Parties, hold such money or
property in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor, as additional Collateral for the Secured Obligations. 

(c) Without the prior written consent of Agent, no Grantor will (i) vote to enable, or take any other action, to permit any Issuer to
issue any Stock of any nature or to issue any other securities or interests convertible into or granting the right to purchase or exchange for any Stock of any nature of any Issuer, except, in each case, as permitted by the Facility Agreement,
(ii) sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, the Pledged Investment Property or Proceeds thereof other than any such action which is permitted by the Facility Agreement, (iii) create,
incur or permit to exist any Lien or option in favor of, or any claim of any Person with respect to, any of the Pledged Investment Property or Proceeds thereof, or any interest therein, except for Permitted Liens, or (iv) enter into any
agreement or undertaking restricting the right or ability of such Grantor or Agent to sell, assign or transfer any of the Pledged Investment Property or Proceeds thereof, except with respect to Permitted Liens and any such action which is permitted
by the Facility Agreement. 
 (d) In the case of each Grantor which is an Issuer, such Issuer agrees that (i) it will be bound by the
terms of this Agreement relating to the Pledged Equity issued by it and will comply with such terms insofar as such terms are applicable to it, (ii) it will notify Agent promptly in writing of the occurrence of any of the events described in
Sections 5.5(a) and 5.5(b) hereof with respect to the Pledged Equity issued by it and (iii) the terms of Sections 6.3(c) and 6.7 hereof shall apply to such Grantor with respect to all actions that may be required of
it pursuant to Section 6.3(c) or 6.7 hereof regarding the Pledged Equity issued by it. 
 5.6
Receivables. Other than in the Ordinary Course of Business consistent with its past practice, such Grantor will not (i) grant any extension of the time of payment of any Receivable, (ii) compromise or settle any Receivable for less
than the full amount thereof, (iii) release, wholly or partially, any Person liable for the payment of any Receivable, (iv) allow any credit or discount whatsoever on any Receivable or (v) amend, supplement or modify any Receivable in
any manner that would reasonably be expected to adversely affect the value thereof, in each case, unless taking the foregoing actions would not reasonably be expected, individually or in the aggregate, to cause a Material Adverse Effect. 

5.7 Intellectual Property. Except as permitted by the Facility Agreement, or except, in each case, where the failure to do so could not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, provided that no such Material Adverse Effect qualifier should apply to Section 5.7(h) hereof: 

(a) Upon the request of Agent, in order to facilitate filings with the United States Patent and Trademark Office and the United States
Copyright Office, each Grantor shall execute and 

  
 16 

 
deliver to Agent one or more Copyright Security Agreements, Trademark Security Agreements, or Patent Security Agreements to further evidence Agent’s Lien on such Grantor’s Patents,
Trademarks, or Copyrights, and the General Intangibles of such Grantor relating thereto or represented thereby. 
 (b) Such Grantor (either
itself or through licensees) will (i) continue to use each Trademark (owned by such Grantor), in order to maintain such Trademark in full force and effect free from any claim of abandonment for non-use,
(ii) maintain as in the past the quality of products and services offered under such Trademark, (iii) use, and cause its licensees and sublicensees to use, such Trademark with the appropriate notice of registration and all other notices
and legends required by Applicable Law, (iv) not adopt or use any mark which is confusingly similar or a colorable imitation of such Trademark unless Agent shall obtain a perfected security interest in such Trademark pursuant to this Agreement
and (v) not (and not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby such Trademark (or any goodwill associated therewith) may become destroyed, harmed, invalidated or impaired in any way. 

(c) Each Grantor (either itself or through licensees) will not do any act, or omit to do any act, whereby as a result of such act or omission,
any Patent owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, will employ, and cause its licensees and sublicensees to employ, each such Patent with the appropriate notice of registration
and all other notices and legends required by Applicable Law, and will take commercially reasonable steps to establish and preserve the Patents in any patentable invention under Applicable Law. 

(d) Each Grantor (either itself or through licensees) (i) will employ, and cause its licensees and sublicensees to employ, each Copyright
owned by such Grantor with the appropriate notice of registration and all other notices and legends required by Applicable Law, and (ii) will not (and will not permit any licensee or sublicensee thereof to) do any act or omit to do any act
whereby such Copyrights may become invalidated or otherwise impaired, and (iii) will not (either itself or through licensees or sublicensees) do any act whereby any such Copyrights may fall into the public domain. 

(e) Each Grantor (either itself or through licensees or sublicensees) will not (and will not permit any licensee or sublicensee thereof to) do
any act or omit to do any act whereby any trade secret may become unenforceable under any Applicable Law and each Grantor shall take reasonable steps to maintain the confidentiality of, and otherwise protect and enforce its rights in, the
Intellectual Property that is necessary in or material to the conduct of such Grantor’s business, including, as applicable (A) protecting the secrecy and confidentiality of its confidential information and trade secrets by having and
enforcing a policy requiring all current employees, consultants, licensees, vendors and contractors with access to such information to execute appropriate confidentiality agreements; (B) taking actions reasonably necessary to ensure that no
trade secret falls into the public domain due to any action of any Grantor; and (C) protecting the secrecy and confidentiality of the source code of all software programs and applications of which it is the owner or licensee by having and
enforcing a policy requiring any licensees (or sublicensees) of such source code to enter into license agreements with commercially reasonable use and non-disclosure restrictions. 

(f) Such Grantor (either itself or through licensees or sublicensees) will not do any act that infringes, misappropriates, dilutes, violates or
otherwise impairs the Intellectual Property or intellectual property rights of any other Person. 
 (g) Such Grantor will notify Agent
promptly if it knows, or has reason to know, that any application or registration relating to any Intellectual Property owned by such Grantor may become unenforceable, invalidated, forfeited, abandoned or dedicated to the public, or of any
determination or development (including the institution of, or any such determination or development in, any proceeding in 

  
 17 

 
the United States Patent and Trademark Office, the United States Copyright Office or any court or tribunal in any country) regarding such Grantor’s ownership of, or the validity of, any such
Intellectual Property or such Grantor’s right to register the same or to own and maintain the same. 
 (h) At the time of delivery of
any Perfection Certificate required by Section 5.1(t) of the Facility Agreement, each Grantor will notify Agent of applications filed for the registration of any Intellectual Property with the United States Patent and
Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof. Upon the request of Agent, within five (5) Business Days, such Grantor shall execute and deliver,
and have recorded, any and all agreements, instruments, documents, and papers as Agent may request to evidence Agent’s security interest in any Intellectual Property owned by such Grantor, including any Copyright, Patent or Trademark and the
goodwill and general intangibles of such Grantor relating thereto or represented thereby. 
 (i) Such Grantor will take all actions that are
necessary or reasonably requested by Agent to maintain and pursue each application (and to obtain the relevant registration or recordation) and to maintain each registration and recordation of all Intellectual Property owned by it. 

(j) In the event that any Intellectual Property owned by a Grantor is, to its knowledge, infringed upon or misappropriated or diluted by a
third party, such Grantor shall, subject to Section 5.1(q) of the Facility Agreement, (i) take such actions as such Grantor shall reasonably deem appropriate under the circumstances to protect such Intellectual Property and
(ii) promptly notify Agent after it learns thereof and sue for infringement, misappropriation or dilution, to seek injunctive relief where appropriate and to recover any and all damages for such infringement, misappropriation or dilution. 

(k) Each Grantor shall require all employees, consultants, and contractors of such Grantor who are involved in the creation or development of
any Intellectual Property for such Grantor to sign agreements that presently assigned all Intellectual Property created or developed for the Grantor to such Grantor, and obligate such employee, consulting or contractor to hold all confidential
information of the Grantor (or of any other Person and held by the Grantor) in confidence. 
 (l) Grantors acknowledge and agree that no
Secured Party shall have any duties with respect to any Intellectual Property or Intellectual Property Licenses of any Grantor. Without limiting the generality of this Section 5.7(l), Grantors acknowledge and agree that no
Secured Party shall be under any obligation to take any steps necessary to preserve rights in the Collateral consisting of Intellectual Property or Intellectual Property Licenses against any other Person, but any Secured Party may do so at its
option from and after the occurrence and during the continuance of an Event of Default, and all expenses incurred in connection therewith (including reasonable fees and expenses of attorneys and other professionals) shall be for the sole account of
Borrower and the other Grantors. 
 5.8 [Reserved]. 

5.9 Other Matters. 
 (a)
Each Grantor authorizes Agent and its Affiliates directors, partners, officers, employees, agents, counsel and advisors to, at any time and from time to time, file or record financing statements, continuation statements, amendments thereto, and
other filing or recording documents or instruments with respect to any Collateral in such forms and in such offices as Agent or such other Person reasonably determines appropriate to perfect, or continue or maintain perfection of, the security
interests of Agent under this Agreement, and such statements, amendments, documents, and instruments may describe the Collateral covered thereby as “all assets of the debtor” of each Grantor, or words of similar effect and may contain any
other information required pursuant to the UCC for the sufficiency of filing office 

  
 18 

 
acceptance of any financing statement, continuation statement or amendment, and each Grantor agrees to furnish any such information to Agent promptly upon Agent’s reasonable request. Any
such financing statement, continuation statement or amendment may be signed by Agent on behalf of any Grantor and may be filed at any time in any jurisdiction. A copy of this Agreement shall be sufficient as a financing statement or other filing or
recording document or instrument for filing or recording in any jurisdiction. Such Grantor also hereby ratifies its authorization for Agent to have filed any initial financing statement or amendment thereto under the UCC (or other similar laws) in
effect in any jurisdiction if filed prior to the date hereof. To the extent permitted by law, each Grantor hereby (i) waives any right under the UCC or any other Applicable Law to receive notice and/or copies of any filed or recorded financing
statements, amendments thereto, continuations thereof or termination statements and (ii) releases and excuses each Secured Party from any obligation under the UCC or any other Applicable Law to provide notice or a copy of any such filed or
recorded documents. As this Agreement constitutes an amendment and restatement of the Existing Guaranty and Security Agreement, the parties to this Agreement do hereby acknowledge and agree that those financing statements currently on record naming
the applicable Grantors as “Debtor” and the Agent as “Secured Party”, shall continue in full force and effect (as amended, if applicable) and shall continue to perfect the security interests and Liens granted under the Existing
Guaranty and Security Agreement and reaffirmed, ratified and re-granted under this Agreement. 
 (b)
Each Grantor shall, at any time and from time and to time, take such steps as the Agent may reasonably request for Agent to insure the continued perfection and priority of Agent’s security interest in any of the Collateral and of the
preservation of its rights therein. 
 (c) If any Grantor shall at any time, acquire a commercial tort claim as set forth in
Section 4.9 hereof, such Grantor shall promptly notify Agent thereof in writing and supplement Schedule 5, therein providing a reasonable description and summary thereof, and upon delivery thereof to Agent, such
Grantor shall be deemed to thereby grant to Agent (and such Grantor hereby grants to Agent) a Lien in and to such commercial tort claim and all Proceeds thereof, all upon the terms of and governed by this Agreement, and such Grantor shall execute
and deliver to Agent, in each case in form and substance reasonably satisfactory to Agent, any document, and take all other action, deemed by Agent to be reasonably necessary or appropriate for Agent to obtain, for the benefit of the Secured
Parties, a perfected security interest in all such commercial tort claims. Any supplement to Schedule 5 delivered pursuant to this Section 5.9(c) shall, after the receipt thereof by Agent, become part of Schedule
5 for all purposes hereunder other than in respect of representations and warranties made prior to the date of such receipt. 
 5.10
Facility Agreement. Each of the Grantors covenants that it will, and, if necessary, will cause or enable Borrower to, fully comply with each of the covenants and other agreements set forth in the Facility Agreement. 

5.11 Agent May Purchase Insurance. If a Grantor at any time or times hereafter shall fail to obtain, maintain or provide to Agent
evidence of any of the policies of insurance or other items required under Section 5.1(e) of the Facility Agreement or to pay any premium relating thereto, then Agent, without waiving or releasing any obligation or default
by such Grantor hereunder, may (but shall be under no obligation to) obtain and maintain such policies of insurance and pay such premiums and take such other actions with respect thereto as Agent deems advisable upon notice to such Grantor. Such
insurance, if obtained by Agent, may, but need not, protect such Grantor’s interests or pay any claim made by or against such Grantor with respect to the Collateral. Such insurance may be more expensive than the cost of insurance such Grantor
may be able to obtain on its own and may be cancelled only upon such Grantor providing evidence that it has obtained the insurance as required above. All sums disbursed by Agent in connection with any such actions shall constitute Secured
Obligations and Guaranteed Obligations payable upon demand. 

  
 19 

 5.12 Further Assurances. 

(a) Each Grantor agrees that from time to time, at its own expense, such Grantor will promptly execute and deliver all further instruments and
documents, and take all further action, that Agent may reasonably request, in order to perfect and protect the security interest and Lien granted hereby, to create, perfect or protect the security interest and Lien purported to be granted hereby or
to enable Agent to exercise and enforce its rights and remedies hereunder with respect to any of the Collateral. 
 (b) Grantor acknowledges
that it is not authorized to file any financing statement or amendment or termination statement with respect to any financing statement filed in connection with this Agreement, the other Loan Documents or the Existing Loan Documents without the
prior written consent of Agent, subject to such Grantor’s rights under Section 9-509(d)(2) of the UCC. 

SECTION 6 REMEDIAL PROVISIONS. 
 6.1
Certain Matters Relating to Receivables. Subject to, in each case, the terms of the Intercreditor Agreement (to the extent applicable): 

(a) At any time and from time to time after the occurrence and during the continuance of an Event of Default, Agent shall have the right to
make test verifications of the Receivables in any manner and through any medium that it reasonably considers advisable, and each Grantor shall furnish all such assistance and information as Agent may reasonably require in connection with such test
verifications. At any time and from time to time after the occurrence and during the continuance of an Event of Default, upon request of the Agent and at the expense of the relevant Grantor, such Grantor shall cause independent public accountants or
others satisfactory to Agent to furnish to Agent reports showing reconciliations, agings and test verifications of, and trial balances for, the Receivables. 

(b) If requested by Agent at any time after the occurrence and during the continuance of an Event of Default, any payments of Receivables, when
collected by any Grantor, (i) shall be forthwith (and, in any event, within two (2) Business Days) deposited by such Grantor in the exact form received, duly indorsed by such Grantor to Agent (for the benefit of the Secured Parties) and
upon notice to such Grantor, in a collateral account maintained under the sole dominion and control of Agent, subject to withdrawal by Agent as provided in Section 6.4 hereof, and (ii) until so turned over, shall be
held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other funds of such Grantor. Each such deposit of Proceeds of Receivables shall be accompanied by a report identifying in reasonable detail the nature
and source of the payments included in the deposit. 
 (c) At any time and from time to time after the occurrence and during the continuance
of an Event of Default, at the request of Agent, each Grantor shall deliver to Agent all original and other documents evidencing, and relating to, the agreements and transactions which gave rise to the Receivables, including all original orders,
invoices and shipping receipts and notify account debtors that the accounts or general intangibles that are Collateral have been collaterally assigned to Agent and that payments in respect thereof shall be made directly to Agent. 

(d) Each Grantor hereby irrevocably authorizes and empowers Agent, in Agent’s sole discretion, at any time after the occurrence and during
the continuance of an Event of Default, without notice to such Grantor: (i) to limit or terminate the ability of a Grantor to collect its Receivables or any thereof; to assert, either directly or on behalf of such Grantor, any claim such
Grantor may from time to time have against account debtors and to otherwise enforce such Grantor’s rights against such account debtors; (ii) to receive and collect any and all damages, awards and other monies resulting therefrom and to
apply the same to the Secured Obligations as set forth in Section 6.5 hereof; and (iii) in its own name or in the 

  
 20 

 
name of others, to communicate with account debtors to verify with them to Agent’s reasonable satisfaction the existence, amount and terms of any account or amounts due under any general
intangible that is Collateral. 
 6.2 Communications with Obligors; Grantors Remain Liable. 

(a) Agent in its own name or in the name of others may at any time after the occurrence and during the continuance of an Event of Default
communicate with obligors under the Receivables to verify with them to Agent’s satisfaction the existence, amount and terms of any Receivables 

(b) Subject to the terms of the Intercreditor Agreement (to the extent applicable), upon the request of Agent at any time after the occurrence
and during the continuance of an Event of Default, each Grantor shall notify obligors on the Receivables that the Receivables have been assigned to Agent and that payments in respect thereof shall be made directly to Agent. 

(c) Anything herein to the contrary notwithstanding, each Grantor shall remain liable in respect of each of the Receivables to observe and
perform all the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of any agreement giving rise thereto. No Secured Party shall have any obligation or Liability under any Receivable (or any
agreement giving rise thereto) by reason of or arising out of any Loan Document or the receipt by Agent or any other Secured Party of any payment relating thereto, nor shall any Secured Party be obligated in any manner to perform any of the
obligations of any Grantor under or pursuant to any Receivable (or any agreement giving rise thereto), to make any payment, to make any inquiry as to the nature or the sufficiency of any payment received by it or as to the sufficiency of any
performance by any party thereunder, to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time or times. 

6.3 Pledged Investment Property and Pledged Collateral. 

(a) Unless an Event of Default shall have occurred and be continuing and until Agent has notified Borrower otherwise, each Grantor shall be
permitted to receive all cash dividends and distributions paid in respect of the Pledged Collateral and all payments made in respect of the Pledged Investment Property, to the extent permitted in the Facility Agreement, and to exercise all voting
and other rights with respect to the Pledged Collateral and Pledged Investment Property; provided, that no vote shall be cast or other right exercised or action taken that could be reasonably likely to materially impair the Collateral or
which would be inconsistent with or result in any violation of any provision of the Facility Agreement, this Agreement or any other Loan Document. 

(b) If an Event of Default shall occur and be continuing: (i) Agent shall have the right to receive any and all cash dividends and
distributions, payments or other Proceeds paid in respect of the Pledged Collateral and Pledged Investment Property and make application thereof to the Secured Obligations as set forth in Section 6.5 hereof, (ii) Agent
shall have the right to cause any or all of the Pledged Collateral and Pledged Investment Property to be registered in the name of Agent or its nominee and (iii) Agent or its nominee may exercise (x) all voting, consent, corporate and
other rights pertaining to such Pledged Collateral and Pledged Investment Property at any meeting of shareholders, partners or members, as the case may be, of the relevant Issuer or Issuers or otherwise (or by written consent) and (y) any and
all rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Pledged Collateral and Pledged Investment Property as if it were the absolute owner thereof (including the right to exchange at its
discretion any and all of the Pledged Collateral and Pledged Investment Property upon the merger, amalgamation, consolidation, reorganization, recapitalization or other fundamental change in the corporate or other structure of any Issuer, or upon
the exercise by any 

  
 21 

 
Grantor or Agent of any right, privilege or option pertaining to such Pledged Collateral and Pledged Investment Property, and in connection therewith, the right to deposit and deliver any and all
of the Pledged Collateral and Pledged Investment Property with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as Agent may determine), all without Liability other than to the extent
such Liability is a result of its own willful misconduct or gross negligence as determined by a court of competent jurisdiction in a final non-appealable order or to account for property actually received by
it, but Agent shall have no duty to any Grantor to exercise any such right, privilege or option and shall not be responsible for any failure to do so or delay in so doing. 

(c) Each Grantor hereby expressly and irrevocably authorizes and instructs, without any further instructions from such Grantor, each Issuer of
the Pledged Collateral and Pledged Investment Property pledged by such Grantor hereunder to (i) comply with any instruction received by it from Agent in writing that (x) states that an Event of Default has occurred and is continuing and
(y) is otherwise in accordance with the terms of this Agreement, and each Grantor agrees that each Issuer shall be fully protected in so complying and (ii) unless otherwise permitted under the Loan Documents, pay any dividends,
distributions or other payments with respect to the Pledged Collateral and Pledged Investment Property directly to Agent. 
 (d) In order to
permit Agent to exercise the voting and other consensual rights that it is entitled to exercise pursuant hereto and to receive all dividends and other distributions that it is entitled to receive hereunder, (i) during the existence of an Event
of Default, each Grantor shall promptly execute and deliver (or cause to be executed and delivered) to Agent all such proxies, dividend payment orders and other instruments as Agent may from time to time reasonably request and (ii) without
limiting the effect of clause (i) above, such Grantor hereby grants to Agent an irrevocable proxy to vote all or any part of the Pledged Collateral and the Pledged Investment Property and to exercise all other rights, powers, privileges and
remedies to which a holder of the Pledged Collateral or the Pledged Investment Property, as applicable, would be entitled (including giving or withholding written consents of shareholders, partners or members, as the case may be, calling special
meetings of shareholders, partners or members, as the case may be, and voting at such meetings), which proxy shall be effective, automatically and without the necessity of any action (including any transfer of any Pledged Collateral or Pledged
Investment Property on the record books of the Issuer thereof) by any other person (including the Issuer of such Pledged Collateral or Pledged Investment Property, as applicable, or any officer or agent thereof) solely during the continuance of an
Event of Default and which proxy shall only terminate upon the Payment in Full in cash of the Secured Obligations or upon an express waiver in writing by Agent and the Required Lenders of the underlying Event of Default in accordance with the terms
of the Facility Agreement. 
 6.4 Proceeds to be Turned Over to Agent. In addition to the rights of Agent specified in
Section 6.1 hereof with respect to payments of Receivables, if an Event of Default shall occur and be continuing and Agent has notified Borrower of the Grantors’ obligations under this
Section 6.4, all Proceeds received by any Grantor consisting of cash, checks and other cash equivalent items shall be held by such Grantor in trust for Agent (for the benefit of the Secured Parties), segregated from other
funds of such Grantor, and shall, upon written request of Agent, forthwith upon receipt by such Grantor, be turned over to Agent in the exact form received by such Grantor (duly indorsed by such Grantor to Agent, if required). Subject to the terms
of the Intercreditor Agreement (if applicable), all Proceeds received by Agent under this Section 6.4 shall be held by Agent in a collateral account maintained under its sole dominion and control. All Proceeds, while held
by Agent (for the benefit of the Secured Parties) in any collateral account (or by such Grantor in trust for Agent (for the benefit of the Secured Parties)) established pursuant hereto, shall continue to be held as collateral security for the
Secured Obligations and shall not constitute payment thereof until applied as provided in Section 6.5 hereof. 

6.5 Application of Proceeds. Agent may apply all or any part of Proceeds from the 

  
 22 

 
sale of, or other realization upon, all or any part of the Collateral (after deducting all reasonable and documented external attorneys’ and other fees and out-of-pocket costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any Collateral or in any way relating to the Collateral or the rights of Agent and
any other Secured Party hereunder) in payment of the Secured Obligations in such order as the Agent shall determine in its discretion, and may pay any other amount required by any Applicable Law. Any balance of such Proceeds remaining after the
Secured Obligations and the Guaranteed Obligations (as applicable) shall have been Paid in Full shall be paid over to the applicable Grantor or to whomsoever may be lawfully entitled to receive the same. The parties hereto understand and agree that
the exercise of remedies hereunder with respect to accounts arising under any Third Party Payor program may be subject to Applicable Law. 

6.6 UCC and Other Remedies. If an Event of Default shall occur and be continuing, Agent may exercise, in addition to all other rights
and remedies granted to them in this Agreement and in any other instrument or agreement securing, evidencing or relating to the Secured Obligations, all rights and remedies of a secured party under the UCC or any other Applicable Law. Without
limiting the generality of the foregoing, Agent, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other
Person (all and each of which demands, defenses (other than defense of payment), advertisements and notices are hereby waived), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof,
and/or may forthwith sell, lease, assign, give options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any
exchange, broker’s board or office of Agent or elsewhere upon such terms and conditions as they may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery with assumption of any credit risk. Agent
shall have the right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in any Grantor,
which right or equity is hereby waived and released. Each Grantor further agrees, at Agent’s request, to assemble the Collateral and make it available to Agent at places which Agent shall reasonably select, whether at such Grantor’s
premises or elsewhere in connection with the exercise of Agent’s remedies hereunder. Agent shall apply the net Proceeds of any action taken by it pursuant to this Section 6.6, after deducting all reasonable documented out-of-pocket costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any way relating to the
Collateral or the rights of Agent hereunder, to the payment in whole or in part of the Secured Obligations, as set forth in Section 6.5 hereof. To the extent permitted by Applicable Law, each Grantor waives all claims,
damages and demands it may acquire against Agent arising out of the exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable and
proper if given at least 10 calendar days before such sale or other disposition. Agent shall not be obligated to make any sale of Collateral regardless of notification of sale having been given. Agent may adjourn any public sale from time to time by
announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor agrees that (A) the internet shall constitute a “place” for
purposes of Section 9-610(b) of the UCC and (B) to the extent notification of sale shall be required by law, notification by mail of the URL where a sale will occur and the time when a sale will
commence at least ten (10) days prior to the sale shall constitute a reasonable notification for purposes of Section 9-611(b) of the UCC. Each Grantor agrees that any sale of Collateral to a licensor
pursuant to the terms of a license agreement between such licensor and a Grantor is sufficient to constitute a commercially reasonable sale (including as to method, terms, manner, and time) within the meaning of
Section 9-610 of the UCC. 
 6.7 Private Sale. Each Grantor recognizes that Agent may be
unable to effect a public sale of any or all the Pledged Collateral and Pledged Investment Property, by reason of certain prohibitions 

  
 23 

 
contained in the Securities Act and applicable state or foreign securities laws or otherwise, or may otherwise determine that a public sale is impracticable, not desirable or not commercially
reasonable, and, accordingly, and may resort to one or more private sales thereof to a restricted group of purchasers that will be obliged to agree, among other things, to acquire such securities for their own account for investment and not with a
view to the distribution or resale thereof. Each Grantor acknowledges and agrees that any such private sale may result in prices and other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances, agrees that
any such private sale shall be deemed to have been made in a commercially reasonable manner. Agent shall be under no obligation to delay a sale of any of the Pledged Collateral or Pledged Investment Property for the period of time necessary to
permit the Issuer thereof to register such securities or other interests for public sale under the Securities Act, or under applicable state or foreign securities laws, even if such Issuer would agree to do so. 

Each Grantor agrees to use its commercially reasonable efforts to do or cause to be done all such other acts as may be necessary to make such
sale or sales of all or any portion of the Pledged Collateral and Pledged Investment Property pursuant to this Section 6.7 and Section 6.11 hereof valid and binding and in compliance with
Applicable Law. Each Grantor further agrees that a breach of any of the covenants contained herein will cause irreparable injury to Agent and the other Secured Parties, that Agent and the other Secured Parties have no adequate remedy at law in
respect of such breach and, as a consequence, that each and every covenant contained herein shall be specifically enforceable against such Grantor (except as such enforceability may be limited by applicable insolvency, bankruptcy, reorganization,
moratorium or other similar laws affecting creditors’ rights generally), and such Grantor hereby waives and agrees not to assert any defenses against an action for specific performance of such covenants. Until all of the Secured Obligations and
all of the Guaranteed Obligations are Paid in Full, each Grantor postpones until such date any and all rights of contribution or subrogation upon the sale or disposition of all or any portion of the Pledged Collateral and Pledged Investment Property
by Agent. 
 6.8 Deficiency. Each Grantor shall remain liable for any deficiency if the Proceeds of any sale or other disposition of
any Collateral are insufficient to Pay in Full the Secured Obligations and the fees and disbursements of any attorneys employed by Agent or any other Secured Party to collect such deficiency. 

6.9 Licenses. Solely for the purpose of enabling Agent (for the benefit of the Secured Parties) to exercise rights and remedies
following and during the continuation of an Event of Default (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, convey, transfer or grant options to purchase any
Collateral), each Grantor hereby grants to Agent, for the benefit of the Secured Parties, (i) an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such Grantor) including in such license the
right to use, practice, license or sublicense any Intellectual Property now owned or hereafter acquired by such Grantor, and wherever the same may be located, and including in such license access to all media in which any of the licensed items may
be recorded or stored and to all computer software and programs used for the compilation or printout thereof, and (ii) an irrevocable license (without payment of rent or other compensation to such Grantor) to use, operate and occupy all Real
Estate owned, operated, leased, subleased or otherwise occupied by such Grantor; provided, in each case, that no such licenses shall be granted with respect to any Excluded Property. 

6.10 Reserved. 
 6.11
Disposition of Collateral. Without limiting the generality of the foregoing, to the fullest extent not prohibited by Applicable Law, Agent may, without demand of performance or other demand, presentment, protest, advertisement or notice of
any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands, defenses, 

  
 24 

 
advertisements and notices are hereby waived), upon the occurrence and during the continuance of any Event of Default (personally or through its agents or attorneys), (i) enter upon the premises
where any Collateral is located, without any obligation to pay rent, through self-help, without judicial process, without first obtaining a final judgment or giving any Grantor or any other Person notice or opportunity for a hearing on Agent’s
claim or action, (ii) collect, receive, appropriate and realize upon any Collateral and (iii) sell, assign, convey, transfer, grant option or options to purchase and deliver any Collateral (and enter into contractual obligations to do any
of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of any Secured Party or elsewhere upon such terms and conditions as it may deem advisable and at such prices as it may deem
best, for cash or on credit or for future delivery without assumption of any credit risk. Agent shall have the right, upon any such public sale or sales and, to the extent permitted by the UCC and other Applicable Law, upon any such private sale, to
purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption of any Grantor, which right or equity is hereby waived and released. 

6.12 Management of the Collateral. Each Grantor further agrees, that, upon the occurrence and during the continuance of any Event of
Default and to the fullest extent not prohibited by Applicable Law and, in each case, subject to the terms of the Intercreditor Agreement (if applicable), (i) at Agent’s written request, it shall assemble the Collateral and make it available to
Agent at places that Agent shall reasonably select, whether at such Grantor’s premises or elsewhere, (ii) without limiting the foregoing, Agent also has the right to require that each Grantor store and keep any Collateral pending further
action by Agent and, while any such Collateral is so stored or kept, provide such guards and maintenance services as shall be necessary to protect the same and to preserve and maintain such Collateral in good condition, (iii) until Agent is
able to sell, assign, convey or transfer any Collateral, Agent shall have the right to hold or use such Collateral to the extent that it deems appropriate for the purpose of preserving the Collateral or its value or for any other purpose deemed
appropriate by Agent, and (iv) Agent may, if it so elects, seek the appointment of a receiver or keeper to take possession of any Collateral and to enforce any of Agent’s remedies (for the benefit of the Secured Parties), with respect to
such appointment without prior notice or hearing as to such appointment. Agent shall not have any obligation to any Grantor to maintain or preserve the rights of any Grantor as against third parties with respect to any Collateral while such
Collateral is in the possession of Agent. 
 6.13 Direct Obligation. Neither Agent nor any other Secured Party shall be required to
make any demand upon, or pursue or exhaust any right or remedy against, any Grantor, any other Guarantor, any other Loan Party or any other Person with respect to the payment of the Secured Obligations or the Guaranteed Obligations or to pursue or
exhaust any right or remedy with respect to any Collateral therefor or any direct or indirect guaranty thereof. All of the rights and remedies of Agent and any other Secured Party under any Loan Document shall be cumulative, may be exercised
individually or concurrently and not exclusive of any other rights or remedies provided by any Applicable Law. To the extent it may lawfully do so, each Grantor absolutely and irrevocably waives and relinquishes the benefit and advantage of, and
covenants not to assert against Agent or any other Secured Party, any valuation, stay, appraisement, extension, redemption or similar laws and any and all rights or defenses it may have as a surety, now or hereafter existing, arising out of the
exercise by them of any rights hereunder. If any notice of a proposed sale or other disposition of any Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least ten (10) calendar days before such
sale or other disposition. 
 6.14 Commercially Reasonable. To the extent that any Applicable Law impose duties on Agent to exercise
remedies in a commercially reasonable manner, each Grantor acknowledges and agrees that it is not commercially unreasonable for Agent to do any of the following: 

(a) fail to incur significant costs, expenses or other Liabilities reasonably deemed as such by Agent to prepare any Collateral for disposition
or otherwise to complete raw material or work in 

  
 25 

 
process into finished goods or other finished products for disposition; 
 (b) fail to
obtain permits, or other consents, for access to any Collateral to sell or for the collection or sale of any Collateral, or, if not required by other Applicable Law, fail to obtain Permits or other consents for the collection or disposition of any
Collateral; 
 (c) fail to exercise remedies against account debtors or other Persons obligated on any Collateral or to remove Liens on any
Collateral or to remove any adverse claims against any Collateral; 
 (d) advertise dispositions of any Collateral through publications or
media of general circulation, whether or not such Collateral is of a specialized nature, or to contact other Persons, whether or not in the same business as any Grantor, for expressions of interest in acquiring any such Collateral; 

(e) exercise collection remedies against account debtors and other Persons obligated on any Collateral, directly or through the use of
collection agencies or other collection specialists, hire one or more professional auctioneers to assist in the disposition of any Collateral, whether or not such Collateral is of a specialized nature, or, to the extent deemed appropriate by Agent,
obtain the services of other brokers, investment bankers, consultants and other professionals to assist Agent in the collection or disposition of any Collateral, or utilize Internet sites that provide for the auction of assets of the types included
in the Collateral or that have the reasonable capacity of doing so, or that match buyers and sellers of assets to dispose of any Collateral; 

(f) dispose of assets in wholesale rather than retail markets; 

(g) disclaim disposition warranties, such as title, possession or quiet enjoyment; or 

(h) purchase insurance or credit enhancements to insure Agent against risks of loss, collection or disposition of any Collateral or to provide
to Agent a guaranteed return from the collection or disposition of any Collateral. 
 Each Grantor acknowledges that the purpose of this
Section 6.14 is to provide a non-exhaustive list of actions or omissions that are commercially reasonable when exercising remedies against any Collateral and that other actions or
omissions by any Secured Party shall not be deemed commercially unreasonable solely on account of not being indicated in this Section 6.14. Without limitation upon the foregoing, nothing contained in this
Section 6.14 shall be construed to grant any rights to any Grantor or to impose any duties on Agent or any other Secured Party that would not have been granted or imposed by this Agreement or by Applicable Law in the
absence of this Section 6.14. 
 SECTION 7 AGENT. 

7.1 Agent’s Appointment as Attorney-in-Fact. 

(a) Each Grantor hereby irrevocably constitutes and appoints Agent and any Affiliates, directors, partners, officers, employees, agents,
counsel and advisors thereof, with full power of substitution, as its true and lawful attorney-in-fact with full power and authority in the place and stead of such
Grantor and in the name of such Grantor or in its own name, for the purpose of carrying out the terms of the Loan Documents, to, upon the occurrence and during the continuance of an Event of Default, take any appropriate action and to execute any
document or instrument that may be necessary or desirable to accomplish the purposes of the Loan Documents, and, without limiting the generality of the foregoing, each Grantor hereby gives Agent and its Affiliates, directors, partners, officers,
employees, agents, counsel and advisors the power and right, on behalf of such Grantor, without notice to or assent by such Grantor, to do 

  
 26 

 
any of the following when an Event of Default has occurred and is continuing (subject, as applicable, to compliance by Agent with Applicable Law with respect to Accounts arising under any Third
Party Payor programs): 
 (i) in the name of such Grantor, in its own name or otherwise, take possession of and indorse and
collect any check, draft, note, acceptance or other instrument for the payment of moneys due under any account or general intangible that is Collateral or with respect to any other Collateral and file any claim or take any other action or proceeding
in any court of law or equity or otherwise deemed appropriate by Agent for the purpose of collecting any such moneys due under any account or general intangible that is Collateral or with respect to any other Collateral whenever payable; 

(ii) in the case of any Intellectual Property owned by and, in the case of Copyrights, exclusively licensed to such Grantor (to
the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property), execute, deliver and have recorded any document that Agent may request in accordance with this Agreement to evidence, effect,
publicize or record Agent’s security interest in such Intellectual Property and the goodwill and general intangibles of such Grantor relating thereto or represented thereby; 

(iii) pay or discharge taxes and Liens levied or placed on or threatened against any Collateral, effect any repair or pay any
insurance called for by the terms of the Facility Agreement (including all or any part of the premiums therefor and the costs thereof); 

(iv) execute, in connection with any sale provided for in Section 6.7 or
Section 6.11 hereof, any document to effect or otherwise necessary or appropriate in relation to evidence the sale of any Collateral; or 

(v) (A) direct any party liable for any payment under any Collateral to make payment of any moneys due or to become due
thereunder directly to Agent or as Agent shall direct, (B) ask or demand for, and collect and receive payment of and receipt for, any moneys, claims and other amounts due or to become due at any time in respect of or arising out of any
Collateral, (C) sign and indorse any invoice, freight or express bill, bill of lading, storage or warehouse receipt, draft against debtors, assignment, verification, notice and other document in connection with any Collateral, (D) commence
and prosecute any suit, action or proceeding at law or in equity in any court of competent jurisdiction to collect any Collateral and to enforce any other right in respect of any Collateral, (E) defend any actions, suits, proceedings, audits,
claims, demands, orders or disputes brought against such Grantor with respect to any Collateral, (F) settle, compromise or adjust any such actions, suits, proceedings, audits, claims, demands, orders or disputes that are related to Collateral
and, in connection therewith, give such discharges or releases as Agent may deem appropriate, (G) assign any Intellectual Property owned by any Grantor or any Intellectual Property Licenses of any Grantor where such Grantor is the licensor
thereunder (to the extent not constituting Excluded Property and to the extent permitted under the applicable Intellectual Property or Intellectual Property License, as applicable) throughout the world on such terms and conditions and in such manner
as Agent shall in its sole discretion determine (except, with respect to Trademarks, subject to reasonable quality control in favor of such Grantor), including the execution and filing of any document necessary to effectuate or record such
assignment, or (H) generally, sell, assign, convey, transfer or grant a Lien on, make any Contractual Obligation with respect to and otherwise deal with, any Collateral as fully and completely as though Agent were the absolute owner thereof for
all purposes and do, at Agent’s option, at any time or from time to time, all acts and things that Agent deems necessary to protect, preserve or realize upon any Collateral 

  
 27 

 
and the Secured Parties’ security interests therein and to effect the intent of the Loan Documents, all as fully and effectively as such Grantor might do; 

(vi) if any Grantor fails to perform or comply with any Contractual Obligation contained herein, then during the existence of
an Event of Default, Agent, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such Contractual Obligation; 

(vii) receive and open all mail addressed to any Grantor and to notify postal authorities to change the address for the
delivery of mail to such Grantor to that of Agent; or 
 (viii) use any Intellectual Property or Intellectual Property
Licenses of such Grantor, including but not limited to any labels, Patents, Trademarks, trade names, URLs, domain names, industrial designs, Copyrights, or advertising matter, in preparing for sale, advertising for sale, or selling Inventory or
other Collateral and to collect any amounts due under Accounts, contracts or negotiable Collateral of such Grantor. 
 (b) The expenses of
Agent incurred in connection with actions undertaken as provided in this Section 7.1, together with, during the existence of an Event of Default as set forth in Section 2.7(b) of the Facility
Agreement, interest thereon at a rate set forth in Section 2.7(b) of the Facility Agreement, from the date of payment by Agent to the date reimbursed by the relevant Grantor, shall be payable by such Grantor to Agent on
written demand by Agent to Borrower. 
 (c) Each Grantor hereby ratifies all that said attorneys shall lawfully do or cause to be done by
virtue of, and in accordance with, this Section 7.1. All powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until this Agreement is terminated and the security
interests created hereby are released. 
 7.2 Authority of Agent. Each Grantor acknowledges that the rights and responsibilities of
Agent under this Agreement with respect to any action taken by Agent or the exercise or non-exercise by Agent of any option, voting right, request, judgment or other right or remedy provided for herein or
resulting or arising out of this Agreement shall, as between Agent and the other Secured Parties, be governed by the Facility Agreement and by such other agreements with respect thereto as may exist from time to time among them, but, as between
Agent and any Grantor, Agent shall be conclusively presumed to be acting as agent for the Secured Parties with full and valid authority so to act or refrain from acting, and no Grantor shall be under any obligation or entitlement to make any inquiry
respecting such authority. 
 7.3 Duty; Obligations and Liabilities. 

(a) Agent’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession shall be to
deal with it in the same manner as Agent deals with similar property for its own account. The powers conferred on Agent hereunder are solely to protect Agent’s interest in the Collateral and shall not impose any duty upon Agent to exercise any
such powers. Agent shall be accountable only for amounts that it receives as a result of the exercise of such powers, and neither it nor any of its Affiliates, directors, partners, officers, employees, agents, counsel or advisors shall be
responsible to any Grantor for any act or failure to act hereunder, except for their own gross negligence, bad faith or willful misconduct, in each case, as determined by a court of competent jurisdiction in a final
non-appealable order. In addition, Agent shall not be liable or responsible for any loss or damage to any Collateral, or for any diminution in the value thereof, by reason of the act or omission of any
warehousemen, carrier, forwarding agency, consignee or other bailee if such Person has been selected by Agent in good faith. 

  
 28 

 (b) No Secured Party and no Affiliates, directors, partners, officers, employees, agents,
counsel or advisors thereof shall be liable for failure to demand, collect or realize upon any Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or
any other Person or to take any other action whatsoever with regard to any Collateral. The powers conferred on Agent hereunder shall not impose any duty upon any other Secured Party to exercise any such powers. The other Secured Parties shall be
accountable only for amounts that they actually receive as a result of the exercise of such powers, and neither they nor any of their respective officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to
act hereunder, except for their own gross negligence or willful misconduct as determined by a court of competent jurisdiction in a final non-appealable order. 

SECTION 8 MISCELLANEOUS. 
 8.1
Amendments in Writing. The provisions of this Agreement may be waived, modified, supplemented or amended only by an instrument in writing signed by Borrower and Agent; provided, however, that annexes and schedules, as
applicable, to this Agreement may be supplemented or modified (but no existing provisions may be modified and no Collateral may be released, except with respect to the removal of items on the schedules in connection with a sale or other Disposition
of Collateral, a merger or Acquisition, in each case, that is permitted under the Facility Agreement) as set forth in Section 5 and Section 8.15 hereof. Notwithstanding anything to the contrary in
the first sentence of this Section 8.1, any time period for performance under this Agreement may be extended, at any time, by Agent in its sole discretion. 

8.2 Notices. All notices, requests and demands to or upon Agent or any Guarantor or Grantor hereunder shall be addressed to such party
and effected in the manner provided for in Section 6.1 of the Facility Agreement and each Guarantor and Grantor hereby appoints the Borrower as its agent to receive notices hereunder. 

8.3 Indemnification by Grantors. Each Grantor and each Guarantor agrees to jointly and severally indemnify, pay, and hold Agent, the
other Secured Parties and the Secured Parties’ Affiliates, officers, directors, employees, agents, and attorneys (the “Indemnitees”) harmless against losses and Liabilities to the extent set forth in
Section 6.11 of the Facility Agreement, the terms of which are incorporated herein by reference as though set forth fully herein. The provisions in this Section 8.3 shall survive Payment in Full of
all Secured Obligations and of all Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement. 

8.4 Enforcement Expenses. 

(a) The terms of Section 6.3 of the Facility Agreement with respect to costs and expenses are incorporated herein by
reference, mutatis mutandis, and the parties hereto agree to such terms.  
 (b) The agreements in this
Section 8.4 shall survive Payment in Full of all Secured Obligations and the Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this
Agreement. 
 8.5 Nature of Remedies. All Secured Obligations and Guaranteed Obligations of each Grantor and rights of Agent and the
other Secured Parties expressed herein or in any other Loan Document shall be in addition to and not in limitation of those provided by Applicable Law. No failure to exercise and no delay in exercising, on the part of Agent or the other Secured
Parties, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any single or partial exercise of any right, 

  
 29 

 
remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. 

8.6 Counterparts; Effectiveness. This Agreement may be executed in several counterparts, and by each Party on separate counterparts,
each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement. 

8.7 Severability. If any provision of this Agreement or any of the other Loan Documents shall be invalid, illegal or unenforceable in
any respect under any law, the validity, legality and enforceability of the remaining provisions hereof or thereof shall not in any way be affected or impaired thereby. The parties hereto shall endeavor in good faith negotiations to replace the
invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provision. 

8.8 Entire Agreement. This Agreement contains the entire understanding of the parties hereto with respect to the matters covered hereby
and supersedes any and all other written and oral communications, negotiations, commitments and writings with respect thereto. All Exhibits, Schedules and Annexes referred to herein are incorporated in this Agreement by reference and constitute a
part of this Agreement. If any provision contained in this Agreement conflicts with any provision of the Facility Agreement, then with regard to such conflicting provisions, the Facility Agreement shall govern and control. 

8.9 Successors; Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns, except, notwithstanding anything to the contrary in this Agreement or any other Loan Document, that Grantors and Guarantors may not assign their rights or obligations hereunder and any such purported, prohibited or
attempted assignment shall be void ab initio. 
 8.10 Applicable Law. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY,
ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN SUCH STATE. 

8.11 Consent to Jurisdiction. EACH PARTY AGREES THAT ALL LEGAL PROCEEDINGS CONCERNING THE INTERPRETATIONS, ENFORCEMENT AND DEFENSE OF
THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND, UNLESS OTHERWISE EXPRESSLY STATED THEREIN, THE OTHER LOAN DOCUMENTS (WHETHER BROUGHT AGAINST A PARTY HERETO OR ITS RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS, SHAREHOLDERS, EMPLOYEES OR AGENTS)
SHALL BE COMMENCED EXCLUSIVELY IN THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW
YORK, BOROUGH OF MANHATTAN FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER THE OTHER LOAN DOCUMENTS OR IN CONNECTION HEREWITH OR WITH THE OTHER LOAN DOCUMENTS OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN, AND HEREBY
IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER OR IS AN INCONVENIENT VENUE FOR
SUCH PROCEEDING. 

  
 30 

 
EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED
MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING
CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW. 
 8.12 Waiver of
Jury Trial. THE PARTIES HERETO, TO THE EXTENT PERMITTED BY LAW, WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING ARISING OUT OF, IN CONNECTION WITH OR RELATING TO, THIS AGREEMENT, THE OTHER LOAN DOCUMENTS AND ANY TRANSACTION
CONTEMPLATED HEREBY AND THEREBY. THIS WAIVER APPLIES TO ANY ACTION, SUIT OR PROCEEDING WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE. EACH PARTY HERETO (A) CERTIFIES THAT NO OTHER PARTY AND NO AGENT, REPRESENTATIVE OR OTHER PERSON AFFILIATED
WITH OR RELATED TO ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN
INDUCED TO ENTER INTO THE LOAN DOCUMENTS, AS APPLICABLE, BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.12. 
 8.13 Set-off. Each Grantor agrees that Agent and the other Secured Parties have all rights of set-off and bankers’ lien provided by Applicable Law, and in addition
thereto, each Grantor agrees that at any time any Event of Default exists, Agent and the other Secured Parties may apply to the payment of any Secured Obligations and the Guaranteed Obligations as set forth in Section 6.5
hereof, whether or not then due, any and all balances, credits, deposits, accounts or moneys of such Grantor then or thereafter with the Secured Parties. 

8.14 Acknowledgements. Each Grantor and each Guarantor hereby acknowledges that: 

(a) it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents to which it is a
party; 
 (b) Neither Agent nor any other Secured Party have any fiduciary relationship with or duty to any Grantor or Guarantor arising out
of or in connection with this Agreement or any of the other Loan Documents, and the relationship between the Grantors and Guarantors, on the one hand, and Agent and the other Secured Parties, on the other hand, in connection herewith or therewith is
solely that of debtor and creditor; and 
 (c) no joint venture is created hereby or by the other Loan Documents or otherwise exists by
virtue of the transactions contemplated hereby among the Grantors, Guarantors and the Secured Parties. 
 8.15 Additional
Grantors/Guarantors. The Grantors shall cause each Person, upon becoming a Subsidiary of a Grantor (other than any Excluded Subsidiary) or upon becoming a Subsidiary, limited liability company, other entity or other Person for which any Grantor
divides or splits itself into (or that receives any assets or property of such Grantor from any such division or split), to guaranty Borrower’s and the other Grantors’ performance of the Secured Obligations and the Guaranteed Obligations
and grant to Agent, for the benefit of the Secured Parties, a security interest in the personal property of such Person (to 

  
 31 

 
the extent such personal property would constitute Collateral) to secure the Secured Obligations, its performance under the Facility Agreement and the other Loan Documents to the extent a party
thereto and Borrower’s, each Guarantor’s and the other Grantors’ performance of the Secured Obligations by becoming a party to this Agreement. Upon execution and delivery by such Person of a joinder agreement in the form of Annex
I hereto, such Person shall become a Grantor and Guarantor for all purposes of this Agreement. 
 8.16 Releases. 

(a) At such time as the Secured Obligations have been Paid in Full, the Collateral shall be automatically released from the Liens created
hereby and this Agreement shall automatically terminate (other than those provisions expressly surviving the Payment in Full of the Secured Obligations or the Guaranteed Obligations), all without delivery of any instrument or performance of any act
by any party, and all rights to the Collateral shall automatically revert to the Grantors. At such time as the Guaranteed Obligations have been Paid in Full, subject to Section 8.18, the guarantees provided in
Section 2 and the remainder of this Agreement shall automatically terminate (other than those provisions expressly surviving the Payment in Full of the Secured Obligations or the Guaranteed Obligations, including those
specific provisions of Section 8 hereof expressly surviving Payment in Full of the Secured Obligations or the Guaranteed Obligations). At the request and sole expense of any Grantor following any such Payment in Full of the
Secured Obligations, Agent shall promptly deliver to the Grantors any Collateral held by Agent hereunder, and execute and deliver to the Grantors such documents as the Grantors shall reasonably request in writing to evidence the termination and
release of the Liens in the Collateral. At the request and sole expense of any Grantor following any such Payment in Full of the Guaranteed Obligations, Agent shall execute and deliver to the Grantors such documents as the Grantors shall reasonably
request in writing to evidence the termination of the guarantees provided in Section 2. 
 (b) If any of the
Collateral shall be sold, transferred or otherwise disposed of by any Grantor in a transaction permitted by the Facility Agreement or with the written consent of Agent and the Required Lenders, then Agent, at the reasonable written request and sole
expense of such Grantor, shall execute and deliver to such Grantor all releases or other documents reasonably necessary for the release of the Liens created hereby on such Collateral; provided that Borrower shall have delivered to Agent, with
reasonable notice prior to the date of the proposed release, a written request for release identifying the relevant Grantor, together with a certification by Borrower stating that such transaction is in compliance with the Facility Agreement and the
other Loan Documents (including the relevant provision of the Loan Documents pursuant to which such transfer or other disposition is permitted, together with any additional evidence reasonably requested by Agent). 

(c) If, in compliance with the terms and provisions of the Loan Documents, (i) all or substantially all of the Stock of any Guarantor is
sold or otherwise transferred to a Person or Persons none of which is a Loan Party in a transaction permitted under the Loan Documents or with the written consent of Agent and the Required Lenders or (ii) any Guarantor becomes an Excluded
Subsidiary as a result of a transaction permitted under the Loan Documents (any such Guarantor, and any Guarantor referred to in clause (i), a “Transferred Guarantor”), such Transferred Guarantor shall, upon the consummation of such
sale or transfer or other transaction, be automatically released from its obligations under this Agreement (including under this Section 8.16) and the other Loan Documents, including its obligations to pledge and grant any
Collateral owned by it and, in the case of a sale of all or substantially all of the Stock of the Transferred Guarantor, the pledge of such Stock to the Agent hereunder shall be automatically released, and, so long as the Borrower shall have
provided the Agent such certifications or documents as the Agent shall reasonably request, the Agent, at the sole expense of the Grantors, shall take such actions as are reasonably necessary and requested by the Grantors in writing to effect each
release described in this Section 8.16. 

  
 32 

 8.17 Obligations and Liens Absolute and Unconditional. Each Grantor and each
Guarantor understands and agrees that the obligations of each Grantor under this Agreement shall be construed as continuing, absolute and unconditional without regard to (i) the validity or enforceability of any Loan Document, any of the
Secured Obligations or any other collateral security therefor or guaranty or right of offset with respect thereto at any time or from time to time held by Agent or any other Secured Party, (ii) any defense,
set-off or counterclaim (other than a defense of payment or performance) which may at any time be available to or be asserted by any Grantor, Guarantor or any other Person against Agent or any other Secured
Party, or (iii) any other circumstance whatsoever (with or without notice to or knowledge of any Grantor or Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of any Grantor or Guarantor for the
Secured Obligations or the Guaranteed Obligations, in bankruptcy or in any other instance. When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Grantor or Guarantor, Agent and any other Secured Party
may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as they may have against any other Grantor or Guarantor or any other Person or against any collateral security for the Secured
Obligations or guaranty for the Guaranteed Obligations or any right of offset with respect thereto, and any failure by Agent or any other Secured Party to make any such demand, to pursue such other rights or remedies or to collect any payments from
any other Grantor or Guarantor or any other Person or to realize upon any such collateral security or guaranty or to exercise any such right of offset, or any release of any other Grantor or Guarantor or any other Person or any such collateral
security, guaranty or right of offset, shall not relieve any Grantor or Guarantor of any obligation or Liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of Agent or
any other Secured Party against any Grantor or Guarantor. For the purposes hereof “demand” shall include the commencement and continuance of any legal proceedings. 

8.18 Reinstatement. Each Grantor and Guarantor agrees that, if any payment made by any Loan Party or other Person and applied to the
Secured Obligations or the Guaranteed Obligations is at any time annulled, avoided, set aside, rescinded, invalidated, declared to be fraudulent or preferential or otherwise required to be refunded or repaid, or the Proceeds of any Collateral are
required to be returned by any Secured Party to such Loan Party, its estate, trustee, receiver or any other party, including any Grantor or Guarantor, under any applicable bankruptcy law, state or federal law, common law or equitable cause, then, to
the extent such payment or repayment is annulled, avoided, set aside, rescinded, invalidated, refunded, repaid or returned, any Lien or other Collateral securing such liability with respect to the Secured Obligations and any guarantee herein
securing the Guaranteed Obligations shall be and remain in full force and effect, as fully as if such payment had never been made. If, prior to any of the foregoing, (i) any Lien or other Collateral securing such Grantor’s Secured
Obligations or Guarantor’s Guaranteed Obligations shall have been released or terminated by virtue of the foregoing or (ii) any provision of the guaranty hereunder shall have been terminated, cancelled or surrendered in connection with the
foregoing payment, such Lien, other Collateral, guaranty or other provision shall be reinstated in full force and effect and such prior release, termination, cancellation or surrender shall not diminish, release, discharge, impair or otherwise
affect the obligations of any such Grantor in respect of any Lien or other Collateral securing, or any such Guarantor in respect of any guaranty guaranteeing such obligation or the amount of such payment. This Section 8.18
shall survive the termination of this Agreement pursuant to Section 8.16 or otherwise. The provisions in this Section 8.18 shall survive Payment in Full of all Secured Obligations and of all
Guaranteed Obligations, any foreclosure under, or any modification, release or discharge of, any or all of the Collateral, and termination of this Agreement. 

8.19 Independent Obligations. The obligations of each Grantor and each Guarantor hereunder are independent of and separate from the
Secured Obligations and the Guaranteed Obligations. During the continuance of any Event of Default, Agent may, at its sole election, proceed directly and at once, without notice, against any Grantor, any Guarantor and any Collateral to collect and
recover the full amount of any Secured Obligation or Guaranteed Obligation (as applicable) then due, without first 

  
 33 

 
proceeding against any other Grantor, any Guarantor, any other Loan Party or any other Collateral or any guaranty and without first joining any other Grantor, any other Guarantor or any other
Loan Party in any proceeding. 
 8.20 No Waiver by Course of Conduct. No Secured Party shall by any act (except by a written signed
instrument by the required Persons pursuant to Section 8.1 hereof and Section 6.6 of the Facility Agreement), delay, indulgence, omission or otherwise be deemed to have waived any right or remedy
hereunder or to have acquiesced in any Default or Event of Default. No failure to exercise, nor any delay in exercising, on the part of any Secured Party, any right, power or privilege hereunder or under any other Loan Document shall operate as a
waiver thereof. No single or partial exercise of any right, power or privilege hereunder or under any other Loan Document shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege. A waiver by any
Secured Party of any right or remedy hereunder or any other Loan Document on any one occasion shall not be construed as a bar to any right or remedy that such Secured Party would otherwise have on any future occasion. 

8.21 Intercreditor Agreement. This Agreement is subject, in the manner and the extent, to the terms set forth in the Intercreditor
Agreement. Any Collateral held by (or in the possession or control of) the ABL Agent (or its agents or bailees) shall be held as agent and bailee for security and Lien perfection purposes in favor of Agent (for the benefit of the Secured Parties) in
accordance with the terms of the Intercreditor Agreement and the Loan Documents. 
 8.22 Relation to Other Loan Documents. The
provisions of this Agreement shall be read and construed with the other Loan Documents referred to below in the manner so indicated. The provisions of any Copyright Security Agreement(s), Trademark Security Agreement(s), and Patent Security
Agreement(s) are supplemental to the provisions of this Agreement, and nothing contained in any Copyright Security Agreement(s), Trademark Security Agreement(s), or Patent Security Agreement(s) shall limit any of the rights or remedies of Agent
hereunder. In the event of any conflict between any provision in this Agreement and a provision in a Copyright Security Agreement, Trademark Security Agreement or Patent Security Agreement, such provision of this Agreement shall control. 

8.23 Amendment and Restatement; Continuation of Obligations and Liens; No Novation. 

(a) This Agreement does not extinguish the outstanding obligations of the Grantors evidenced by the Existing Guaranty and Security Agreement or
discharge or release any Lien or security interest or any other security under the Existing Loan Documents or the Loan Documents, all of which obligations, Liens and security interests continue under this Agreement and the other Loan Documents (in
each case, as expanded, increased and enlarged hereby, as applicable). Nothing herein contained shall be construed as a substitution or novation of the original obligations or other obligations (including, without limitation, any “Guaranteed
Obligations” or “Secured Obligations”) under the Existing Guaranty and Security Agreement, which shall remain in full force and effect, except as amended hereby and by the other Loan Documents, and shall continue at all times under
this Agreement, as amended hereby and thereby. 
 (b) All of the security interests, Liens and collateral granted under the Existing Guaranty
and Security Agreement are hereby reaffirmed, ratified and confirmed in all respects and all parties hereto agree that such security interests, Liens and collateral continue under this Agreement. 

(c) Each Grantor acknowledges and confirms that, as of the Agreement Date, it has no defense, set off, claim or counterclaim arising on or
prior to the Agreement Date against any of the Secured Parties with regard to the indebtedness, liabilities and obligations created under the Existing Guaranty and Security Agreement and the Liens and security interests granted pursuant to the
Existing Loan Documents 

  
 34 

 
to secure the indebtedness, liabilities and obligations (including, without limitation, the “Guaranteed Obligations”, the “Secured Obligations” and the
“Obligations,” as applicable) of the Grantors to the Secured Parties under the Existing Guaranty and Security Agreement, as amended and restated hereby, and that the term “Obligations” as used in the Loan Documents (or any other
term used therein to describe or refer to the indebtedness, liabilities and obligations of the Grantors to the Secured Parties) includes, without limitation, the indebtedness, liabilities and obligations of the Guarantors under this Agreement, as
the same further may be amended, modified, supplemented and/or restated from time to time. The Loan Documents and all agreements, instruments and documents executed or delivered in connection with any of the foregoing shall each be deemed to be
amended to the extent necessary to give effect to the provisions of this Section 8.23. From and after the date hereof, all references in the Loan Documents to the “Guaranty and Security Agreement” shall be deemed to refer to this
Agreement. From and after the date hereof, all references in the Loan Documents to (i) a “Guarantor” or the “Guarantors” shall be deemed to refer to the defined terms “Guarantor” or the “Guarantors” (as
applicable) under this Agreement, (ii) the “Guaranteed Obligations” shall be deemed to refer to the defined term “Guaranteed Obligations” under this Agreement and (iii) the “Secured Obligations” shall be
deemed to refer to the defined term “Secured Obligations” under this Agreement. Cross-references in the Loan Documents to particular section numbers in the Existing Guaranty and Security Agreement shall be deemed to be cross-references to
the corresponding sections, as applicable, of this Agreement. 
 (d) The provisions of Sections 6.29, 6.30 and 6.31 of the Facility Agreement
are incorporated herein mutatis mutandis. 
 [SIGNATURE PAGES FOLLOW] 

  
 35 

 IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed
and delivered as of the date first above written. 
  

									
	GRANTORS AND GUARANTORS:	 		 	ENDOLOGIX, INC.,
		 		 		 	a Delaware corporation,
as Grantor and Guarantor
					
		 		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 		 	Name: Vaseem Mahboob
		 		 		 	Title: Chief Financial Officer
				
		 		 		 	CVD/RMS ACQUISITION CORP.,
		 		 		 	a Delaware corporation,
as Grantor and Guarantor
					
		 		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 		 	Name: Vaseem Mahboob
		 		 		 	Title: Chief Financial Officer and Secretary
				
		 		 		 	NELLIX, INC.,
		 		 		 	a Delaware corporation,
as Grantor and Guarantor
					
		 		 		 	By:	 	 /s/ Vaseem, Mahboob

		 		 		 	Name: Vaseem Mahboob
		 		 		 	Title: Chief Financial Officer and Secretary
				
		 		 		 	TRIVASCULAR TECHNOLOGIES, INC.,
		 		 		 	a Delaware corporation,
as Grantor and Guarantor
					
		 		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 		 	Name: Vaseem Mahboob
		 		 		 	Title: Chief Financial Officer and Secretary

  

  
 [Signature Page to
Amended and Restated Guaranty and Security Agreement] 

									
	GRANTORS AND GUARANTORS
CONTINUED:	 		 	TRIVASCULAR, INC.,
		 		 		 	a California corporation,
as Grantor and Guarantor
					
		 		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 		 	Name: Vaseem Mahboob
		 		 		 	Title: Chief Financial Officer and Secretary
				
		 		 		 	ENDOLOGIX CANADA, LLC,
		 		 		 	a Delaware limited liability company,
as Grantor and Guarantor
					
		 		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 		 	Name: Vaseem Mahboob
		 		 		 	Title: Chief Financial Officer and Secretary
				
		 		 		 	TRIVASCULAR SALES LLC,
		 		 		 	a Texas limited liability company,
as Grantor and Guarantor
					
		 		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 		 	Name: Vaseem Mahboob
		 		 		 	Title: Chief Financial Officer and Secretary
				
		 		 		 	RMS/ENDOLOGIX SIDEWAYS MERGER CORP.,
		 		 		 	a Delaware corporation,
as Grantor and Guarantor
					
		 		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 		 	Name: Vaseem Mahboob
		 		 		 	Title: Chief Financial Officer and Secretary

  

  
 [Signature Page to
Amended and Restated Guaranty and Security Agreement] 

									
	AGENT:	 		 	 DEERFIELD PRIVATE DESIGN FUND IV, L.P.,

as Agent

				
		 		 		 	By: Deerfield Mgmt IV, L.P., General Partner
				
		 		 		 	By: J.E. Flynn Capital IV, LLC, General Partner
					
		 		 		 	By:	 	 /s/ David J.
Clark                                        

		 		 		 	Name:	 	David J. Clark

		 		 		 	Title:	 	Authorized Signatory

  

  
 [Signature Page to
Amended and Restated Guaranty and Security Agreement] 

 ANNEX I 

FORM OF JOINDER TO GUARANTY AND SECURITY AGREEMENT 

This JOINDER AGREEMENT (this “Agreement”) dated as of
[            ], 20[        ] is executed by the undersigned in favor of Deerfield Private Design Fund IV, L.P., as Agent, for the benefit of the
Secured Parties in connection with that certain Amended and Restated Guaranty and Security Agreement dated as of August 9, 2018, by and among Agent and the Guarantors and Grantors party thereto (as amended, restated, supplemented or otherwise
modified from time to time, the “Guaranty and Security Agreement”). Capitalized terms not otherwise defined herein are being used herein as defined in the Guaranty and Security Agreement, or if not defined therein, in the Facility
Agreement (as defined therein). 
 Each Person signatory hereto is required to execute this Agreement pursuant to
Section 8.15 of the Guaranty and Security Agreement. 
 In consideration of the premises and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each such Person hereby agrees as follows: 
 1. Each
such Person assumes all the obligations of a Grantor and a Guarantor under the Guaranty and Security Agreement and agrees that such Person is a Grantor and a Guarantor and bound as a Grantor and a Guarantor under the terms of the Guaranty and
Security Agreement, as if it had been an original signatory to such agreement. In furtherance of the foregoing, such Person hereby mortgages, pledges, assigns, hypothecates and transfers to Agent, for the benefit of the Secured Parties, and hereby
grants to Agent, for the benefit of the Secured Parties, a Lien on and security interest in all of its Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration
or otherwise) of the Secured Obligations. For the avoidance of doubt, the Collateral does not include any Excluded Property. 
 2. Schedules
1, 1A, 2, 3, 4, 5, 6, 7, 8, 9 and 10 of the Guaranty and Security Agreement are hereby amended to add the information relating to each such Person set out on Schedules 1, 1A, 2, 3, 4, 5, 6, 7, 8, 9 and 10, respectively, hereof. Each such Person
hereby makes to Agent and the other Secured Parties the representations and warranties set forth in the Guaranty and Security Agreement applicable to such Person and the applicable Collateral and confirms that such representations and warranties are
true and correct in all material respects (without duplication of any materiality qualifier) as of the date hereof after giving effect to such amendment to such Schedules (except to the extent stated to relate to a specific earlier date, in which
case, as of such earlier date). 
 3. In furtherance of its obligations under Section 5.2 of the Guaranty and
Security Agreement, each such Person agrees to deliver to Agent appropriately complete UCC financing statements naming such Person as debtor and Agent as secured party, and describing its Collateral and such other documentation as Agent (or its
successors or assigns) may require to evidence, protect and perfect the Liens created by the Guaranty and Security Agreement, as modified hereby. Each such Person acknowledges the authorizations given to Agent and its Related Parties and their
counsel under the Section 5.9 of the Guaranty and Security Agreement and otherwise. 
 4. Each such Person’s
address for notices under the Guaranty and Security Agreement shall be the address of the Borrower set forth in the Facility Agreement and each such Person hereby appoints the Borrower as its agent to receive notices hereunder. 

 5. Agent acknowledges that upon the effectiveness of this Agreement, the undersigned shall
have the rights of a Grantor and Guarantor under the Guaranty and Security Agreement. 
 6. This Agreement shall be deemed to be part of, and
a modification to, the Guaranty and Security Agreement and shall be governed by all the terms and provisions of the Guaranty and Security Agreement, with respect to the modifications intended to be made to such agreement, which terms are
incorporated herein by reference, are ratified and confirmed and shall continue in full force and effect as valid and binding agreements of each such person or entity enforceable against such Person, except as such enforceability may be limited by
applicable insolvency, bankruptcy, reorganization, moratorium or other similar laws affecting creditors’ rights generally. Each such Person hereby waives notice of Agent’s acceptance of this Agreement. Each such Person will deliver an
executed original of this Agreement to Agent. This Agreement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission
thereof shall be deemed an original, but all of which together shall constitute one and the same agreement. 
  

  
 [remainder of page
intentionally left blank] 

 IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as
of the date first above written. 
  

			
	[add signature block for each new Grantor]
	
[                         
               ],
 a
[                        ], as a Grantor and Guarantor

		
	By:	 	  

	Name:	 	  

	
	Acknowledged and agreed to as of the year and date first written above:
	
	AGENT:
	
	DEERFIELD PRIVATE DESIGN FUND IV, L.P., as Agent
	
	By: Deerfield Mgmt IV, L.P., General Partner
	
	By: J.E. Flynn Capital IV, LLC, General Partner
		
	By:	 	
                     
            

	Name:	 	James E. Flynn
	Title:	 	President

 SCHEDULE 1 

PLEDGED EQUITY AND PLEDGED DEBT INSTRUMENTS 

Pledged Equity: 
  

													
	 Grantor
(owner of
Record of
such
Pledged
Equity)
	  	 Issuer
	  	 Par Value
	  	 No. of
Shares,
Units
or
Interests
Owned
	  	 Total
Shares,
Units
or
Interests
Authorized
and
Outstanding
	  	 Percentage
of Shares, Units or
Interests
Owned
	  	 Certificate
(Indicate
No.)

	Endologix, Inc.	  	Nellix, Inc.	  	$0.001	  	100 Shares	  	1,000 Shares Authorized; 100 Shares Outstanding	  	100%	  	65
							
	Endologix, Inc.	  	CVD/RMS Acquisition Corp.	  	$0.001	  	100 Shares	  	100 Shares Authorized and Outstanding	  	100%	  	4
							
	Endologix, Inc.	  	RMS/Endologix Sideways Merger Corp.	  	$0.001	  	100 Shares	  	100 Shares Authorized and Outstanding	  	100%	  	Com-1
							
	Endologix, Inc.	  	TriVascular Technologies, Inc.	  	$0.001	  	100 Shares	  	1,000 Shares Authorized; 100 Shares Outstanding	  	100%	  	60
							
	Endologix, Inc.	  	ELGX International Holdings GP	  	N.A.	  	Unspecified Number of Partnership Interests	  	Unspecified Number of Partnership Interests	  	100%	  	N.A.
							
	Endologix, Inc.	  	Endologix Bermuda L.P.	  	N.A.	  	Unspecified Number of Partnership Interests	  	Unspecified Number of Partnership Interests	  	99%	  	N.A.

													
	 Grantor
(owner of
Record of
such
Pledged
Equity)
	  	 Issuer
	  	 Par Value
	  	 No. of
Shares,
Units
or
Interests
Owned
	  	 Total
Shares,
Units
or
Interests
Authorized
and
Outstanding
	  	 Percentage
of Shares, Units or
Interests
Owned
	  	 Certificate

(Indicate
No.)

	ELGX International Holdings GP	  	Endologix Bermuda L.P.	  	N.A.	  	Unspecified Number of Partnership Interests	  	Unspecified Number of Partnership Interests	  	1%	  	N.A.
							
	Endologix, Inc.	  	Endologix Singapore Private Limited	  	N.A.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	100%	  	N.A.
							
	Endologix, Inc.	  	Endologix New Zealand Co.	  	N.A.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	100%	  	N.A.
							
	Endologix, Inc.	  	ELGX South Korea Ltd	  	N.A.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	100%	  	N.A.
							
	TriVascular Technologies, Inc.	  	TriVascular,Inc.	  	$0.01	  	100 Shares	  	100 Shares Authorized and Outstanding	  	100%	  	CS-4
							
	TriVascular, Inc.	  	TriVascular Sales LLC	  	N.A.	  	1,000 Units of Membership Interests	  	1,000 Units of Membership Interests	  	100%	  	N.A.
							
	TriVascular, Inc.	  	TriVascular
Germany
GmbH	  	N.A.	  	Unspecified number of Company Interests	  	Unspecified number of Company Interests	  	100%	  	N.A.
							
	TriVascular, Inc.	  	TriVascular
Switzerland
Sarl	  	N.A.	  	Unspecified number of Company Interests	  	Unspecified number of Company Interests	  	100%	  	N.A.
							
	TriVascular,	  	Endologix	  	N.A.	  	1,000 Units of Membership	  	1,000 Units of	  	100%	  	N.A.

													
	 Grantor
(owner of
Record of
such
Pledged
Equity)
	  	 Issuer
	  	 Par
Value
	  	 No. of
Shares,
Units
or
Interests
Owned
	  	 Total
Shares,
Units
or
Interests
Authorized
and
Outstanding
	  	 Percentage
of Shares, Units or
Interests
Owned
	  	 Certificate
(Indicate
No.)

	Inc.	  	Canada, LLC	  		  	Interests	  	Membership Interests	  		  	
							
	TriVascular, Inc.	  	TriVascular, Inc.
Italia Sarl	  	N.A.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	100%	  	N.A.
							
	Endologix Bermuda L.P.	  	Endologix International Holdings B.V.	  	N.A.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	100%	  	N.A.
							
	Endologix International Holdings B.V.	  	Endologix Poland spolkda z ograniczona odpowiedzialnoscia	  	N.A.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	100%	  	N.A.
							
	Endologix International Holdings B.V.	  	Endologix Italia Sarl	  	N.A.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	100%	  	N.A.
							
	Endologix International Holdings B.V.	  	Endologix International B.V.	  	N.A.	  	Unspecified Number of Company Interests	  	Unspecified Number of Company Interests	  	100%	  	N.A.

 Pledged Debt Instruments: 
  

											
	 Grantor (owner
of Record of such
Pledged
Debt
Instrument)
	  	 Issuer
	  	 Description of Debt
	  	 Final
Maturity
	  	 Principal
Amount
	  	 Certificate
(Indicate
No.)

	N.A.	  		  		  		  		  	

 SCHEDULE 1A 

PLEDGED INVESTMENT PROPERTY 
  

					
	 Name of Issuer
	  	 Description and Value of Security
	  	 Loan Party/Subsidiary

	Cianna Medical, Inc.	  	8,677 Shares of Series A Preferred Stock	  	Endologix, Inc.

 See Schedule 1. 

 SCHEDULE 2 

FILINGS AND PERFECTION 
 To be
attached. 

 FIRST SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT 

This FIRST SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT (this “Supplement”) made as of August 9, 2018, by Endologix, Inc.,
a Delaware corporation (“Endologix” or “Borrower”), and TriVascular, Inc., a Delaware corporation (“TriVascular”; TriVascular and Endologix are each individually a “Grantor” and
collectively “Grantors”), in favor of Deerfield Private Design Fund IV, L.P., in its capacity as Agent for the Secured Parties (each as defined in the Facility Agreement referenced below) (in such capacity,
“Grantee”): 
 W I T N E S S E T H 

WHEREAS, Borrower, the other Loan Parties (including TriVascular) from time to time party thereto, the financial institutions from time to
time party thereto as Lenders and Grantee have entered into that certain Amended and Restated Facility Agreement dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Facility
Agreement”), pursuant to which Grantee and the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrower (collectively, the “Loans”).

 WHEREAS, pursuant to the terms of that certain Amended and Restated Guaranty and Security Agreement dated as of the date hereof, by and
among Grantee, Grantors and the other Loan Parties from time to time party thereto (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”), Grantors have
granted to Grantee, for its benefit and the benefit of the other Secured Parties, a security interest and Lien upon substantially all assets (including the Collateral) of Grantors, including all right, title and interest of Grantors in, to
and under all now owned and hereafter acquired (a) trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, trade dress, service marks, logos and other source or business identifiers of
each Grantor, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or
in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof, or otherwise, and all common-law rights related thereto, and (b) the
right to obtain all renewals thereof (all of the foregoing in clauses (a) and (b), collectively, together with “Trademarks” as defined in the Guaranty and Security Agreement,
“Trademarks”), together with the goodwill of the business symbolized by Grantors’ Trademarks, and all income, royalties, damages and payments with respect to the foregoing, to secure the payment of all Secured Obligations, in
each case other than Excluded Property. 
 WHEREAS, Grantors and Grantee are parties to that certain Trademark Security Agreement, dated
April 3, 2017 (as the same heretofore may have been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the “Trademark Security Agreement”). 

 NOW, THEREFORE, in consideration of the premises set forth herein and for other good and
valuable consideration, receipt and sufficiency of which are hereby acknowledged, Grantors agree to supplement the Trademark Security Agreement as follows: 

(e) Incorporation of Facility Agreement, Guaranty and Security Agreement and Trademark Security Agreement. The representations and
warranties contained in the Facility Agreement, the Guaranty and Security Agreement and the Trademark Security Agreement to the extent applicable to Grantors are hereby incorporated herein in their entirety by this reference thereto. The provisions
of Sections 1.2 and 6.4 of the Facility Agreement are incorporated herein by reference thereto mutatis mutandis. Unless otherwise noted herein, all capitalized terms used herein but not otherwise defined herein shall have the respective
meanings ascribed to such terms in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement. In the event of a conflict between a provision of the Guaranty and Security Agreement and a provision of this Supplement
(or the Trademark Security Agreement as amended and/or supplemented by this Supplement), the provision of the Guaranty and Security Agreement shall control. 

(f) Grant and Reaffirmation of Grant of Security Interests. To secure the payment of the Secured Obligations, Grantors hereby grant to
Grantee, for its benefit and the benefit of the other Secured Parties, and hereby reaffirm their prior grant pursuant to the Guaranty and Security Agreement and the Trademark Security Agreement of, a continuing Lien on and security interest in
Grantors’ entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “Trademark Collateral”), whether now owned or existing or
hereafter created, acquired or arising: 
 each Trademark listed on Schedule A annexed hereto and all other Trademarks, together with
any reissues, continuations or extensions thereof, all of the goodwill of the business connected with the use of, and symbolized by, each such Trademark, and all proceeds and products with respect to the foregoing; and 

all income, royalties, damages and payments relating to the foregoing, including without limitation, damages payable with respect to any claim
by Grantors against third parties for past, present or future (i) infringement or dilution of each such Trademark, or (ii) injury to the goodwill associated with each such Trademark, and all proceeds and products with respect to the
foregoing. 
 Notwithstanding the foregoing, no Trademark Collateral shall include any Excluded Property. 

(g) Incorporation of the Trademark Security Agreement. The terms and provisions of the Trademark Security Agreement are hereby
incorporated by reference, and this Supplement shall be considered an amendment and supplement to and part of the Trademark Security Agreement, all of the provisions of which Trademark Security Agreement are and remain in full force and effect. Any
reference after the date hereof in any Loan Document to the Trademark Security Agreement shall be a reference to the Trademark Security Agreement as amended and supplemented by this Supplement. 

(h) Reaffirmation of Obligations. Each Grantor hereby reaffirms its obligations (including, without limitation, the Obligations
(including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Trademark Security Agreement, the Guaranty and Security Agreement and all other Loan Documents. Each Grantor hereby
further ratifies and reaffirms the validity and enforceability of all of the Liens and security interests heretofore granted, pursuant to and in connection with the Trademark Security Agreement, the Security Agreement or any other Loan Document, to
Grantee 

 
(for the benefit of the Secured Parties), as collateral security for the obligations (including, without limitation, the Obligations (including any
Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Loan Documents in accordance with their respective terms, and acknowledges that all of such Liens and security interests, and all
Collateral (including, without limitation, the Trademark Collateral (as defined in the Trademark Security Agreement)) heretofore pledged as security for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)), continue to be and remain collateral for such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) from and after the date hereof. 
 (i)
Ratification. Each Grantor hereby restates, ratifies and reaffirms each and every term and condition set forth in the Trademark Security Agreement effective as of the date hereof and as amended hereby. 

(j) Governing Law. This Supplement is governed by and construed and enforced in accordance with the laws of the State of New York
applicable to contracts made and to be performed in such State. 
 (k) Counterparts. This Supplement may be executed in several
counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the
same agreement. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first
written above. 
  

			
	ENDOLOGIX, INC.
		
	By:	 	 /s/ Vaseem Mahboob

	Name:	 	Vaseem Mahboob
	Title:	 	Chief Financial Officer

 First Supplement to Trademark Security Agreement 

 IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first
written above. 
  

			
	TRIVASCULAR, INC.
		
	By:	 	 /s/ Vaseem Mahboob

	Name:	 	Vaseem Mahboob
	Title:	 	Chief Financial Officer and Secretary

 First Supplement to Trademark Security Agreement 

	
	 Agreed and accepted as of
 the date first
written above:

	
	DEERFIELD PRIVATE DESIGN FUND IV, L.P., as Agent and Grantee
	
	By: Deerfield Mgmt IV, L.P., General Partner
	
	By: J.E. Flynn Capital IV, LLC, General Partner
	
	By: /s/ David J.
Clark                                    
	Name: David J. Clark
	Title: Authorized Signatory

 First Supplement to Trademark Security Agreement 

 SCHEDULE A 

 

													
	 Mark
	  	 Application No.
	  	 Application Date
	  	 Registration No.
	  	 Registration

Date
	  	 Status of

Mark
	  	 Owner/

Applicant

							
	DURAPLY	  	86362822	  	8/11/14	  	5433696	  	3/27/18	  	Registered	  	Endologix, Inc.
							
	EVAS FORWARD	  	86116940	  	11/12/13	  	5306786	  	10/10/17	  	Registered	  	Endologix, Inc.
							
	VELA	  	85857988	  	2/22/13	  	5296578	  	9/26/17	  	Registered	  	Endologix, Inc.
							
	ANGIOTIP	  	85767055	  	10/30/12	  	5205176	  	5/16/17	  	Registered	  	Endologix, Inc.
							
	ACTIVESEAL	  	85518608	  	1/17/12	  	5396605	  	2/6/18	  	Registered	  	Endologix, Inc.
							
	OVATION ALTO	  	86047894	  	8/26/13	  	5195890	  	5/2/17	  	Registered	  	TriVascular, Inc.
							
	DESIGN ONLY	  	86854470	  	12/18/18	  	N/A	  	N/A	  	 Published (Pending) –
 Intent to
Use
	  	Endologix, Inc.
							
	ALLEGRO	  	86758465	  	9/16/15	  	N/A	  	N/A	  	 Published (Pending) –
 Intent to
Use
	  	TriVascular, Inc.
							
	VERTA	  	87116482	  	7/26/16	  	N/A	  	N/A	  	 Pending
 (Intent to use)
	  	Endologix, Inc.

  

  
 First Supplement to Trademark Security
Agreement 

 FIRST SUPPLEMENT TO PATENT SECURITY AGREEMENT 

This FIRST SUPPLEMENT TO PATENT SECURITY AGREEMENT (this “Supplement”) made as of August 9, 2018, by Endologix, Inc., a
Delaware corporation (“Endologix” or “Borrower”), Nellix, Inc., a Delaware corporation (“Nellix”), TriVascular, Inc., a Delaware corporation (“TriVascular”; TriVascular, Endologix
and Nellix are each individually a “Grantor” and collectively “Grantors”), in favor of Deerfield Private Design Fund IV, L.P., in its capacity as Agent for the Secured Parties (each as defined in the Facility
Agreement referenced below) (in such capacity, “Grantee”): 
 W I T N E S S E T H 

WHEREAS, Borrower, the other Loan Parties (including Nellix and TriVascular) from time to time party thereto, the financial institutions from
time to time party thereto as Lenders and Grantee have entered into that certain Amended and Restated Facility Agreement dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Facility
Agreement”), pursuant to which Grantee and the Lenders have agreed, subject to the terms and conditions thereof, to make certain loans to, and other credit accommodations in favor of, Borrower (collectively, the “Loans”).

 WHEREAS, pursuant to the terms of that certain Amended and Restated Guaranty and Security Agreement dated as of the date hereof, by and
among Grantee, Grantors and the other Loan Parties from time to time party thereto (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”), Grantors have
granted to Grantee, for its benefit and the benefit of the other Secured Parties, a security interest and Lien upon substantially all assets (including the Collateral) of Grantors, including all right, title and interest of Grantors in, to
and under all now owned and hereafter acquired (a) letters patent of the United States or any political subdivision thereof of each Grantor, all reissues and extensions thereof and all goodwill associated therewith, (b) applications for
letters patent of the United States and all divisions of each Grantor, continuations and continuations-in-part thereof and (c) rights to, and the rights to obtain
any reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of all the foregoing (all of the foregoing in clauses (a), (b)
and (c), collectively, together with all “Patents” as defined in the Guaranty and Security Agreement, “Patents”), together with the goodwill of the business symbolized by Grantors’ Patents, and all income, royalties,
damages and payments with respect to the foregoing, to secure the payment of all Secured Obligations, in each case other than Excluded Property. 

WHEREAS, Grantors and Grantee are parties to a certain Patent Security Agreement dated April 3, 2017 (as the same heretofore may have
been and hereafter may be amended, restated, supplemented or otherwise modified from time to time, the “Patent Security Agreement”). 

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, receipt and sufficiency of
which are hereby acknowledged, Grantors agree to supplement the Patent Security Agreement as follows: 

 1. Incorporation of Facility Agreement, Guaranty and Security Agreement and Patent
Security Agreement. The representations and warranties contained in the Facility Agreement, the Guaranty and Security Agreement and the Patent Security Agreement to the extent applicable to Grantors are hereby incorporated herein in their
entirety by this reference thereto. The provisions of Sections 1.2 and 6.4 of the Facility Agreement are incorporated herein by reference thereto mutatis mutandis. Unless otherwise noted herein, all capitalized terms used herein but not
otherwise defined herein shall have the respective meanings ascribed to such terms in the Guaranty and Security Agreement, or if not defined therein, in the Facility Agreement. In the event of a conflict between a provision of the Guaranty and
Security Agreement and a provision of this Supplement (or the Patent Security Agreement as amended and/or supplemented by this Supplement), the provision of the Guaranty and Security Agreement shall control. 

2. Grant and Reaffirmation of Grant of Security Interests. To secure the payment of the Secured Obligations, Grantors grant to Grantee,
for its benefit and the benefit of the other Secured Parties, and hereby reaffirm their prior grant pursuant to the Guaranty and Security Agreement and the Patent Security Agreement of, a continuing Lien on and security interest in Grantors’
entire right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the “Patent Collateral”), whether now owned or existing or hereafter created,
acquired or arising: 
 (a) each Patent listed on Schedule A annexed hereto and all other Patents, together with any
reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions thereof, all of the goodwill of the business connected with the use
of, and symbolized by, each such Patent, and all proceeds and products with respect to the foregoing; and 
 (b) all income,
royalties, damages and payments at any time due or payable or asserted under and with respect to the foregoing, including without limitation, damages payable with respect to any claim by Grantors against third parties for past, present or future
(i) infringement or dilution of each such Patent, or (ii) injury to the goodwill associated with each such Patent, and all proceeds and products with respect to the foregoing. 

Notwithstanding the foregoing, no Patent Collateral shall include any Excluded Property. 

3. Incorporation of the Patent Security Agreement. The terms and provisions of the Patent Security Agreement are hereby incorporated by
reference and this Supplement shall be considered an amendment and supplement to and part of the Patent Security Agreement, all of the provisions of which Patent Security Agreement are and remain in full force and effect. Any reference after the
date hereof in any Loan Document to the Patent Security Agreement shall be a reference to the Patent Security Agreement as amended and supplemented by this Supplement. 

4. Reaffirmation of Obligations. Each Grantor hereby reaffirms its obligations (including, without limitation, the Obligations
(including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Patent Security Agreement, the Guaranty and Security Agreement and all other Loan Documents. Each Grantor hereby
further ratifies and reaffirms the validity and enforceability of all of the Liens and security interests 

 
heretofore granted, pursuant to and in connection with the Patent Security Agreement, the Security Agreement or any other Loan Document, to Grantee (for the benefit of the Secured Parties), as
collateral security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) under the Loan Documents in accordance
with their respective terms, and acknowledges that all of such Liens and security interests, and all Collateral (including, without limitation, the Patent Collateral (as defined in the Patent Security Agreement)) heretofore pledged as security for
such obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)), continue to be and remain collateral for such obligations
(including, without limitation, the Obligations(including any Non-Callable Make Whole Amount, any CoC Fee and any Exit Payment)) from and after the date hereof. 

5. Ratification. Each Grantor hereby restates, ratifies and reaffirms each and every term and condition set forth in the Patent Security
Agreement effective as of the date hereof and as amended hereby. 
 6. Governing Law. This Supplement is governed by and construed and
enforced in accordance with the laws of the State of New York applicable to contracts made and to be performed in such State. 
 7.
Counterparts. This Supplement may be executed in several counterparts, and by each Party on separate counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an
original, but all of which together shall constitute one and the same agreement. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first
written above. 
  

			
	ENDOLOGIX, INC.
		
	By:	 	 /s/ Vaseem Mahboob

	Name:	 	Vaseem Mahboob
	Title:	 	Chief Financial Officer

  
 First Supplement to Patent Security
Agreement 

 IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first
written above. 
  

			
	NELLIX, INC.
		
	By:	 	 /s/ Vaseem Mahboob

	Name:	 	Vaseem Mahboob
	Title:	 	Chief Financial Officer and Secretary

  
 First Supplement to Patent Security
Agreement 

 IN WITNESS WHEREOF, each Grantor has duly executed this Supplement as of the date first
written above. 
  

			
	TRIVASCULAR, INC.
		
	By:	 	 /s/ Vaseem Mahboob

	Name:	 	Vaseem Mahboob
	Title:	 	Chief Financial Officer and Secretary

  
 First Supplement to Patent Security
Agreement 

			
	Agreed and Accepted
	As of the Date First Written Above:
	
	DEERFIELD PRIVATE DESIGN FUND IV, L.P., as Agent and Grantee as Agent
	
	By: Deerfield Mgmt IV, L.P., General Partner
	
	By: J.E. Flynn Capital IV, LLC, General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

  
 First Supplement to Patent Security
Agreement 

 SCHEDULE A 

 

											
	 Description/Title
	  	 Application
No.
	  	 Application
Date
	  	 Patent No.
	  	 Registration
Date
	  	 Owner/

Applicant

	Bifurcated vascular graft
deployment device	  	09505038	  	2/16/00	  	6210422	  	4/3/01	  	Endologix, Inc.
						
	Method of deploying
bifurcated vascular graft	  	09086247	  	5/28/98	  	6156063	  	12/5/00	  	Endologix, Inc.
						
	Bifurcated vascular graft
deployment device	  	08802478	  	2/20/97	  	6090128	  	7/18/00	  	Endologix, Inc.
						
	Inflatable implant	  	12628623	  	12/1/09	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Ptfe layers and methods of
manufacturing	  	12250946	  	10/14/08	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Ptfe layers and methods of
manufacturing	  	12250915	  	10/14/08	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Hybrid modular
endovascular graft	  	11097718	  	4/1/05	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Non-degradable low
swelling, water soluble
radiopaque hydrogel polymer	  	11097467	  	4/1/05	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Delivery system and method
for bifurcated graft	  	11205793	  	8/15/05	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Methods, compositions
and devices for embolizing body
lumens	  	11031311	  	1/7/05	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Endoluminal prosthesis
endoleak management	  	10691849	  	10/22/03	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Layered endovascular graft	  	10803153	  	3/17/04	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Delivery system and method
for bifurcated graft	  	10686863	  	10/16/03	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Inflatable intraluminal graft	  	10289137	  	11/5/02	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Endovascular graft	  	10289136	  	11/5/02	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Advanced endovascular graft	  	10091641	  	3/5/02	  	N/A	  	N/A	  	Trivascular, Inc.

  

 

  
 First Supplement to Patent Security
Agreement 

											
	 Description/Title
	  	 Application
No.
	  	 Application
Date
	  	 Patent No.
	  	 Registration
Date
	  	 Owner/

Applicant

	Delivery system and method
for bifurcated graft	  	10122474	  	4/11/02	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Layered endovascular graft	  	09970576	  	10/3/01	  	N/A	  	N/A	  	Trivascular, Inc.
						
	Dual inflatable arterial
prosthesis	  	15540246	  	6/27/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	Catheter system and methods
of using same	  	15632064	  	6/23/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	Catheter system and methods
of using same	  	15639028	  	6/30/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	Apparatus and method of
placement of a graft or graft
system	  	15610242	  	5/31/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	Stent graft delivery system	  	15676869	  	8/14/17	  	N/A	  	N/A	  	Nellix, Inc.        
						
	Endovascular graft	  	15686214	  	8/25/17	  	N/A	  	N/A	  	TriVascular, Inc.
						
	Advanced endovascular graft	  	15686218	  	8/25/17	  	N/A	  	N/A	  	TriVascular, Inc.
						
	Endovascular graft for
aneurysms involving major
branch vessels	  	15638559	  	6/30/17	  	N/A	  	N/A	  	TriVascular, Inc.
						
	Systems and methods for
guidewire crossover for
bifurcated	  	15491074	  	4/19/17	  	N/A	  	N/A	  	TriVascular, Inc.
						
	Low profile stent graft and
delivery system	  	15263469	  	9/13/16	  	N/A	  	N/A	  	TriVascular, Inc.
						
	Endoluminal prosthesis
systems and methods	  	15737223	  	12/15/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	Endovascular graft systems
and methods for deployment
in main and branch arteries	  	65/529663	  	7/7/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	Stent grants and methods of
enhancing flexibility of stent
grafts by thermal pleating	  	65/532737	  	7/14/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	Endoluminal device and
polymer	  	62/575827	  	10/23/17	  	N/A	  	N/A	  	Endologix, Inc.

  

  
 First Supplement to Patent Security
Agreement 

											
	 Description/Title
	  	 Application
No.
	  	 Application
Date
	  	 Patent
No.
	  	 Registration
Date
	  	 Owner/

Applicant

	Systems and Methods with
Stents and Filling Structure	  	62/382207	  	8/31/16	  	N/A	  	N/A	  	Endologix, Inc.
						
	STENTS, GRAFTS,
DELIVERY SYSTEMS,
AND METHODS	  	62/481560	  	4/4/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	ENDOVASCULAR
SYSTEMS, DEVICES,
AND METHODS
ALLOWING FOR BRANCH DEVICE
PLACEMENT IN POCKET
OF MAIN GRAFT	  	62/489213	  	4/24/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	ENDOVASCULAR GRAFT
SYSTEMS AND
METHODS FOR
DEPLOYMENT IN MAIN AND
BRANCH ARTERIES	  	62/529669	  	7/7/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	 STENT GRAFTS AND
METHODS OF ENHANCING
FLEXIBILITY OF STENT GRAFTS BY THERMAL

PLEATING
	  	62/532737	  	7/14/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	STENT GRAFT	  	15/911629	  	3/5/18	  	N/A	  	N/A	  	Endologix, Inc.
						
	INTERNAL ILIAC
PRESERVATION
DEVICES AND METHODS	  	15/965649	  	4/__/18	  	N/A	  	N/A	  	Endologix, Inc.
						
	MODULATION OF
INFLAMMATORY
RESPONSE FOLLOWING ENDOVASCULAR
TREATMENT	  	62/661569	  	4/23/18	  	N/A	  	N/A	  	Endologix, Inc.
						
	ADVANCED KINK
RESISTANT STENT
GRAFT	  	16/005269	  	6/11/18	  	N/A	  	N/A	  	Endologix, Inc.
						
	LOW PROFILE STENT
GRAFT AND DELIVERY
SYSTEM	  	15/985572	  	5/21/18	  	N/A	  	N/A	  	Endologix, Inc.

  

  
 First Supplement to Patent Security
Agreement 

											
	 Description/Title
	  	 Application
No.
	  	 Application
Date
	  	 Patent No.
	  	 Registration
Date
	  	 Owner/

Applicant

	SYSTEMS AND
METHODS WITH STENT
AND FILLING
STRUCTURE	  	15/774511	  	8/30/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	LONGITUDINALLY
EXTENDABLE STENT
GRAFT SYSTEMS AND
METHODS	  	15/774548	  	1/23/18	  	N/A	  	N/A	  	Endologix, Inc.
						
	GRAFT SYSTEMS
HAVING FILLING
STRUCTURES
SUPPORTED BY
SCAFFOLDS AND
METHODS FOR THEIR
USE	  	16/035497	  	7/13/18	  	N/A	  	N/A	  	Endologix, Inc.
						
	PRE-FIXATION DEVICE
FOR NELLIX AND OTHER
EVAS DEVICES	  	62/678956	  	5/31/18	  	N/A	  	N/A	  	Endologix, Inc.
						
	SYSTEMS AND
METHODS WITH
FENESTRATED GRAFT
AND FILLING
STRUCTURE	  	16/066595	  		  	N/A	  	N/A	  	Endologix, Inc.
						
	MODULATION OF
INFLAMMATORY
RESPONSE FOLLOWING
ENDOVASCULAR
TREATMENT	  	62/661569	  	4/23/18	  	N/A	  	N/A	  	Endologix, Inc.
						
	ENDOLUMINAL DEVICE
AND POLYMER	  	62/575827	  	10/23/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	Implantable vascular graft	  	12/860280	  	8/20/10	  	20100318174	  		  	Endologix, Inc.
						
	Endoluminal vascular
prosthesis	  	11/623679	  	1/16/07	  	2007012412	  		  	Endologix, Inc.
						
	Delivery catheter for
endovascular device	  	13/835491	  	3/15/13	  	9498363	  	11/22/16	  	Trivascular, Inc.
						
	Stent-graft with improved
flexibility	  	15568834	  	10/24/17	  	N/A	  	N/A	  	TriVascular, Inc.

  

  
 First Supplement to Patent Security
Agreement 

											
	 Description/Title
	  	 Application
No.
	  	 Application
Date
	  	 Patent No.
	  	 Registration
Date
	  	 Owner/

Applicant

	System and methods of
Endovasular Aneurysm
Treatment	  	14682414	  	8/21/17	  	N/A	  	N/A	  	Nellix, Inc.
						
	Stent graft systems with
restraints in circumferential
channels and methods thereof	  	62/678961	  	5/31/18	  	N/A	  	N/A	  	Endologix, Inc.
						
	Percutaneous method and
device to treat dissections	  	15/429090	  	2/9/17	  	N/A	  	N/A	  	Endologix, Inc.
						
	Endovascular delivery
system with an improved radiopague
marker scheme	  	16/049560	  	7/30/18	  	N/A	  	N/A	  	Nellix, Inc.

  

  
 First Supplement to Patent Security
Agreement 

 SCHEDULE 3 

GRANTOR INFORMATION 
  

									
	 GRANTOR
(exact legal name)
	  	 STATE/
COUNTRY
OF
ORGANIZATION
	  	 FEDERAL
EMPLOYER
IDENTIFICATION
NUMBER
	  	 CHIEF EXECUTIVE
OFFICE
	  	ORGANIZATIONAL
IDENTIFICATION
NUMBER
	Endologix, Inc.	  	Delaware	  	68-0328265	  	2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.	  	2338745
					
	CVD/RMS Acquisition Corp.	  	Delaware	  	33-0928438	  	2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.	  	2955166
					
	RMS/Endologix Sideways Merger Corp	  	Delaware	  	03-0512974	  	2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.	  	3530477
					
	Nellix, Inc.	  	Delaware	  	94-3398416	  	2 Musick, Irvine, County
of Orange, CA 92618 U.S.A.	  	3359980
					
	TriVascular Technologies, Inc.	  	Delaware	  	87-0807313	  	3910 Brickway Blvd.,
County of Santa Rosa,
Sonoma, CA 95403 U.S.A.	  	4387054
					
	TriVascular, Inc.	  	California	  	68-0402620	  	3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.	  	C2065374
					
	Endologix
Canada, LLC	  	Delaware	  	47-2442872	  	3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.	  	5647226
					
	TriVascular Sales LLC	  	Texas	  	46-0859179	  	3910 Brickway Blvd.,
Santa Rosa, County of
Sonoma, CA 95403 U.S.A.	  	801644988

 SCHEDULE 4 

PLACES OF BUSINESS / LOCATION OF COLLATERAL 
  

									
	 Grantor
	  	 Location
	  	 Specify
Whether
Location
Has
(i)
Inventory
and/or
Equipment,
(ii) Books
and
Records, or
(iii) Both
	  	 Interest
	  	 Lessor/Property

Owner/Lessee

	Endologix, Inc.	  	2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.	  	Both	  	Lease	  	The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
					
	Endologix, Inc.	  	33 & 35 Hammond, Irvine, County of Orange, CA 92618 U.S.A	  	Inventory and/or Equipment	  	Lease	  	The Northwestern Mutual Life Insurance Company, att: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
					
	Endologix, Inc.	  	 378 Commercial Street, Malden, MA 02148
 165
Chubb Avenue, Lyndhurst, NJ 07071
 1130 Commerce Blvd, Swedesboro, NJ 08085

2250 Outerloop Drive, Louisville, KY 40219
	  	Inventory
and/or
Equipment	  	Third
Party
Warehouse	  	UPS
					
	Endologix, Inc.	  	54 Yangcheon-ro, Gangseo-gu, Seoul 07522	  	Inventory
and/or
Equipment (no other Collateral is located at this location)	  	Third
Party
Warehouse	  	TNT Express Korea
					
	Endologix, Inc.	  	 10 Anson Road #21-04 & #21-04A

International Plaza
	  	Inventory
and/or
Equipment (no other	  	Occupied	  	Endologix Singapore Private Limited

									
	 Grantor
	  	 Location
	  	 Specify
Whether
Location
Has
(i)
Inventory
and/or
Equipment,
(ii) Books
and
Records, or
(iii) Both
	  	 Interest
	  	 Lessor/Property

Owner/Lessee

					
		  	Singapore 079903	  	Collateral is located at this location)	  		  	
					
	Endologix, Inc.	  	A-311, M-Sate, 114 Beopwon-ro, Songpa-gu, Seoul, South Korea	  	Inventory
and/or
Equipment (no other
Collateral is located at this location)	  	Occupied	  	N.A.
					
	Endologix, Inc.	  	Grantor and each Guarantor’s sales representatives hold Trunk Inventory in their possession for sales calls and procedures, which Trunk Inventory is not held at a specific location or locations.	  	Inventory
and/or
Equipment (no other Collateral is located at this location)	  	N.A.	  	N.A.
					
		  	Certain Inventory of the Grantor and each Guarantor is held by numerous third parties on a consignment basis at various locations.	  	Inventory
and/or
Equipment (no other Collateral is located at this location)	  	N.A.	  	N.A.
					
	CVD/RMS
Acquisition
Corp.	  	2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.	  	Books and Records	  	Occupied	  	The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
					
	Nellix, Inc.	  	2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.	  	Books and Records	  	Occupied	  	The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618

									
	 Grantor
	  	 Location
	  	 Specify
Whether
Location
Has
(i)
Inventory
and/or
Equipment,
(ii) Books
and
Records, or
(iii) Both
	  	 Interest
	  	 Lessor/Property

Owner/Lessee

	RMS/Endologix Sideways Merger Corp.	  	2 Musick, Irvine,
County of Orange,
CA 92618 U.S.A.	  	Books and Records	  	Occupied	  	The Northwestern Mutual Life Insurance Company, attn: William A. Budge, 19 Hammond, Suite 501, Irvine, California 92618
					
	TriVascular
Technologies,
Inc.	  	3910 Brickway
Blvd., Santa Rosa,
County of Sonoma,
CA 95403 U.S.A.	  	Books and Records	  	Occupied	  	Sonoma Airport
Properties LLC
					
	TriVascular, Inc.	  	3910 Brickway
Blvd., Santa Rosa,
County of Sonoma,
CA 95403 U.S.A.	  	Both	  	Lease	  	Sonoma Airport
Properties LLC
					
	TriVascular Sales LLC	  	3910 Brickway
Blvd., Santa Rosa,
County of Sonoma,
CA 95403 U.S.A.	  	Books and Records	  	Occupied	  	Sonoma Airport
Properties LLC
					
	Endologix
Canada, LLC	  	3910 Brickway
Blvd., Santa Rosa,
County of
Sonoma, CA
95403 U.S.A.	  	Books and Records	  	Occupied	  	Sonoma Airport
Properties LLC

 SCHEDULE 5 

COMMERCIAL TORT CLAIMS 
 None. 

 SCHEDULE 6 

ACCOUNTS 
  

											
	ENTITY	  	COUNTRY	  	ACCT	  	CURR	  	BANK	  	USE
	Endologix Inc	  	US	  	XXXXX1702	  	USD	  	Bank of America	  	Operating account
						
	Endologix Inc	  	US	  	XXXXX1689	  	USD	  	Bank of America	  	Payroll account
						
	Endologix Inc	  	US	  	XXXXX5279	  	USD	  	Wells Fargo	  	Old Operating account
						
	Endologix Inc	  	US	  	XXXXX5311	  	USD	  	Wells Fargo	  	Old payroll account
						
	Endologix Inc	  	Us	  	XXXXX3910	  	USD	  	Bank of America	  	Lockbox account
						
	Endologix Inc	  	US	  	XXXXX4066	  	USD	  	Bank of America	  	Credit Card Cash Collateral account
						
	Trivascular Inc	  	US	  	XXXXX5539	  	USD	  	Silicon Valley Bank	  	Operating account
						
	Trivascular Inc	  	The Netherlands	  	XXXXX8640	  	EUR	  	KBC Bank NV Nederland	  	Currency account
						
	Trivascular Inc	  	UK London	  	XXXXX8709	  	GBP	  	National Westminster Bank	  	Currency account
						
	Trivascular Sales LLC	  	US	  	XXXXX7400	  	USD	  	Silicon Valley Bank	  	Payroll account
						
	Endologix Canada LLC	  	Canada	  	XXXXX7912	  	CAD	  	Bank of Montreal	  	Operating account

 SCHEDULE 7 

REAL PROPERTY 
 None. 

 SCHEDULE 8 

COPYRIGHTS 
 None. 

 SCHEDULE 9 

INTELLECTUAL PROPERTY LICENSES 
  

	1.	 Inbound License Agreement, dated as of February 22, 2006, by and between Incept LLC and Nellix, Inc.

  

	2.	 Inbound Amendment No. 1. to License Agreement, dated as of April 30, 2012, by and between Incept LLC
and Nellix, Inc. 

  

	3.	 Inbound Amendment No. 2 to License Agreement, dated as of December 3, 2014, by and between Incept LLC
and Nellix, Inc. 

  

	4.	 Inbound Master License Agreement, dated as of May 5, 2008, by and between SurModics, Inc. and Endologix,
Inc. 

  

	5.	 Inbound Development and OEM Device Supply Agreement, dated as of August 5, 2015, by and between Bard
Peripheral Vascular, Inc. and Endologix, Inc. 

  

	6.	 Inbound License Agreement, dated as of June 22, 2011, by and between NorMedix, LLC and Endologix, Inc.

  

	7.	 Inbound Settlement and Patent License Agreement, dated as of March 17, 2016, by and between LifePort
Sciences, LLC and Endologix, Inc. 

  

	8.	 Inbound License Agreement, dated as of July 23, 2013, by and between Thomas L. Fogarty and Endologix, Inc.

  

	9.	 Inbound License Agreement, dated as of March 28, 2008, by and between Trivascular, Inc. (formerly
Trivascular 2, Inc.) and Boston Scientific Scimed, Inc. and Endovascular Technologies, Inc. 

 SCHEDULE 10 

PATENTS 
 See attached. 

 PATENT SCHEDULE 
  

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Stent graft	  	US9757262B2	  	US13943246A	  	2013-07-16
						
	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US9700701B2	  	US13544426A	  	2012-07-09
						
	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US9687374B2	  	US15379268A	  	2016-12-14
						
	ENDOLOGIX INC.	  	US	  	Percutaneous method and device to treat dissections	  	US9579103B2	  	US12771711A	  	2010-04-30
						
	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US9549835B2	  	US14462485A	  	2014-08-18

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Method and system for treating aneurysms	  	US9415195B2	  	US13441762A	  	2012-04-06
						
	ENDOLOGIX INC.	  	US	  	Devices and methods to treat vascular dissections	  	US9393100B2	  	US13988175A	  	2013-05-17
						
	ENDOLOGIX INC.	  	US	  	Method for forming materials in situ within a medical device	  	US9289536B2	  	US14201332A	  	2014-03-07
						
	ENDOLOGIX INC.	  	US	  	Apparatus and method of placement of a graft or graft system	  	US9149381B2	  	US14172126A	  	2014-02-04
						
	ENDOLOGIX INC.	  	US	  	Stent graft	  	US8821564B2	  	US13397952A	  	2012-02-16
						
	ENDOLOGIX INC.	  	US	  	Apparatus and methods for repairing aneurysms	  	US8814928B2	  	US12616928A	  	2009-11-12

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US8808350B2	  	US13408952A	  	2012-02-29
						
	ENDOLOGIX INC.	  	US	  	Graft systems having semi-permeable filling structures and methods for their use	  	US8801768B2	  	US13355705A	  	2012-01-23
						
	ENDOLOGIX INC	  	US	  	Bifurcated graft deployment systems and methods	  	US8764812B2	  	US13745682A	  	2013-01-18
						
	ENDOLOGIX INC.	  	US	  	Apparatus and method of placement of a graft or graft system	  	US8672989B2	  	US13546950A	  	2012-07-11
						
	ENDOLOGIX INC.	  	US	  	Graft deployment system	  	US8568466B2	  	US13269332A	  	2011-10-07
						
	ENDOLOGIX INC.	  	US	  	Dual concentric guidewire and methods of bifurcated graft deployment	  	US8523931B2	  	US11623022A	  	2007-01-12

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Stent graft	  	US8491646B2	  	US12837398A	  	2010-07-15
						
	ENDOLOGIX INC.	  	US	  	Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve	  	US8377110B2	  	US10820455A	  	2004-04-08
						
	ENDOLOGIX INC.	  	US	  	Bifurcated graft deployment systems and methods	  	US8357192B2	  	US13046541A	  	2011-03-11
						
	ENDOLOGIX INC.	  	US	  	Bifurcated graft deployment systems and methods	  	US8236040B2	  	US12101863A	  	2008-04-11
						
	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US8216295B2	  	US12496446A	  	2009-07-01
						
	ENDOLOGIX INC.	  	US	  	Apparatus and method of placement of a graft or graft system	  	US8221494B2	  	US12390346A	  	2009-02-20

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Methods and systems for endovascular aneurysm treatment	  	US8182525B2	  	US12421297A	  	2009-04-09
						
	ENDOLOGIX INC.	  	US	  	Single puncture bifurcation graft deployment system	  	US8167925B2	  	US12732095A	  	2010-03-25
						
	ENDOLOGIX INC.	  	US	  	Bifurcation graft deployment catheter	  	US8147535B2	  	US11189101A	  	2005-07-25
						
	ENDOLOGIX INC.	  	US	  	Material for creating multi-layered films and methods for making the same	  	US8133559B2	  	US13100483A	  	2011-05-04
						
	ENDOLOGIX INC.	  	US	  	Stent graft	  	US8118856B2	  	US12844266A	  	2010-07-27
						
	ENDOLOGIX INC.	  	US	  	Graft systems having filling structures supported by scaffolds and methods for their use	  	US8048145B2	  	US11413460A	  	2006-04-28

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Graft deployment system	  	US8034100B2	  	US10722367A	  	2003-11-25
						
	ENDOLOGIX INC.	  	US	  	Material for creating multi-layered films and methods for making the same	  	US7951448B2	  	US12858274A	  	2010-08-17
						
	ENDOLOGIX INC	  	US	  	Self expanding bifurcated endovascular prosthesis	  	US7892277B2	  	US11417883A	  	2006-05-03
						
	ENDOLOGIX INC.	  	US	  	Material for creating multi-layered films and methods for making the same	  	US7790273B2	  	US11752750A	  	2007-05-23
						
	ENDOLOGIX INC.	  	US	  	Devices for repairing aneurysms	  	US7682383B2	  	US10481386A	  	2004-06-14
						
	ENDOLOGIX INC.	  	US	  	System and methods for endovascular aneurysm treatment	  	US7666220B2	  	US11482503A	  	2006-07-07

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Methods and systems for endovascular aneurysm treatment	  	US7530988B2	  	US11187471A	  	2005-07-22
						
	ENDOLOGIX INC	  	US	  	Self expanding bifurcated endovascular prosthesis	  	US7520895B2	  	US10119525A	  	2002-04-08
						
	ENDOLOGIX INC	  	US	  	Bifurcation graft deployment catheter	  	US6953475B2	  	US10675060A	  	2003-09-30
						
	ENDOLOGIX INC.	  	US	  	Implantable vascular graft	  	US6733523B2	  	US09891620A	  	2001-06-26
						
	ENDOLOGIX INC	  	US	  	Single puncture bifurcation graft
deployment system	  	US6663665B2	  	US09795993A	  	2001-02-28
						
	ENDOLOGIX INC.	  	US	  	Bifurcation graft deployment catheter	  	US6660030B2	  	US09747094A	  	2000-12-22

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	US	  	Endoluminal vascular prosthesis	  	US6508835B1	  	US09723979A	  	2000-11-28
						
	ENDOLOGIX INC.	  	US	  	Bifurcation graft deployment catheter	  	US6500202B1	  	US09525778A	  	2000-03-15
						
	ENDOLOGIX INC.	  	US	  	Dual wire placement catheter	  	US6440161B1	  	US09348356A	  	1999-07-07
						
	ENDOLOGIX INC.	  	US	  	Single puncture bifurcation graft
deployment system	  	US6261316B1	  	US09266661A	  	1999-03-11
						
	ENDOLOGIX INC.	  	US	  	Articulating bifurcation graft	  	US6197049B1	  	US09251363A	  	1999-02-17
						
	ENDOLOGIX INC.	  	US	  	Endoluminal vascular prosthesis	  	US6187036B1	  	US09210280A	  	1998-12-11

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Segmented stent for flexible stent delivery system	  	US6187034B1	  	US09229856A	  	1999-01-13
						
	ENDOLOGIX INC.	  	US	  	Endoluminal vascular prosthesis	  	US6077296A	  	US0934689A	  	1998-03-04
						
	ENDOLOGIX INC.	  	US	  	Stent delivery system featuring a flexible balloon	  	US6022359A	  	US09229519A	  	1999-01-13
						
	ENDOLOGIX INC.	  	US	  	Radially expandable stent featuring accordion stops	  	US5931866A	  	US09028305A	  	1998-02-24
						
	ENDOLOGIX INC.	  	US	  	DUAL INFLATABLE ARTERIAL PROSTHESIS	  	US20180021045A1	  	US15540246A	  	2017-06-27
						
	ENDOLOGIX INC.	  	US	  	CATHETER SYSTEM AND METHODS OF USING SAME	  	US20170304098A1	  	US15632064A	  	2017-06-23

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	CATHETER SYSTEM AND METHODS OF USING SAME	  	US20170296791A1	  	US15639028A	  	2017-06-30
						
	ENDOLOGIX INC	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20170266025A1	  	US15610242A	  	2017-05-31
						
	ENDOLOGIX INC.	  	US	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	  	US20170239035A1	  	US15310198A	  	2016-11-10
						
	ENDOLOGIX INC.	  	US	  	METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES	  	US20170238937A1	  	US15438682A	  	2017-02-21
						
	ENDOLOGIX INC	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20170128246A1	  	US15414499A	  	2017-01-24
						
	ENDOLOGIX INC	  	US	  	METHOD AND SYSTEM FOR TREATING ANEURYSMS	  	US20170007263A1	  	US15205365A	  	2016-07-08

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	METHOD FOR FORMING HYDROGELS AND MATERIALS THEREFOR	  	US20160367731A1	  	US15256462A	  	2016-09-02
						
	ENDOLOGIX INC.	  	US	  	DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS	  	US20160302798A1	  	US15194159A	  	2016-06-27
						
	ENDOLOGIX INC.	  	US	  	SYSTEMS AND METHODS FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE	  	US20160030051A1	  	US14776385A	  	2015-09-14
						
	ENDOLOGIX INC	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20150366688A1	  	US14840428A	  	2015-08-31
						
	ENDOLOGIX INC.	  	US	  	METHOD AND SYSTEM FOR TREATING ANEURYSMS	  	US20150250989A1	  	US14717938A	  	2015-05-20
						
	ENDOLOGIX INC.	  	US	  	FENESTRATED PROSTHESIS	  	US20150173923A1	  	US14581675A	  	2014-12-23

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Apparatus and Methods for Repairing Aneurysms	  	US20150012081A1	  	US14330812A	  	2014-07-14
						
	ENDOLOGIX INC.	  	US	  	STENT GRAFT	  	US9907642	  	US14461308A	  	2014-08-15
						
	ENDOLOGIX INC	  	US	  	ENDOLUMENAL VASCULAR PROSTHESIS WITH NEOINTIMA INHIBITING POLYMERIC SLEEVE	  	US20130253638A1	  	US13731908A	  	2012-12-31
						
	ENDOLOGIX INC.	  	US	  	Methods and Systems for Treating Aneurysms	  	US20120184982A1	  	US13354094A	  	2012-01-19
						
	ENDOLOGIX INC.	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20120109279A1	  	US13287907A	  	2011-11-02
						
	ENDOLOGIX INC.	  	US	  	FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE	  	US20110276078A1	  	US12966852A	  	2010-12-13

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	US	  	SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS	  	US20110224782A1	  	US13027077A	  	2011-02-14
						
	ENDOLOGIX INC.	  	US	  	ENDOLUMINAL VASCULAR PROSTHESIS	  	US20110218617A1	  	US13039157A	  	2011-03-02
						
	ENDOLOGIX INC	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20110054587A1	  	US12769546A	  	2010-04-28
						
	ENDOLOGIX INC	  	US	  	IMPLANTABLE VASCULAR GRAFT	  	US20100318174A1	  	US12860280A	  	2010-08-20
						
	ENDOLOGIX INC	  	US	  	IMPLANTABLE VASCULAR GRAFT	  	US20100318181A1	  	US12860310A	  	2010-08-20
						
	ENDOLOGIX INC.	  	US	  	UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE	  	US20100261662A1	  	US12757900A	  	2010-04-09

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	US	  	GRAFT DEPLOYMENT SYSTEM	  	US20100179636A1	  	US12726257A	  	2010-03-17
						
	ENDOLOGIX INC.	  	US	  	STENT GRAFT DELIVERY SYSTEM	  	US20100036360A1	  	US12429474A	  	2009-04-24
						
	ENDOLOGIX INC.	  	US	  	DOCKING APPARATUS AND METHODS OF USE	  	US20090319029A1	  	US12478208A	  	2009-06-04
						
	ENDOLOGIX INC.	  	US	  	GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS	  	US20100004728A1	  	US12371087A	  	2009-02-13
						
	ENDOLOGIX INC.	  	US	  	METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE	  	US20090155337A1	  	US12269677A	  	2008-11-12
						
	ENDOLOGIX INC.	  	US	  	STENT	  	US20090105806A1	  	US12257149A	  	2008-10-23

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Multi-segmented graft deployment system	  	US20080071343A1	  	US11522292A	  	2006-09-15
						
	ENDOLOGIX INC	  	US	  	IMPLANTABLE VASCULAR GRAFT	  	US20070299497A1	  	US11764715A	  	2007-06-18
						
	ENDOLOGIX INC.	  	US	  	Methods and systems for aneurysm treatment using filling structures	  	US20070150041A1	  	US11444603A	  	2006-05-31
						
	ENDOLOGIX INC	  	US	  	ENDOLUMINAL VASCULAR PROSTHESIS	  	US20070112412A1	  	US11623679A	  	2007-01-16
						
	ENDOLOGIX INC.	  	US	  	Method and apparatus for decompressing aneurysms	  	US20070078506A1	  	US11580201A	  	2006-10-12
						
	ENDOLOGIX INC.	  	US	  	Method and apparatus for decompressing aneurysms	  	US20050245891A1	  	US11104303A	  	2005-04-12

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC.	  	US	  	Vascular stent-graft apparatus	  	US20040167607A1	  	US10787404A	  	2004-02-24
						
	ENDOLOGIX INC.	  	US	  	Stent-graft with positioning anchor	  	US20040116997A1	  	US10668901A	  	2003-09-22
						
	ENDOLOGIX INC.	  	US	  	Flexible vascular graft	  	US20010025195A1	  	US09728582A	  	2000-12-01
						
	ENDOLOGIX INC	  	US	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	  	US20170239035A1	  	US15310198A	  	2016-11-10
						
	ENDOLOGIX INC	  	US	  	DUAL INFLATABLE ARTERIAL PROSTHESIS	  	US20180021045A1	  	US15540246A	  	2017-06-27
						
	ENDOLOGIX INC	  	US	  	ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS	  		  	US15737223	  	2017-12-15

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	US	  	Systems and Methods with Stents and Filling Structure	  		  	62/382207	  	2016-08-31
						
	ENDOLOGIX INC	  	US	  	STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS	  		  	62/481560	  	2017-04-04
						
	ENDOLOGIX INC	  	US	  	ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT	  		  	62/489213	  	2017-04-24
						
	ENDOLOGIX INC	  	US	  	ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES	  		  	62/529669	  	2017-07-07
						
	ENDOLOGIX INC	  	US	  	STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING	  		  	62/532737	  	2017-07-14
						
	ENDOLOGIX INC	  	US	  	STENT GRAFT	  		  	15/911629	  	2018-03-05

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	US	  	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS	  		  	15/965649	  	2018-04-
						
	ENDOLOGIX INC	  	US	  	 MODULATION OF INFLAMMATORY
 RESPONSE
FOLLOWING
ENDOVASCULAR TREATMENT
	  		  	62/661569	  	2018-4-23
						
	ENDOLOGIX INC	  	US	  	ADVANCED KINK RESISTANT STENT GRAFT	  		  	16/005269	  	2018-6-11
						
	ENDOLOGIX INC	  	US	  	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	  		  	15/985572	  	2018-5-21
						
	ENDOLOGIX INC	  	US	  	SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE	  		  	15/774511	  	2017-8-30
						
	ENDOLOGIX INC	  	US	  	 LONGITUDINALLY EXTENDABLE
 STENT GRAFT SYSTEMS
AND
METHODS
	  		  	15/774548	  	2018-1-23

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	US	  	 GRAFT SYSTEMS HAVING FILLING
 STRUCTURES
SUPPORTED BY
SCAFFOLDS AND METHODS FOR THEIR USE
	  		  	16/035497	  	2018-7-13
						
	ENDOLOGIX INC	  	US	  	PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES	  		  	62/678956	  	2018-5-31
						
	ENDOLOGIX INC	  	US	  	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	  		  	16/066595	  	
						
	ENDOLOGIX INC	  	US	  	 MODULATION OF INFLAMMATORY
 RESPONSE
FOLLOWING
ENDOVASCULAR TREATMENT
	  		  	62/661569	  	2018-4-23
						
	ENDOLOGIX INC.	  	US	  	FENESTRATED PROSTHESIS	  	US8945202	  	12/769581	  	2015-2-3
						
	ENDOLOGIX INC.	  	US	  	Fenestrated prosthesis	  	US8945202	  	12/769581	  	4/28/10

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX, INC.	  	US	  	 Bifurcated vascular graft deployment

device
	  	US6210422	  	09/505038	  	2/16/00
						
	ENDOLOGIX, INC.	  	US	  	Method of deploying bifurcated vascular graft	  	US6156063	  	09/086247	  	5/28/98
						
	ENDOLOGIX, INC.	  	US	  	 Bifurcated vascular graft deployment

device
	  	US6090128	  	08/802478	  	2/20/97
						
	ENDOLOGIX, INC.	  	US	  	 Endovascular prosthesis with improved
 sealing
means for aneurysmal arterial
disease and method of use
	  	US5665117	  	08/620072	  	3/21/96
						
	ENDOLOGIX, INC.	  	US	  	Locking assembly for coupling guidewire to delivery system	  		  	15/317905	  	12/9/16
						
	Endologix, Inc. and The Cleveland Clinic Foundation	  	US	  	Fenestrated prosthesis	  	US8945202	  	US12769581	  	4/28/10

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Endologix, Inc.	  	US	  	 Single puncture bifurcation graft
 deployment
system
	  	US7691135	  	US10690227	  	10/21/03
						
	Endologix, Inc.	  	US	  	Bifurcated vascular graft and method and apparatus for deploying same	  	US6951572	  	US10639255	  	8/12/03
						
	Endologix, Inc.	  	US	  	Radiation delivery balloon catheter	  	US6699170	  	US09688396	  	10/16/00
						
	Endologix, Inc.	  	US	  	Dual wire placement catheter	  	US6689157	  	US10035729	  	12/21/01
						
	Endologix, Inc.	  	US	  	Method for delivering radiation to an intraluminal site in the body	  	US6685618	  	US09944649	  	8/31/01
						
	Endologix, Inc.	  	US	  	Radiation delivery catheters and dosimetry methods	  	US6491619	  	US09648563	  	8/25/00

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Endologix, Inc.	  	US	  	Endoluminal vascular prosthesis	  	US6331190	  	US09483411	  	1/14/00
						
	Endologix, Inc.	  	US	  	 Bifurcated vascular graft deployment

device
	  	US6210422	  	US09505038	  	2/16/00
						
	Endologix, Inc.	  	US	  	Method of deploying bifurcated vascular graft	  	US6156063	  	US09086247	  	5/28/98
						
	Endologix, Inc.	  	US	  	 Bifurcated vascular graft deployment

device
	  	US6090128	  	US08802478	  	2/20/97
						
	Endologix, Inc.	  	US	  	Axially non-contracting flexible radially expandable stent	  	US6083259	  	US09192803	  	11/16/98
						
	Endologix, Inc.	  	US	  	 Endovascular prosthesis with improved
 sealing
means for aneurysmal arterial
disease and method of use
	  	US5665117	  	US08620072	  	3/21/96

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Endologix, Inc.	  	US	  	Apparatus and method of placement of a graft or graft system	  		  	US14172126	  	2/4/14
						
	Endologix, Inc. and The Cleveland Clinic Foundation	  	US	  	Apparatus and method of placement of a graft or graft system	  		  	US12769506	  	4/28/10
						
	Endologix, Inc.	  	US	  	Stent graft delivery system	  		  	US12429474	  	4/24/09
						
	ENDOLOGIX INC	  	WO	  	ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS	  	WO2016210363A1	  	PCT/US2016/039414	  	2016-06-24
						
	ENDOLOGIX INC	  	JP	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	  	JP2017517321A	  	JP2016569901	  	2015-05-05
						
	ENDOLOGIX INC	  	CN	  	Endoluminal Prosthesis Systems and Methods	  		  	201680037099.X	  	2017-12-22

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	JP	  	DUAL INFLATABLE ARTERIAL PROSTHESIS	  		  	2017-534803	  	2017-06-28
						
	ENDOLOGIX INC	  	US	  	ENDOLUMINAL DEVICE AND POLYMER	  		  	62/575827	  	2017-10-23
						
	TRIVASCULAR INC	  	US	  	Advanced Endovascular Graft	  	US9788934B2	  	US14799656A	  	2015-07-15
						
	ENDOLOGIX INC	  	WO	  	DUAL INFLATABLE ARTERIAL PROSTHESIS	  	WO2016109757A1	  	PCT/US2015/068204	  	2015-12-30
						
	ENDOLOGIX INC	  	WO	  	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	  	WO2017117068A1	  	PCT/US2016/068575	  	2016-12-23
						
	ENDOLOGIX INC	  	WO	  	SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE	  	WO2017197313A1	  	PCT/US2017/032490	  	2017-05-12

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	PCT	  	SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE	  		  	PCT/US2017/049482	  	2017-08-30
						
	ENDOLOGIX INC	  	PCT	  	LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS	  		  	PCT/US2018/014920	  	2018-01-23
						
	ENDOLOGIX INC	  	PCT	  	STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING	  		  	PCT/US2018/042158	  	2018-7-13
						
	ENDOLOGIX INC	  	PCT	  	 ENDOVASCULAR SYSTEMS,
 DEVICES, AND
METHODS
ALLOWING FOR BRANCH DEVICE PLACEMENT IN CHANNEL OF MAIN GRAFT
	  		  	PCT/US2018/028959	  	2018-4-23
						
	ENDOLOGIX INC	  	PCT	  	ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES	  		  	PCT/US2018/041152	  	7/6/2018

											
	ENDOLOGIX INC	  	EP	  	DUAL CONCENTRIC GUIDEWIRE AND METHODS OF BIFURCATED GRAFT DEPLOYMENT | DOPPELTER KONZENTRISCHER FÜHRUNGSDRAHT UND VERFAHREN ZUM EINSATZ EINES VERZWEIGTEN IMPLANTATS | FIL DE GUIDAGE CONCENTRIQUE	  	EP2117631B1	  	EP2008727613A	  	2008-01-11

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
		  		  	 MIXTE ET PROCÉDÉS DE

DÉPLOIEMENT DE GREFFON À DEUX BRANCHES
	  		  		  	
						
	ENDOLOGIX INC	  	EP	  	 DEVICES FOR REPAIRING
 ANEURYSMS | VORRICHTUNG
ZUM AUSBESSERN EINES ANEURYSMAS | DISPOSITIFS DE REPARATION D’ANEVRISMES
	  	EP1397089B1	  	EP2002730505A	  	2002-06-17
						
	ENDOLOGIX INC	  	EP	  	CATHETER SYSTEM | Kathetersystem | Systèmes de cathéter	  	EP2520320B1	  	EP2012178965A	  	2009-06-30
						
	ENDOLOGIX INC	  	EP	  	 DEVICES FOR REPAIRING
 ANEURYSMS | VORRICHTUNG
ZUM AUSBESSERN EINES ANEURYSMAS | PROTHÈSE POUR LE TRAITEMENT DES ANÉVRISMES
	  	EP2260795B1	  	EP201011024A	  	2002-06-17
						
	ENDOLOGIX INC	  	EP	  	SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME UTILISANT DES STRUCTURES DE REMPLISSAGE	  	EP1962722B1	  	EP2006850439A	  	2006-12-18

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	EP	  	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES
ECHAFAUDAGES	  	EP1874231B1	  	EP2006751879A	  	2006-04-28
						
	ENDOLOGIX INC	  	EP	  	GRAFT DEPLOYMENT SYSTEM | IMPLANTAT-ABLAGESYSTEM | SYSTEME DE DEPLOIEMENT DE TUBE PROTHETIQUE	  	EP1572034B1	  	EP2003790040A	  	2003-11-25
						
	ENDOLOGIX INC	  	EP	  	STENT GRAFT | STENT-IMPLANTAT | GREFFON DE STENT	  	EP2459127B1	  	EP2010806904A	  	2010-07-27
						
	ENDOLOGIX INC	  	EP	  	STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT	  	EP1542616B1	  	EP2003754880A	  	2003-09-22
						
	ENDOLOGIX INC	  	EP	  	Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires	  	EP2422745B1	  	EP2011180827A	  	2005-07-22

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	EP	  	Catheter system | Kathetersystem | Système de cathéter	  	EP2293838B1	  	EP2009774381A	  	2009-06-30
						
	ENDOLOGIX INC	  	EP	  	Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire	  	EP1778131B1	  	EP2005773726A	  	2005-07-22
						
	ENDOLOGIX INC	  	EP	  	IMPLANTABLE VASCULAR GRAFT | IMPLANTIERBARE GEFÄSSPROTHESE | GREFFE VASCULAIRE IMPLANTABLE	  	EP1333787B1	  	EP2001990900A	  	2001-11-08
						
	ENDOLOGIX INC	  	EP	  	Bifurcated vascular graft and method and apparatus for deploying same | Abzweigendes Gefässtransplantat sowie Verfahren und Gerät zu dessen Entfaltung | Implant vasculaire à deux branches, procédé et
appareil pour sa mise en place	  	EP1009325B1	  	EP1998906274A	  	1998-02-06
						
	ENDOLOGIX INC	  	EP	  	SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM | EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG | SYSTEME DE DEPLOIEMENT D’UNE GREFFE AU NIVEAU D’UNE BIFURCATION,
A L’AIDE D’UN SEUL ORIFICE	  	EP1159024B1	  	EP2000916167A	  	2000-03-07

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	EP	  	SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS | SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE | PROTHESE ENDOVASCULAIRE BIFURQUEE A DILATATION AUTOMATIQUE	  	EP1087729B1	  	EP1999957012A	  	1999-05-28
						
	ENDOLOGIX INC	  	EP	  	ENDOLUMINAL VASCULAR
PROSTHESIS | PROTHESE IM
INNEREN EINES GEFÄSSES |
PROTHESE VASCULAIRE
ENDOLUMINALE	  	EP1059893B1	  	EP1998930137A	  	1998-06-15
						
	ENDOLOGIX INC	  	EP	  	ENDOLUMINAL VASCULAR PROSTHESIS | ENDOLUMINALE VASKULÄRE PROTHESE | PROTHESE VASCULAIRE ENDOLUMINALE	  	EP1146833B1	  	EP1999973254A	  	1999-11-10
						
	ENDOLOGIX INC	  	EP	  	DUAL INFLATABLE ARTERIAL PROSTHESIS | DOPPELTE AUFBLASBARE ARTERIENPROTHESE | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE	  	EP3240508A1	  	EP2015876323A	  	2015-12-30
						
	ENDOLOGIX INC	  	EP	  	FORMING HYDROGELS AND MATERIALS THEREFOR | HERSTELLUNG VON HYDROGELEN UND MATERIALIEN DAFÜR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI	  	EP3113722A4	  	EP2015758921A	  	2015-03-06

											
	ENDOLOGIX INC	  	EP	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | MODULARE STENTPROTHESENSYSTEME UND VERFAHREN MIT AUFBLASBAREN	  	EP3148483A4	  	EP2015800658A	  	2015-05-05

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
		  		  	FÜLLSTRUKTUREN | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES	  		  		  	
						
	ENDOLOGIX INC	  	EP	  	LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | VERRIEGELUNGSANORDNUNG ZUR KOPPLUNG EINES FÜHRUNGSDRAHTS AN EIN AUSGABESYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN
FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION	  	EP3139860A1	  	EP2016790254A	  	2016-06-29
						
	ENDOLOGIX INC	  	EP	  	FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | FÜLLSTRUKTUR FÜR EIN PROTHESENSYSTEM UND VERWENDUNGSVERFAHREN | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ
D’UTILISATION	  	EP2519191A4	  	EP2010841580A	  	2010-12-21
						
	ENDOLOGIX INC	  	EP	  	METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | VERFAHREN ZUR HERSTELLUNG VON MATERIALIEN IN SITU IN EINER MEDIZINISCHEN VORRICHTUNG | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF
MÉDICAL	  	EP2968692A1	  	EP2014712991A	  	2014-03-07

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	EP	  	DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION	  	EP2299933A4	  	EP2009770704A	  	2009-06-04
						
	ENDOLOGIX INC	  	EP	  	SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS	  	EP2299931A4	  	EP2009759453A	  	2009-06-04
						
	ENDOLOGIX INC	  	EP	  	BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTEME UND VERFAHREN ZUR FREISETZUNG EINER BIFURKATIONSPROTHESE | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS	  	EP2268227A4	  	EP2009730087A	  	2009-04-10
						
	ENDOLOGIX INC	  	EP	  	METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | VERFAHREN UND SYSTEM ZUR ENDOVASKULÄREN BEHANDLUNG VON ANEURYSMEN | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE	  	EP2693980A1	  	EP2012716880A	  	2012-04-06

											
	ENDOLOGIX INC	  	EP	  	STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE	  	EP2278939A4	  	EP2009733719A	  	2009-04-24

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	EP	  	CATHETER SYSTEM AND METHODS OF USING SAME | KATHETERSYSTEM UND VERFAHREN ZU SEINER VERWENDUNG | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION	  	EP2680915A1	  	EP2012709432A	  	2012-02-29
						
	ENDOLOGIX INC	  	EP	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE DISPOSITION DE
GREFFE OU DE SYSTÈME DE GREFFE	  	EP2635241A2	  	EP2011781956A	  	2011-11-02
						
	ENDOLOGIX INC	  	EP	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | VORRICHTUNG UND VERFAHREN ZUR POSITIONIERUNG EINER GEFÄSSPROTHESE BZW. EINES GEFÄSSPROTHESENSYSTEMS | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE
GREFFE OU D’UN SYSTÈME DE GREFFE	  	EP2429452A1	  	EP2010717383A	  	2010-04-28
						
	ENDOLOGIX INC	  	WO	  	SYSTEMS AND METHODS WITH GRAFT BODY, INFLATABLE FILL CHANNEL, AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS À CORPS DE GREFFE, CANAL DE REMPLISSAGE GONFLABLE ET STRUCTURE DE REMPLISSAGE	  	WO2017197313A1	  	PCT/US2017/32490A	  	2017-05-12

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	WO	  	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE | SYSTÈMES ET PROCÉDÉS AVEC GREFFON FENESTRÉ ET STRUCTURE DE REMPLISSAGE	  	WO2017117068A1	  	PCT/US2016/68575A	  	2016-12-23
						
	ENDOLOGIX INC	  	WO	  	LOCKING ASSEMBLY FOR COUPLING GUIDEWIRE TO DELIVERY SYSTEM | ENSEMBLE DE VERROUILLAGE POUR ACCOUPLER UN FIL-GUIDE À UN SYSTÈME DE DISTRIBUTION	  	WO2017004265A1	  	PCT/US2016/40197A	  	2016-06-29
						
	ENDOLOGIX INC	  	WO	  	ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS | SYSTÈMES ET PROCÉDÉS DE PROTHÈSE ENDOLUMINALE	  	WO2016210363A1	  	PCT/US2016/39414A	  	2016-06-24
						
	ENDOLOGIX INC	  	WO	  	DUAL INFLATABLE ARTERIAL PROSTHESIS | DOUBLE PROTHÈSE ARTÉRIELLE GONFLABLE	  	WO2016109757A1	  	PCT/US2015/68204A	  	2015-12-30
						
	ENDOLOGIX INC	  	WO	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES | SYSTÈMES ET PROCÉDÉS DE GREFFE D’ENDOPROTHÈSE MODULAIRE COMPRENANT DES STRUCTURES DE REMPLISSAGE GONFLABLES	  	WO2015183489A1	  	PCT/US2015/29292A	  	2015-05-05

											
	ENDOLOGIX INC	  	WO	  	FORMING HYDROGELS AND MATERIALS THEREFOR | FORMATION D’HYDROGELS ET MATÉRIAUX POUR CEUX-CI	  	WO2015134906A1	  	PCT/US2015/19251A	  	2015-03-06

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	WO	  	METHOD FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE | MÉTHODE DE FORMATION DE MATÉRIAUX IN SITU DANS UN DISPOSITIF MÉDICAL	  	WO2014159093A1	  	PCT/US2014/21928A	  	2014-03-07
						
	ENDOLOGIX INC	  	WO	  	METHOD AND SYSTEM FOR ENDOVASCULAR ANEURYSM TREATMENT | PROCÉDÉ ET SYSTÈME POUR TRAITEMENT D’ANÉVRISME ENDOVASCULAIRE	  	WO2012139054A1	  	PCT/US2012/32612A	  	2012-04-06
						
	ENDOLOGIX INC	  	WO	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE DISPOSITION DE GREFFE OU DE SYSTÈME DE GREFFE	  	WO2012061526A3	  	PCT/US2011/59012A	  	2011-11-02
						
	ENDOLOGIX INC	  	WO	  	CATHETER SYSTEM AND METHODS OF USING SAME | SYSTÈME DE CATHÉTER ET SES PROCÉDÉS D’UTILISATION	  	WO2012118901A1	  	PCT/US2012/27151A	  	2012-02-29
						
	ENDOLOGIX INC	  	WO	  	METHODS AND SYSTEMS FOR TREATING ANEURYSMS | PROCÉDÉS ET SYSTÈMES DE TRAITEMENT D’ANÉVRISMES	  	WO2012100059A1	  	PCT/US2012/21878A	  	2012-01-19
						
	ENDOLOGIX INC	  	WO	  	DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS | DISPOSITIFS ET PROCÉDÉS DE TRAITEMENT DE DISSECTIONS VASCULAIRES	  	WO2012068298A1	  	PCT/US2011/61061A	  	2011-11-16

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	WO	  	STENT GRAFT | ENDOPROTHÈSE COUVERTE	  	WO2011017123A3	  	PCT/US2010/43432A	  	2010-07-27
						
	ENDOLOGIX INC	  	WO	  	STENT GRAFT | ENDOPROTHÈSE COUVERTE	  	WO2011008989A3	  	PCT/US2010/42181A	  	2010-07-15
						
	ENDOLOGIX INC	  	WO	  	PERCUTANEOUS METHOD AND DEVICE TO TREAT DISSECTIONS | PROCÉDÉ ET DISPOSITIF PERCUTANÉS POUR TRAITER DES DISSECTIONS	  	WO2010127305A3	  	PCT/US2010/33274A	  	2010-04-30
						
	ENDOLOGIX INC	  	WO	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM | APPAREIL ET PROCÉDÉ DE PLACEMENT D’UNE GREFFE OU D’UN SYSTÈME DE GREFFE	  	WO2010127040A1	  	PCT/US2010/32843A	  	2010-04-28
						
	ENDOLOGIX INC	  	WO	  	BIFURCATED GRAFT DEPLOYMENT SYSTEMS AND METHODS | SYSTÈMES DE DÉPLOIEMENT DE GREFFON À PLUSIEURS BRANCHES, ET PROCÉDÉS	  	WO2009126906A8	  	PCT/US2009/40239A	  	2009-04-10
						
	ENDOLOGIX INC	  	WO	  	CATHETER SYSTEM | SYSTÈME DE CATHÉTER	  	WO2010002931A1	  	PCT/US2009/49316A	  	2009-06-30

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	WO	  	 DESIGN AND METHOD OF
 PLACEMENT OF A GRAFT OR
GRAFT SYSTEM | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS | CONCEPTION ET PROCÉDÉ DE MISE EN PLACE D’UN GREFFON OU D’UN SYSTÈME DE GREFFONS
	  	WO2009105699A1	  	PCT/US2009/34755A	  	2009-02-20
						
	ENDOLOGIX INC	  	WO	  	METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE | PROCÉDÉ ET AGENT DE STABILISATION <I>IN SITU</I> DU TISSU VASCULAIRE	  	WO2009064806A1	  	PCT/US2008/83267A	  	2008-11-12
						
	ENDOLOGIX INC	  	WO	  	STENT | ENDOPROTHÈSE VASCULAIRE	  	WO2009055615A1	  	PCT/US2008/81022A	  	2008-10-23
						
	ENDOLOGIX INC	  	DE	  	EINE EINZIGE PUNKTION ERFORDENDES ENTFALTUNGSSYSTEM FÜR EIN GEFÄSSIMPLANTAT MIT VERZWEIGUNG	  	DE60031381T2	  	DE60031381A	  	2000-03-07
						
	ENDOLOGIX INC	  	DE	  	SELBSTEXPANDIERENDE, SICH VERZWEIGENDE, ENDOVASKULARE PROTHESE	  	DE69933560T2	  	DE69933560A	  	1999-05-28
						
	ENDOLOGIX INC	  	DE	  	ENDOLUMINALE VASKULÄRE PROTHESE	  	DE69927055T2	  	DE69927055A	  	1999-11-10

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	AU	  	Bifurcated vascular graft and method and apparatus for deploying same | Bifurcated vascular graft deployment device	  	AU725117B2	  	AU199861540A	  	1998-02-06
						
	ENDOLOGIX INC	  	AU	  	Implantable vascular graft	  	AU200230661A	  	AU200230661A	  	2001-11-08
						
	ENDOLOGIX INC	  	EP	  	DEVICES FOR REPAIRING ANEURYSMS	  	EP1397089	  	EP02730505.1	  	2017-04-19
						
	ENDOLOGIX INC	  	EP	  	DEVICES FOR REPAIRING ANEURYSMS	  	EP1397089	  	EP02730505.1	  	2017-04-19
						
	ENDOLOGIX INC	  	EP	  	DEVICES FOR REPAIRING ANEURYSMS	  	EP1397089	  	EP02730505.1	  	2017-04-19
						
	ENDOLOGIX INC	  	EP	  	DEVICES FOR REPAIRING ANEURYSMS	  	EP2260795	  	EP10011024.6	  	2016-05-25

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	EP	  	DEVICES FOR REPAIRING ANEURYSMS	  	EP2260795	  	EP10011024.6	  	2016-05-25
						
	ENDOLOGIX INC	  	EP	  	DEVICES FOR REPAIRING ANEURYSMS	  	EP2260795	  	EP10011024.6	  	2016-05-25
						
	ENDOLOGIX INC	  	EP	  	DEVICES FOR REPAIRING ANEURYSMS	  	EP2260795	  	EP10011024.6	  	2016-05-25
						
	ENDOLOGIX INC	  	EP	  	DEVICES FOR REPAIRING ANEURYSMS	  	EP2260795	  	EP10011024.6	  	2016-05-25
						
	ENDOLOGIX INC	  	EP	  	ADVANCED KINK-RESISTANT STENT GRAFT	  	EP2833827	  	13714471.3	  	2018-01-31
						
	ENDOLOGIX INC	  	EP	  	ADVANCED KINK-RESISTANT STENT GRAFT	  	EP2833827	  	13714471.3	  	2018-01-31

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	EP	  	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	  		  	EP13717893.5	  	2014-11-06
						
	ENDOLOGIX INC	  	EP	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	  		  	EP15800658.5	  	2016-11-21
						
	ENDOLOGIX INC	  	EP	  	ANEURYSM SAC ACCESS CONDUIT	  		  	15852460.3	  	2017-04-12
						
	ENDOLOGIX INC	  	EP	  	DUAL INFLATABLE ARTERIAL PROSTHESIS	  		  	15876323.5	  	2017-07-13
						
	ENDOLOGIX INC	  	EP	  	Endoluminal Prosthesis Systems and Methods	  		  	16815450.8	  	2017-12-19
						
	ENDOLOGIX INC	  	CN	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	  		  	2015800393484	  	2017-01-19

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	CN	  	DUAL INFLATABLE ARTERIAL PROSTHESIS	  		  	2015800763903	  	2017-08-17
						
	ENDOLOGIX INC	  	JP	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	  		  	2016-569901	  	2016-11-28
						
	ENDOLOGIX INC	  	CN	  	Endoluminal Prosthesis Systems and Methods	  		  	201680037099.X	  	2017-12-22
						
	ENDOLOGIX INC	  	JP	  	DUAL INFLATABLE ARTERIAL PROSTHESIS	  		  	2017-534803	  	2017-06-28
						
	ENDOLOGIX INC	  	JP	  	Endoluminal Prosthesis Systems and Methods	  		  	PCT/US2016/039414	  	2017-12-22

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	NELLIX INC.	  	US	  	Stent-graft with positioning anchor	  	US9814612B2	  	US14697433A	  	2015-10-21
						
	NELLIX INC.	  	US	  	System and methods for endovascular aneurysm treatment	  	US9737425B2	  	US14537749A	  	2014-11-10
						
	NELLIX INC.	  	US	  	Stent graft delivery system	  	US9730700B2	  	US14586110A	  	2015-04-23
						
	NELLIX INC.	  	US	  	Methods for deploying a positioning anchor with a stent-graft	  	US9113999B2	  	US11876458A	  	2007-10-22
						
	NELLIX INC.	  	US	  	Sealing apparatus and methods of use	  	US8945199B2	  	US12478225A	  	2009-06-04
						
	NELLIX INC.	  	US	  	Stent graft delivery system	  	US8926682B2	  	US13243941A	  	2011-09-23

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	NELLIX INC.	  	US	  	System and methods for endovascular aneurysm treatment	  	US8906084B2	  	US12684074A	  	2010-01-07
						
	NELLIX INC.	  	US	  	Graft systems having filling structures supported by scaffolds and methods for their use	  	US8870941B2	  	US13285897A	  	2011-10-31
						
	NELLIX INC.	  	US	  	STENT GRAFT DELIVERY SYSTEM	  	US20180028192A1	  	US15676869A	  	2017-08-14
						
	NELLIX INC.	  	US	  	SEALING APPRATUS AND METHODS OF USE	  	US20150148892A1	  	US14612048A	  	2015-02-02
						
	NELLIX INC.	  	US	  	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE	  	US10022249	  	US14525019A	  	2014-10-27
						
	NELLIX, INC.	  	US	  	System and methods of Endovascular Aneurysm Treatment	  		  	14/682414	  	8/21/17

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Nellix, Inc.	  	US	  	Vascular stent-graft apparatus and forming method	  	US6695833	  	US09671550	  	9/27/00
						
	ENDOLOGIX INC	  	EP	  	Systems for endovascular aneurysm treatment | Systeme zur Behandlung von endovaskulären Aneurysmen | Systèmes pour le traitement d’anévrisme endovasculaire	  	EP1778131B1	  	EP2005773726A	  	2005-07-22
						
	NELLIX INC.	  	EP	  	Method for forming a vascular stent-graft | Verfahren zur Herstellung eines vaskulären Stent-Grafts | Procédé de formation d’un stent-greffe vasculaire.	  	EP1355587B1	  	EP2001973590A	  	2001-09-26
						
	NELLIX INC	  	EP	  	METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES | VERFAHREN UND SYSTEME ZUR BEHANDLUNG VON ANEURYSMEN UNTER VERWENDUNG VON FÜLLSTRUKTUREN | PROCEDES ET SYSTEMES POUR LE TRAITEMENT DE L’ANEVRISME
UTILISANT DES STRUCTURES DE REMPLISSAGE	  	EP1962722A4	  	EP2006850439A	  	2006-12-18
						
	ENDOLOGIX INC	  	EP	  	Systems for endovascular aneurysm treatment | Systeme zur endovaskulären Aneurysma-Therapie | Systèmes pour le traitement d’anévrismes endovasculaires	  	EP2422745A1	  	EP2011180827A	  	2005-07-22

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX INC	  	EP	  	DOCKING APPARATUS AND METHODS OF USE | ANDOCKVORRICHTUNG UND VERWENDUNGSVERFAHREN | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION	  	EP2299933A1	  	EP2009770704A	  	2009-06-04
						
	ENDOLOGIX INC	  	EP	  	SEALING APPARATUS AND METHODS OF USE | VERSCHLUSSGERÄT UND ANWENDUNGSVERFAHREN | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS	  	EP2299931A1	  	EP2009759453A	  	2009-06-04
						
	ENDOLOGIX INC	  	EP	  	STENT GRAFT DELIVERY SYSTEM | STENTGRAFT-ABLAGESYSTEM | SYSTÈME DE MISE EN PLACE D ENDOPROTHÈSE VASCULAIRE	  	EP2278939A1	  	EP2009733719A	  	2009-04-24
						
	ENDOLOGIX INC	  	EP	  	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS | TRANSPLANTATIONSSYSTEM MIT DURCH GERÜSTE UNTERSTÜTZTEN FÜLLSTRUKTUREN | SYSTEMES DE GREFFE PRESENTANT DES STRUCTURES DE REMPLISSAGE SOUTENUES PAR DES
ECHAFAUDAGES	  	EP1874231A2	  	EP2006751879A	  	2006-04-28
						
	ENDOLOGIX INC	  	EP	  	STENT-GRAFT WITH POSITIONING ANCHOR | STENT-GRAFT MIT POSITIONIERUNGSVERANKERUNG | ENDOPROTHESE A ANCRAGE DE POSITIONNEMENT	  	EP1542616A2	  	EP2003754880A	  	2003-09-22

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	NELLIX INC.	  	WO	  	FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE | STRUCTURE DE REMPLISSAGE POUR UN SYSTÈME DE GREFFE ET PROCÉDÉ D’UTILISATION	  	WO2011082040A1	  	PCT/US2010/061621	  	2010-12-21
						
	NELLIX INC.	  	WO	  	DOCKING APPARATUS AND METHODS OF USE | APPAREIL DE FIXATION ET PROCÉDÉS D’UTILISATION	  	WO2009158170A1	  	PCT/US2009/046308	  	2009-06-04
						
	NELLIX INC.	  	WO	  	SEALING APPARATUS AND METHODS OF USE | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS | DISPOSITIF DE FERMETURE ET PROCÉDÉS D’UTILISATION ASSOCIÉS	  	WO2009149294A1	  	PCT/US2009/046310	  	2009-06-04
						
	NELLIX INC.	  	WO	  	STENT GRAFT DELIVERY SYSTEM | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE | SYSTÈME DE MISE EN PLACE D’ENDOPROTHÈSE VASCULAIRE	  	WO2009132309A1	  	PCT/US2009/041718	  	2009-04-24
						
	NELLIX INC.	  	WO	  	GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS | ENDOCADRE DE GREFFE AYANT DES CARACTÉRISTIQUES VARIABLES AXIALEMENT	  	WO2009103011A1	  	PCT/US2009/034136	  	2009-02-13
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US9867727B2	  	US14320773A	  	2014-07-01

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US9788934B2	  	US14799656A	  	2015-07-15
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft for aneurysms involving major branch vessels	  	US9724186B2	  	US14050835A	  	2013-10-10
						
	TRIVASCULAR INC.	  	US	  	System and method of pivoted stent deployment	  	US9713523B2	  	US14452343A	  	2014-08-05
						
	TRIVASCULAR INC.	  	US	  	Systems and methods for guidewire crossover for bifurcated prostheses	  	US9655754B2	  	US14323059A	  	2014-07-03
						
	TRIVASCULAR INC.	  	US	  	Bifurcated endovascular prosthesis having tethered contralateral leg	  	US9585774B2	  	US14823076A	  	2015-08-11
						
	TRIVASCULAR INC.	  	US	  	PTFE layers and methods of
manufacturing	  	US9549829B2	  	US14458349A	  	2014-08-13

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Delivery catheter for endovascular device	  	US9498363B2	  	US13835491A	  	2013-03-15
						
	TRIVASCULAR INC	  	US	  	Low profile stent and delivery system	  	US9463101B2	  	US14923477A	  	2015-10-27
						
	TRIVASCULAR INC.	  	US	  	PTFE layers and methods of
manufacturing	  	US9446553B2	  	US14230318A	  	2014-03-31
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US9351858B2	  	US14704013A	  	2015-05-05
						
	TRIVASCULAR INC.	  	US	  	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	  	US9308301B2	  	US13089960A	  	2011-04-19
						
	TRIVASCULAR INC.	  	US	  	Endovascular delivery system with an improved radiopaque marker scheme	  	US9233015B2	  	US13803050A	  	2013-03-14

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Low profile stent graft and delivery system	  	US9192462B2	  	US13803037A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	Fenestrated inflatable graft	  	US9144486B2	  	US13652471A	  	2012-10-15
						
	TRIVASCULAR INC.	  	US	  	Bifurcated endovascular prosthesis having tethered contralateral leg	  	US9132025B2	  	US13803067A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	Endovascular delivery system with flexible and torqueable hypotube	  	US9066828B2	  	US13803062A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US9050754B2	  	US12729182A	  	2010-03-22
						
	TRIVASCULAR INC.	  	US	  	Durable stent graft with tapered struts and stable delivery methods and devices	  	US8992595B2	  	US13799207A	  	2013-03-13

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	In vitro testing of endovascular device	  	US8978448B2	  	US13649066A	  	2012-10-10
						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft delivery system and method of treatment	  	US8900288B2	  	US12566104A	  	2009-09-24
						
	TRIVASCULAR INC.	  	US	  	Method of delivering advanced endovascular graft and system	  	US8864814B2	  	US13246651A	  	2011-09-27
						
	TRIVASCULAR INC.	  	US	  	PTFE layers and methods of
manufacturing	  	US8840824B2	  	US12910281A	  	2010-10-22
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US8801769B2	  	US13737351A	  	2013-01-09
						
	TRIVASCULAR INC.	  	US	  	Apparatus for manufacturing an endovascular graft section	  	US8783316B2	  	US12697504A	  	2010-02-01

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	PTFE layers and methods of
manufacturing	  	US8728372B2	  	US12915636A	  	2010-10-29
						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US8709065B2	  	US12491336A	  	2009-06-25
						
	TRIVASCULAR INC.	  	US	  	Virtual prototyping and testing for medical device development	  	US8666714B2	  	US13523765A	  	2012-06-14
						
	TRIVASCULAR INC.	  	US	  	Asymmetric stent apparatus and method	  	US8663309B2	  	US11861828A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US8361136B2	  	US12566793A	  	2009-09-25
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US8348989B2	  	US11429735A	  	2006-05-08

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated graft	  	US8328861B2	  	US11941434A	  	2007-11-16
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft and method of delivery	  	US8241346B2	  	US13246643A	  	2011-09-27
						
	TRIVASCULAR INC.	  	US	  	Inflatable porous implants and methods for drug delivery	  	US8267989B2	  	US12860364A	  	2010-08-20
						
	TRIVASCULAR INC.	  	US	  	Inflatable intraluminal graft	  	US8226708B1	  	US10168053A	  	2002-06-14
						
	TRIVASCULAR INC.	  	US	  	Stent and delivery system for deployment thereof	  	US8226701B2	  	US11861756A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	Virtual prototyping and testing for medical device development	  	US8224632B2	  	US12904994A	  	2010-10-14

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Dual chamber cuff structure	  	US8216297B2	  	US11504434A	  	2006-08-14
						
	TRIVASCULAR INC.	  	US	  	Barbed radially expandable stent	  	US8167927B2	  	US13245661A	  	2011-09-26
						
	TRIVASCULAR INC.	  	US	  	Securement assembly and method for expandable endovascular device	  	US8083789B2	  	US11941450A	  	2007-11-16
						
	TRIVASCULAR INC.	  	US	  	System and method of pivoted stent deployment	  	US8066755B2	  	US11861716A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	Constant force material delivery system and method	  	US7971751B2	  	US12724068A	  	2010-03-15
						
	TRIVASCULAR INC.	  	US	  	Passive hemostatic sheath valve	  	US7901379B2	  	US11298285A	  	2005-12-09

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Virtual prototyping and testing for medical device development	  	US7840393B1	  	US09679725A	  	2000-10-04
						
	TRIVASCULAR INC.	  	US	  	Inflatable porous implants and methods for drug delivery	  	US7803178B2	  	US10769532A	  	2004-01-30
						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US7766954B2	  	US11333595A	  	2006-01-17
						
	TRIVASCULAR INC.	  	US	  	Constant force material delivery system and method	  	US7708163B2	  	US11360077A	  	2006-02-23
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US7682475B2	  	US11870748A	  	2007-10-11
						
	TRIVASCULAR INC.	  	US	  	Method for manufacturing an endovascular graft section	  	US7678217B2	  	US11522490A	  	2006-09-15

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Inflatable implant	  	US7632291B2	  	US10461853A	  	2003-06-13
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US7615071B2	  	US11390732A	  	2006-03-28
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for
expandable intracorporeal device	  	US7338518B2	  	US11201028A	  	2005-08-10
						
	TRIVASCULAR INC.	  	US	  	Passive hemostatic sheath valve	  	US7241276B2	  	US10636871A	  	2003-08-06
						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US7147660B2	  	US10327711A	  	2002-12-20
						
	TRIVASCULAR INC.	  	US	  	Kink resistant endovascular graft	  	US7150758B2	  	US10384103A	  	2003-03-06

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Radially expandable stent	  	US7147661B2	  	US10029559A	  	2001-12-20
						
	TRIVASCULAR INC.	  	US	  	Method and apparatus for shape forming endovascular graft material	  	US7147455B2	  	US10868292A	  	2004-06-14
						
	TRIVASCULAR INC.	  	US	  	Method for manufacturing an endovascular graft section	  	US7125464B2	  	US10029557A	  	2001-12-20
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US7081129B2	  	US10132754A	  	2002-04-24
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US7090693B1	  	US10029584A	  	2001-12-20
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for
expandable intracorporeal device	  	US7066951B2	  	US10419312A	  	2003-04-17

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Method and apparatus for shape forming endovascular graft material	  	US6776604B1	  	US10029570A	  	2001-12-20
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated endovascular graft	  	US6761733B2	  	US09917371A	  	2001-07-27
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for endovascular graft	  	US6733521B2	  	US09834278A	  	2001-04-11
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for
expandable intracorporeal device	  	US6602280B2	  	US09774733A	  	2001-01-31
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US6395019B2	  	US09133978A	  	1998-08-14
						
	TRIVASCULAR INC	  	US	  	ENDOVASCULAR GRAFT	  	US20170348125A1	  	US15686214A	  	2017-08-25

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC	  	US	  	ADVANCED ENDOVASCULAR GRAFT	  	US20170348087A1	  	US15686218A	  	2017-08-25
						
	TRIVASCULAR INC	  	US	  	ENDOVASCUALR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS	  	US20170296327A1	  	US15638559A	  	2017-06-30
						
	TRIVASCULAR INC	  	US	  	SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES	  	US20170216064A1	  	US15491074A	  	2017-04-19
						
	TRIVASCULAR INC	  	US	  	Low Profile Stent Graft and Delivery System	  	US9987123	  	US15263469A	  	2016-09-13
						
	TRIVASCULAR INC	  	US	  	BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG	  	US20170035549A1	  	US15299542A	  	2016-10-21
						
	TRIVASCULAR INC.	  	US	  	DELIVERY CATHETER FOR ENDOVASCULAR DEVICE	  	US20170035590A1	  	US15298166A	  	2016-10-19

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC	  	US	  	PTFE LAYERS AND METHODS OF MANUFACTURING	  	US20160367354A1	  	US15251011A	  	2016-08-30
						
	TRIVASCULAR INC	  	US	  	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME	  	US10034787	  	US14970621A	  	2015-12-16
						
	TRIVASCULAR INC	  	US	  	NON-DEGRADABLE, LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGEL POLYMER	  	US20160193392A1	  	US15068415A	  	2016-03-11
						
	TRIVASCULAR INC.	  	US	  	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS	  	US9956101	  	US14958085A	  	2015-12-03
						
	TRIVASCULAR INC.	  	US	  	STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT	  	US20160113796A1	  	US14920828A	  	2015-10-22
						
	TRIVASCULAR INC.	  	US	  	ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE	  	US20150265446A1	  	US14717080A	  	2015-05-20

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS	  	US20150250481A1	  	US14643217A	  	2015-03-10
						
	TRIVASCULAR INC.	  	US	  	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM	  	US20150164667A1	  	US14631818A	  	2015-02-25
						
	TRIVASCULAR INC.	  	US	  	DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES	  	US20150157479A1	  	US14615337A	  	2015-02-05
						
	TRIVASCULAR INC.	  	US	  	TANDEM MODULAR ENDOGRAFT	  	US20150088244A1	  	US14492674A	  	2014-09-22
						
	TRIVASCULAR INC.	  	US	  	ENDOLEAK ISOLATION SLEEVES AND METHODS OF USE	  	US20150073523A1	  	US14481834A	  	2014-09-09
						
	TRIVASCULAR INC.	  	US	  	GATE WIRE FOR CONTRALATERAL LEG ACCESS	  	US20140194970A1	  	US14151373A	  	2014-01-09

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	SAC LINER FOR ANEURYSM REPAIR	  	US20140194973A1	  	US14151195A	  	2014-01-09
						
	TRIVASCULAR INC.	  	US	  	ASYMMETRIC STENT APPARATUS AND METHOD	  	US20140135899A1	  	US14157350A	  	2014-01-16
						
	TRIVASCULAR INC.	  	US	  	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	  	US20130268056A1	  	US13803033A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	ADVANCED KINK RESISTANT STENT GRAFT	  	US9993328	  	US13803046A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	VASCULAR GRAFT HAVING
LIMITED END STRUCTURE	  	US20130096665A1	  	US13650705A	  	2012-10-12
						
	TRIVASCULAR INC.	  	US	  	INFLATABLE INTRALUMINAL GRAFT	  	US20120265290A1	  	US13532887A	  	2012-06-26

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM	  	US20120191174A1	  	US13297219A	  	2011-11-15
						
	TRIVASCULAR INC.	  	US	  	SYSTEM AND METHOD OF PIVOTED STENT DEPLOYMENT	  	US20120083870A1	  	US13277117A	  	2011-10-19
						
	TRIVASCULAR INC.	  	US	  	BARBED RADIALLY EXPANDABLE STENT WITH SLOTTED STRUTS	  	US20120016457A1	  	US13245652A	  	2011-09-26
						
	TRIVASCULAR INC.	  	US	  	FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT	  	US20110218609A1	  	US13024255A	  	2011-02-09
						
	TRIVASCULAR INC.	  	US	  	HINGED ENDOVASCULAR DEVICE	  	US20100331958A1	  	US12747499A	  	2010-09-07
						
	TRIVASCULAR INC.	  	US	  	Inflatable Implant	  	US20100076481A1	  	US12628623A	  	2009-12-01

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	METHOD OF DELIVERING ADVANCED ENDOVASCULAR GRAFT	  	US20100016943A1	  	US12566808A	  	2009-09-25
						
	TRIVASCULAR INC.	  	US	  	MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY	  	US20090099649A1	  	US12245620A	  	2008-10-03
						
	TRIVASCULAR INC.	  	US	  	ALIGNMENT STENT APPARATUS AND METHOD	  	US20090082845A1	  	US11861746A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	SYSTEM AND METHOD OF
SECURING STENT BARBS	  	US20090082847A1	  	US11861731A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	APPARATUS FOR SECURING STENT BARBS	  	US20090082841A1	  	US11861739A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	PTFE LAYERS AND METHODS OF MANUFACTURING	  	US20090036971A1	  	US12250915A	  	2008-10-14

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	PTFE LAYERS AND METHODS OF MANUFACTURING	  	US20090036973A1	  	US12250946A	  	2008-10-14
						
	TRIVASCULAR INC.	  	US	  	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	  	US20060222596A1	  	US11097467A	  	2005-04-01
						
	TRIVASCULAR INC.	  	US	  	Hybrid modular endovascular graft	  	US20060224232A1	  	US11097718A	  	2005-04-01
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated graft	  	US20060009833A1	  	US11205793A	  	2005-08-15
						
	TRIVASCULAR INC.	  	US	  	Methods, compositions and devices for embolizing body lumens	  	US20050158272A1	  	US11031311A	  	2005-01-07
						
	TRIVASCULAR INC.	  	US	  	Endoluminal prosthesis endoleak management	  	US20050090804A1	  	US10691849A	  	2003-10-22

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US20050027347A1	  	US10640368A	  	2003-08-13
						
	TRIVASCULAR INC.	  	US	  	Layered endovascular graft	  	US20040220664A1	  	US10803153A	  	2004-03-17
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated graft	  	US20040138734A1	  	US10686863A	  	2003-10-16
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US20030216802A1	  	US10289136A	  	2002-11-05
						
	TRIVASCULAR INC.	  	US	  	Inflatable intraluminal graft	  	US20030225453A1	  	US10289137A	  	2002-11-05
						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US20030120338A1	  	US10091641A	  	2002-03-05

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated graft	  	US20030004560A1	  	US10122474A	  	2002-04-11
						
	TRIVASCULAR INC.	  	US	  	Layered endovascular graft	  	US20020010508A1	  	US09970576A	  	2001-10-04
						
	TRIVASCULAR, INC.	  	US	  	Stent-graft with improved flexibility	  		  	15/568834	  	10/24/17
						
	Trivascular, Inc.	  	US	  	Passive hemostatic sheath valve	  	US7901379	  	US11298285	  	12/9/05
						
	Trivascular, Inc.	  	US	  	Fluid mixing apparatus and method	  	US7178978	  	US10658074	  	9/8/03
						
	Trivascular, Inc.	  	US	  	 Delivery system and method for
 expandable
intracorporeal device
	  	US6602280	  	US09774733	  	1/31/01

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	Endovascular graft	  	US6395019	  	US09133978	  	8/14/98
						
	Trivascular, Inc.	  	US	  	Layered endovascular graft	  	US6331191	  	US09200317	  	11/25/98
						
	Trivascular, Inc.	  	US	  	Endovascular graft having longitudinally displaceable sections	  	US6132457	  	US09177295	  	10/22/98
						
	Trivascular, Inc.	  	US	  	Low profile stent graft and delivery system	  		  	US15263469	  	9/13/16
						
	Trivascular, Inc.	  	US	  	Delivery catheter for endovascular device	  		  	US15298166	  	10/19/16
						
	Trivascular, Inc.	  	US	  	Bifurcated endovascular prosthesis having tethered contralateral leg	  		  	US15299542	  	10/21/16

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US15251011	  	8/30/16
						
	Trivascular, Inc.	  	US	  	Endovascular delivery system with an improved radiopaque marker scheme	  		  	US14970621	  	12/16/15
						
	Trivascular, Inc.	  	US	  	 Non-degradable, low swelling, water

soluble radiopaque hydrogel polymer
	  		  	US15068415	  	3/11/16
						
	Trivascular, Inc.	  	US	  	 Internal iliac preservation devices and

methods
	  		  	US14958085	  	12/3/15
						
	Trivascular, Inc.	  	US	  	Stent graft delivery system with access conduit	  		  	US14920828	  	10/22/15
						
	Trivascular, Inc.	  	US	  	Bifurcated endovascular prosthesis having tethered contralateral leg	  		  	US14823076	  	8/11/15

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	Low profile stent and delivery system	  		  	US14923477	  	10/27/15
						
	Trivascular, Inc.	  	US	  	Endovascular delivery system with flexible and torqueable hypotube	  		  	US14717080	  	5/20/15
						
	Trivascular, Inc.	  	US	  	Inflatable occlusion wire-balloon for aortic applications	  		  	US14643217	  	3/10/15
						
	Trivascular, Inc.	  	US	  	Advanced endovascular graft and delivery system	  		  	US14631818	  	2/25/15
						
	Trivascular, Inc.	  	US	  	Durable stent graft with tapered struts and stable delivery methods and devices	  		  	US14615337	  	2/5/15
						
	Trivascular, Inc.	  	US	  	Tandem modular endograft	  		  	US14492674	  	9/22/14

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	Endoleak isolation sleeves and methods of use	  		  	US14481834	  	9/9/14
						
	Trivascular, Inc.	  	US	  	Sac liner for aneurysm repair	  		  	US14151195	  	1/9/14
						
	Trivascular, Inc.	  	US	  	Gate wire for contralateral leg access	  		  	US14151373	  	1/9/14
						
	Trivascular, Inc.	  	US	  	Asymmetric stent apparatus and method	  		  	US14157350	  	1/16/14
						
	Trivascular, Inc.	  	US	  	Low profile stent graft and delivery system	  		  	US13803033	  	3/14/13
						
	Trivascular, Inc.	  	US	  	Advanced kink resistant stent graft	  		  	US13803046	  	3/14/13

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	Vascular graft having limited end structure	  		  	US13650705	  	10/12/12
						
	Trivascular, Inc.	  	US	  	Inflatable intraluminal graft	  		  	US13532887	  	6/26/12
						
	Trivascular, Inc.	  	US	  	Advanced endovascular graft and delivery system	  		  	US13297219	  	11/15/01
						
	Trivascular, Inc.	  	US	  	 System and method of pivoted stent

deployment
	  		  	US13277117	  	10/19/11
						
	Trivascular, Inc.	  	US	  	 Barbed radially expandable stent with
 slotted
struts
	  		  	US13245652	  	9/26/11
						
	Trivascular, Inc.	  	US	  	Fill tube manifold and delivery methods for endovascular graft	  		  	US13024255	  	2/9/11

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	Hinged endovascular device	  		  	US12747499	  	9/7/10
						
	Trivascular, Inc.	  	US	  	Inflatable implant	  		  	US12628623	  	12/1/09
						
	Trivascular, Inc.	  	US	  	 Method of delivering advanced
 endovascular
graft
	  		  	US12566808	  	9/25/09
						
	Trivascular, Inc.	  	US	  	Modular vascular graft for low profile percutaneous delivery	  		  	US12245620	  	10/3/08
						
	Trivascular, Inc.	  	US	  	System and method of securing stent barbs	  		  	US11861731	  	9/26/07
						
	Trivascular, Inc.	  	US	  	Alignment stent apparatus and method	  		  	US11861746	  	9/26/07

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	Apparatus for securing stent barbs	  		  	US11861739	  	9/26/07
						
	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US12250946	  	10/14/08
						
	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US12250915	  	10/14/08
						
	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US11106150	  	4/13/05
						
	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US11106131	  	4/13/05
						
	Trivascular, Inc.	  	US	  	Hybrid modular endovascular graft	  		  	US11097718	  	4/1/05

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	 Non-degradable low swelling, water

soluble radiopaque hydrogel polymer
	  		  	US11097467	  	4/1/05
						
	Trivascular, Inc.	  	US	  	Delivery system and method for bifurcated graft	  		  	US11205793	  	8/15/05
						
	Trivascular, Inc.	  	US	  	Modular endovascular graft	  		  	US11077938	  	3/11/05
						
	Trivascular, Inc.	  	US	  	Methods, compositions and devices for embolizing body lumens	  		  	US11031311	  	1/7/05
						
	Trivascular, Inc.	  	US	  	 Endoluminal prosthesis endoleak

management
	  		  	US10691849	  	10/22/03
						
	Trivascular, Inc.	  	US	  	Endovascular graft joint and method for manufacture	  		  	US10640368	  	8/13/03

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	Layered endovascular graft	  		  	US10803153	  	3/17/04
						
	Trivascular, Inc.	  	US	  	Delivery system and method for bifurcated graft	  		  	US10686863	  	10/16/03
						
	Trivascular, Inc.	  	US	  	Inflatable intraluminal graft	  		  	US10289137	  	11/5/02
						
	Trivascular, Inc.	  	US	  	Endovascular graft	  		  	US10289136	  	11/5/02
						
	Trivascular, Inc.	  	US	  	Advanced endovascular graft	  		  	US10091641	  	3/5/02
						
	Trivascular, Inc.	  	US	  	Delivery system and method for bifurcated graft	  		  	US10122474	  	4/11/02

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	Trivascular, Inc.	  	US	  	Layered endovascular graft	  		  	US09970576	  	10/3/01
						
	TRIVASCULAR INC.	  	EP	  	ADVANCED KINK-RESISTANT STENT GRAFT | HOCHENTWICKELTES KNICKBESTÄNDIGES STENTTRANSPLANTAT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE	  	EP2833827B1	  	EP2013714471A	  	2013-03-21
						
	TRIVASCULAR INC.	  	EP	  	INFLATABLE IMPLANT | AUFBLASBARES IMPLANTAT | IMPLANT GONFLABLE	  	EP1635738B1	  	EP2004776568A	  	2004-06-14
						
	TRIVASCULAR INC.	  	EP	  	 ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | ENDOVASKULÄRES

TRANSPLANTAT FÜR ANEURYSMEN MIT BETEILIGUNG VON GROSSEN VERZWEIGTEN GEFÄSSEN | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES
VAISSEAUX RAMIFIÉS PRINCIPAUX
	  	EP2906144B1	  	EP2013780282A	  	2013-10-10

											
	TRIVASCULAR INC.	  	EP	  	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT UND SYSTEM ZU SEINER VERABREICHUNG | GREFFE ENDOVASCULAIRE AVANCÉE ET	  	EP2640319B1	  	EP2011841183A	  	2011-11-15

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
		  		  	SYSTÈME DE POSE ASSOCIÉ	  		  		  	
						
	TRIVASCULAR INC.	  	EP	  	DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | EINFÜHRKATHETER FÜR EINE ENDOVASKULÄRE VORRICHTUNG | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE	  	EP2833845B1	  	EP2013771941A	  	2013-04-01
						
	TRIVASCULAR INC.	  	EP	  	Endovascular graft | Endovaskuläres Gewebe | Greffe endovasculaire	  	EP1464301B1	  	EP200475832A	  	1999-02-09
						
	TRIVASCULAR INC.	  	EP	  	PTFE LAYERS AND METHODS OF MANUFACTURING | PTFE-LAGEN UND HERSTELLUNGSVERFAHREN | COUCHES DE PTFE ET PROCEDES DE FABRICATION	  	EP1888318B1	  	EP2006740124A	  	2006-03-30
						
	TRIVASCULAR INC.	  	EP	  	ADVANCED ENDOVASCULAR GRAFT | FORTSCHRITTLICHES ENDOVASKULÄRES TRANSPLANTAT | GREFFON ENDOVASCULAIRE EVOLUE	  	EP1467679B1	  	EP2002796047A	  	2002-12-20

											
	TRIVASCULAR INC.	  	EP	  	Non-degradable low swelling, water soluble radiopaque hydrogels | Nicht abbaubares, schwach anschwellendes, wasserlösliches röntgendichtes Hydrogelpolymer | Polymère absorbant
l’eau, radiopaque, soluble dans l’eau, à faible gonflement et non dégradable	  	EP2332590B1	  	EP2010194236A	  	2006-03-28

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	EP	  	Endovascular graft | Endovaskuläres Transplantat | Greffe endovasculaire	  	EP2147658B1	  	EP200913660A	  	1999-02-09
						
	TRIVASCULAR INC.	  	EP	  	Kink resistant endovascular graft | Knickbeständiges Stentimplantat | Stent à greffer resistant au pliage	  	EP2319456B1	  	EP2010183146A	  	2004-03-05
						
	TRIVASCULAR INC.	  	EP	  	Delivery system for graft | Abgabesystem für Graft | Système de mise en place pour prothèse	  	EP2145607B1	  	EP2009175398A	  	2004-10-15
						
	TRIVASCULAR INC.	  	EP	  	DELIVERY SYSTEM FOR BIFURCATED GRAFT | VORRICHTUNG ZUR PLATZIERUNG VON ZWEIGETEILTEN ENDOPROTHESEN | SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION	  	EP1377234B1	  	EP2002725639A	  	2002-04-11
						
	TRIVASCULAR INC.	  	EP	  	Advanced endovascular graft | Erweitertes endovaskuläres Transplantat | Greffe endovasculaire évoluée	  	EP2135583B1	  	EP20099090A	  	2002-12-20
						
	TRIVASCULAR INC.	  	EP	  	KINK RESISTANT ENDOVASCULAR GRAFT | KNICKFESTES ENDOVASKULÄRES IMPLANTAT | IMPLANT ENDOVASCULAIRE RÉSISTANT A LA DÉFORMATION	  	EP1601314B1	  	EP2004718097A	  	2004-03-05

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	EP	  	NON-DEGRADABLE LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGELS | NICHT-ABBAUBARE WENIG QUELLENDE WASSERLÖSLICHE RÖNTGENDICHTE HYDROGELS | HYDROGEL RADIOPAQUE, SOLUBLE DANS
L’EAU, NON DEGRADABLE ET A FAIBLE GONFLEMENT	  	EP1874370B1	  	EP2006739747A	  	2006-03-28
						
	TRIVASCULAR INC.	  	EP	  	INFLATABLE INTRALUMINAL GRAFT | AUFBLASBARER INTRALUMINALER PFROPFEN | GREFFON INTRALUMINAL GONFLABLE	  	EP1176926B1	  	EP2000907760A	  	2000-03-03
						
	TRIVASCULAR INC.	  	EP	  	ENDOVASCULAR GRAFT | ENDOVASKULÄRES IMPLANTAT | GREFFON ENDOVASCULAIRE	  	EP1054648B1	  	EP1999906812A	  	1999-02-09
						
	TRIVASCULAR INC.	  	EP	  	STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | STENTGRAFTEINFÜHRUNGSSYSTEM MIT ZUGANGSKANAL | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES	  	EP3209249A1	  	EP2015852460A	  	2015-10-22

											
	TRIVASCULAR INC.	  	EP	  	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | VORRICHTUNGEN UND VERFAHREN ZUR INTERNEN BECKENKONSERVIERUNG | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE	  	EP3226814A1	  	EP2015816618A	  	2015-12-03

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	EP	  	INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | AUFBLASBARER OKKLUSIONSDRAHTBALLON FÜR ANWENDUNGEN IN DER AORTA | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES	  	EP3116439A1	  	EP2015711020A	  	2015-03-10
						
	TRIVASCULAR INC.	  	EP	  	SYSTEMS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTEME FÜR FÜHRUNGSDRAHTÜBERGANG FÜR VERZWEIGTE PROTHESEN | SYSTÈMES POUR UN CROISEMENT DE FIL-GUIDE
POUR DES PROTHÈSES BIFURQUÉES	  	EP3091944A1	  	EP2014752969A	  	2014-07-30
						
	TRIVASCULAR INC.	  	Germany	  	 SYSTEMS FOR GUIDEWIRE
 CROSSOVER FOR
BIFURCATED
PROSTHESES
	  	3091944	  	14752969.7	  	7/18/2018
						
	TRIVASCULAR INC.	  	UK	  	 SYSTEMS FOR GUIDEWIRE
 CROSSOVER FOR
BIFURCATED
PROSTHESES
	  	3091944	  	14752969.7	  	7/18/2018
						
	TRIVASCULAR INC.	  	IT	  	 SYSTEMS FOR GUIDEWIRE
 CROSSOVER FOR
BIFURCATED
PROSTHESES
	  	3091944	  	14752969.7	  	7/18/2018

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	EP	  	TANDEM MODULAR ENDOGRAFT | MODULARES TANDEM-ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM	  	EP3049021A1	  	EP2014782021A	  	2014-09-23
						
	TRIVASCULAR INC.	  	EP	  	DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | DAUERHAFTES STENTIMPLANTAT MIT KONISCHEN STREBEN UND STABILE FREISETZUNGSVERFAHREN SOWIE VORRICHTUNGEN | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC
ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES	  	EP2833830A4	  	EP2013772199A	  	2013-03-29
						
	TRIVASCULAR INC.	  	EP	  	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | ENDOVASKULÄRES FREISETZUNGSSYSTEM MIT VERBESSERTEM RÖNTGENMARKERSCHEMA | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR
RADIO-OPAQUE AMÉLIORÉE	  	EP2861189A1	  	EP2013733113A	  	2013-05-31

											
	TRIVASCULAR INC.	  	EP	  	BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | GEGABELTE ENDOVASKULÄRE PROTHESE MIT ANGEBUNDENEM KONTRALATERALEM BEIN | PROTHÈSE ENDOVASCULAIRE	  	EP2861183A1	  	EP2013733115A	  	2013-05-31

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
		  		  	BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE	  		  		  	
						
	TRIVASCULAR INC.	  	EP	  	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | FLACHES STENTTRANSPLANTAT UND FREISETZUNGSSYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE	  	EP2833829A1	  	EP2013717893A	  	2013-03-21
						
	TRIVASCULAR INC	  	EP	  	ALIGNMENT STENT APPARATUS AND METHOD | VORRICHTUNG UND VERFAHREN ZUR STENTAUSRICHTUNG | APPAREIL D’ENDOPROTHÈSE D’ALIGNEMENT ET PROCÉDÉ	  	EP2194919A4	  	EP2008834027A	  	2008-09-25
						
	TRIVASCULAR INC	  	EP	  	MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY | MODULARER GEFÄSSERSATZ FÜR PERKUTANE FREISETZUNG MIT NIEDRIGEM PROFIL | GREFFON VASCULAIRE MODULAIRE POUR ADMINISTRATION PERCUTANÉE À PROFIL
RÉDUIT	  	EP2194921A4	  	EP2008835032A	  	2008-10-03

											
	TRIVASCULAR INC	  	EP	  	METHOD AND APPARATUS FOR MANUFACTURING AN ENDOVASCULAR GRAFT SECTION | VERFAHREN UND VORRICHTUNG ZUR HERSTELLUNG EINES ENDOVASKULÄREN TRANSPLANTATABSCHNITTS | PROCEDE ET APPAREIL DE	  	EP1465685A4	  	EP2002805657A	  	2002-12-20

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
		  		  	FABRICATION D’UNE SECTION DE GREFFON ENDOCORONAIRE	  		  		  	
						
	TRIVASCULAR INC	  	WO	  	ENDOLUMINAL PROSTHESIS DEPLOYMENT DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE	  	WO2017019913A1	  	WO2016US44583A	  	2016-07-28
						
	TRIVASCULAR INC	  	WO	  	STENT-GRAFT WITH IMPROVED FLEXIBILITY | GREFFON DE STENT À FLEXIBILITÉ AMÉLIORÉE	  	WO2016183128A1	  	WO2016US31728A	  	2016-05-11
						
	TRIVASCULAR INC	  	WO	  	BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT | DÉPLOIEMENT DE PROTHÈSE ENDOLUMINALE ASSISTÉ PAR BALLONNET	  	WO2016191602A1	  	WO2016US34427A	  	2016-05-26
						
	TRIVASCULAR INC	  	WO	  	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS | DISPOSITIFS ET PROCÉDÉS DE PRÉSERVATION DE L’ILIAQUE INTERNE	  	WO2016090112A1	  	WO2015US63686A	  	2015-12-03
						
	TRIVASCULAR INC	  	WO	  	STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT | SYSTEME DE POSE DE GREFFE ET PROTHESE ENDOVASCULAIRE AVEC CONDUIT D’ACCES	  	WO2016065208A1	  	WO2015US57016A	  	2015-10-22

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC	  	WO	  	INFLATABLE OCCLUSION WIRE- BALLOON FOR AORTIC APPLICATIONS | BALLONNET DE FIL D’OCCLUSION GONFLABLE POUR APPLICATIONS AORTIQUES	  	WO2015138402A1	  	WO2015US19626A	  	2015-03-10
						
	TRIVASCULAR INC	  	WO	  	SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES | SYSTÈMES ET PROCÉDÉS POUR UN CROISEMENT DE FIL-GUIDE POUR DES PROTHÈSES
BIFURQUÉES	  	WO2015105530A1	  	WO2014US48769A	  	2014-07-30
						
	TRIVASCULAR INC	  	WO	  	TANDEM MODULAR ENDOGRAFT | ENDOGREFFE MODULAIRE EN TANDEM	  	WO2015048004A1	  	WO2014US56953A	  	2014-09-23
						
	TRIVASCULAR INC	  	WO	  	ENDOVASCULAR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS | GREFFON ENDOVASCULAIRE POUR ANÉVRISMES METTANT EN JEU DES VAISSEAUX RAMIFIÉS PRINCIPAUX	  	WO2014059114A3	  	WO2013US64290A	  	2013-10-10
						
	TRIVASCULAR INC	  	WO	  	SAC LINER FOR ANEURYSM REPAIR | REVÊTEMENT SAC POUR RÉPARATION D’ANÉVRISME	  	WO2014110231A3	  	WO2014US10828A	  	2014-01-09
						
	TRIVASCULAR INC	  	WO	  	GATE WIRE FOR CONTRALATERAL LEG ACCESS | FIL GUIDE POUR PERMETTRE UN ACCÈS À UN JAMBAGE CONTROLATÉRAL	  	WO2014110254A1	  	WO2014US10870A	  	2014-01-09

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC	  	WO	  	BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG | PROTHÈSE ENDOVASCULAIRE BIFURQUÉE POSSÉDANT UNE JAMBE CONTROLATÉRALE AVEC ATTACHE	  	WO2013188134A1	  	WO2013US43630A	  	2013-05-31
						
	TRIVASCULAR INC	  	WO	  	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME | SYSTÈME DE POSE ENDOVASCULAIRE AYANT UNE TECHNIQUE DE MARQUEUR RADIO-OPAQUE AMÉLIORÉE	  	WO2013188132A1	  	WO2013US43615A	  	2013-05-31
						
	TRIVASCULAR INC	  	WO	  	ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE | SYSTÈME DE POSE ENDOVASCULAIRE POURVU D’UN HYPOTUBE FLEXIBLE ET POUVANT ÊTRE SOUMIS À UN COUPLE DE TORSION	  	WO2013188133A1	  	WO2013US43623A	  	2013-05-31
						
	TRIVASCULAR INC	  	WO	  	DELIVERY CATHETER FOR ENDOVASCULAR DEVICE | CATHÉTER DE DÉLIVRANCE POUR DISPOSITIF ENDOVASCULAIRE	  	WO2013151924A1	  	WO2013US34787A	  	2013-04-01

											
	TRIVASCULAR INC	  	WO	  	DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES | ENDOPROTHÈSE VASCULAIRE DURABLE AVEC ENTRETOISES CONIQUES ET PROCÉDÉS ET DISPOSITIFS DE DÉLIVRANCE STABLES	  	WO2013151896A1	  	WO2013US34654A	  	2013-03-29

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC	  	WO	  	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM | ENDOPROTHÈSE VASCULAIRE À PROFIL BAS ET SYSTÈME DE DÉLIVRANCE	  	WO2013151793A1	  	WO2013US33250A	  	2013-03-21
						
	TRIVASCULAR INC	  	WO	  	ADVANCED KINK-RESISTANT STENT GRAFT | ENDOPROTHÈSE ÉVOLUÉE RÉSISTANT AU PLIAGE	  	WO2013151794A3	  	WO2013US33252A	  	2013-03-21
						
	TRIVASCULAR INC	  	WO	  	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM | GREFFE ENDOVASCULAIRE AVANCÉE ET SYSTÈME DE POSE ASSOCIÉ	  	WO2012068175A3	  	WO2011US60873A	  	2011-11-15
						
	TRIVASCULAR INC	  	WO	  	FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT | COLLECTEUR DE TUBE DE REMPLISSAGE ET PROCÉDÉS DE POSE DE GREFFON ENDOVASCULAIRE	  	WO2011100367A3	  	WO2011US24248A	  	2011-02-09
						
	TRIVASCULAR INC	  	DE	  	ENDOVASKULÄRES IMPLANTAT	  	DE69918272T2	  	DE69918272A	  	1999-02-09

											
	TRIVASCULAR INC	  	CA	  	VIRTUAL PROTOTYPING AND TESTING FOR MEDICAL DEVICE DEVELOPMENT | ESSAI ET PROTOTYPAGE VIRTUELS DE MISE AU POINT DE DISPOSITIFS MEDICAUX	  	CA2424252C	  	CA2424252A	  	2001-09-28

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC	  	CA	  	DELIVERY SYSTEM AND METHOD FOR BIFURCATED GRAFT | METHODE ET SYSTEME DE MISE EN PLACE D’UN GREFFON A BIFURCATION	  	CA2443104C	  	CA2443104A	  	2002-04-11
						
	TRIVASCULAR INC	  	CA	  	ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE	  	CA2501892C	  	CA2501892A	  	1999-02-09
						
	TRIVASCULAR INC	  	CA	  	INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE	  	CA2640263C	  	CA2640263A	  	2000-03-03
						
	TRIVASCULAR INC	  	CA	  	INFLATABLE INTRALUMINAL GRAFT | GREFFON INTRALUMINAL GONFLABLE	  	CA2376253C	  	CA2376253A	  	2000-03-03
						
	TRIVASCULAR INC	  	CA	  	ENDOVASCULAR GRAFT | GREFFON ENDOVASCULAIRE	  	CA2319052C	  	CA2319052A	  	1999-02-09
						
	TRIVASCULAR INC	  	AU	  	Modular vascular graft for low profile percutaneous delivery	  	AU2008308474B2	  	AU2008308474A	  	2008-10-03
						
	TRIVASCULAR INC	  	AU	  	Advanced endovascular graft	  	AU2009230748B2	  	AU2009230748A	  	2009-10-26
						
	TRIVASCULAR INC	  	AU	  	Advanced endovascular graft	  	AU2009201682B2	  	AU2009201682A	  	2009-04-28
						
	TRIVASCULAR INC	  	AU	  	Method and apparatus for manufacturing an endovascular graft section	  	AU2008258148B2	  	AU2008258148A	  	2008-12-17
						
	TRIVASCULAR INC	  	AU	  	Advanced endovascular graft	  	AU2002360765C1	  	AU2002360765A	  	2002-12-20

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC	  	AU	  	Method and apparatus for manufacturing an endovascular graft section	  	AU2002366805B8	  	AU2002366805A	  	2002-12-20
						
	TRIVASCULAR INC	  	AU	  	Virtual prototyping and testing for medical device development	  	AU2001293179A1	  	AU2001293179A	  	2001-09-28
						
	TRIVASCULAR INC	  	AU	  	Delivery system and method for
expandable intracorporeal device	  	AU200133250A	  	AU200133250A	  	2001-02-01
						
	TRIVASCULAR INC	  	JP	  	ADVANCED KINK-RESISTANT STENT GRAFT	  	6297023	  	2015-504610	  	3/2/2018
						
	TRIVASCULAR INC	  	UK	  	 INFLATABLEOCCLUSIONWIRE-
 BALLOON FOR
AORTIC
APPLICATIONS
	  	15711020.6	  	3116439	  	2/7/2018
						
	TRIVASCULAR INC	  	UK	  	 PASSIVE HEMOSTATIC SHEATH
 VALVE
	  	04780128.7	  	1651135	  	2/28/2018
						
	TRIVASCULAR INC	  	CN	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	  		  	201810370663.0	  	2015-5-5
						
	ENDOLOGIX, INC.	  	CN	  	CATHETER SYSTEM AND METHODS OF USING SAME	  	ZL201510649289.4	  	201510649289.4	  	2018-6-8
						
	ENDOLOGIX, INC.	  	JP	  	CATHETER SYSTEM AND METHODS OF USING SAME	  	6294669	  	2013-556828	  	2018-2-23
						
	TRIVASCULAR INC	  	Germany	  	 PASSIVE HEMOSTATIC SHEATH
 VALVE
	  	1651135	  	04780128.7	  	2018-2-28
						
	ENDOLOGIX, INC.	  	JP	  	BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT	  		  	2017-560952	  	5/26/2016

											
	ENDOLOGIX, Inc.	  	EP	  	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	  		  	16882476.1	  	12/23/2016

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	ENDOLOGIX, Inc.	  	JP	  	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	  		  	2018-534852	  	12/23/2016
						
	ENDOLOGIX INC.	  	US	  	 STENT GRAFT SYSTEMS WITH
 RESTRAINTS IN
CIRCUMFERENTIAL
 CHANNELS AND METHODS
THEREOF
	  		  	62/678961	  	5/31/2018
						
	ENDOLOGIX INC.	  	US	  	 PERCUTANEOUS METHOD AND
 DEVICE TO TREAT
DISSECTIONS
	  		  	15/429090	  	2/9/2017
						
	NELLIX, INC.	  	US	  	 SYSTEM AND METHODS FOR
 ENDOVASCULAR
ANEURYSM
TREATMENT
	  	2018-0064566	  	15/682414	  	8/21/2017
						
	TRIVASCULAR INC.	  	US	  	 ENDOVASCULAR DELIVERY
 SYSTEM WITH AN
IMPROVED
RADIOPAQUE MARKER SCHEME
	  		  	16/049560	  	7/30/2018
						
	ENDOLOGIX INC.	  	PCT	  	SINGLE PUNCTURE BIFURCATION GRAFT DEPLOYMENT SYSTEM	  	WO2000053251	  	PCT/US2000/006070	  	3/7/2000
						
	ENDOLOGIX INC.	  	PCT	  	GRAFT DEPLOYMENT SYSTEM	  	WO2004047885	  	PCT/US2003/37685	  	11/25/2003
						
	ENDOLOGIX INC.	  	PCT	  	 DUAL CONCENTRIC GUIDEWIRE
 AND METHODS OF
BIFURCATED GRAFT DEPLOYMENT
	  	WO2008089097	  	PCT/US2008/050915	  	1/11/2008
						
	ENDOLOGIX INC.	  	PCT	  	 ENDOLUMENAL VASCULAR
 PROSTHESIS WITH
NEOINTIMA
INHIBITING POLYMERIC SLEEVE
	  	WO2005096997	  	PCT/US2005/11522	  	4/6/2005
						
	ENDOLOGIX INC.	  	PCT	  	IMPLANTABLE VASCULAR GRAFT	  	WO2002039888	  	PCT/US2001/47028	  	11/8/2001
						
	ENDOLOGIX INC.	  	PCT	  	DUAL WIRE PLACEMENT CATHETER	  	WO2001003762	  	PCT/US2000/016352	  	6/14/2000
						
	ENDOLOGIX INC.	  	PCT	  	 MULTI-SEGMENTED GRAFT
 DEPLOYMENT
SYSTEM
	  	WO2008034106	  	PCT/US2007/78565	  	9/14/2007

											
	ENDOLOGIX INC.	  	PCT	  	METHOD AND APPARATUS FOR DECOMPRESSING ANEURYSMS	  	WO2005099807	  	PCT/US2005/12306	  	4/12/2005

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application
Date

						
	TRIVASCULAR INC.	  	EP	  	 ENDOLUMINAL PROSTHESIS
 DEPLOYMENT DEVICES
AND
METHODS
	  	3328326	  	16831382.3	  	7/28/2016
						
	TRIVASCULAR INC.	  	EP	  	BALLOON ASSISTED ENDOLUMINAL PROSTHESIS DEPLOYMENT	  	3302356	  	16800744.1	  	5/26/2016
						
	TRIVASCULAR INC.	  	EP	  	 STENT-GRAFT WITH IMPROVED
 FLEXIBILITY
	  	3294210	  	16793394.4	  	5/11/2016
						
	TRIVASCULAR INC.	  	EP	  	PTFE LAYERS AND METHODS OF MANUFACTURING	  	3095585	  	16171681.6	  	3/30/2006

 SCHEDULE 11 

TRADEMARKS 
 See attached. 

 Trademarks 

 

													
	 Grantor
	  	 Country
	  	 Mark
	  	 Application No.
	  	 Application Date
	  	 Registration No.
	  	 Registration Date

	Endologix, Inc.	  	U.S.	  	

	  	86/854470	  	12/18/15	  		  	
							
	Endologix, Inc.	  	U.S.	  	ACTIVESEAL	  	85/518,608	  	01/17/12	  	5396605	  	02/06/18
							
	Endologix, Inc.	  	U.S.	  	AFX	  	85/069,068	  	06/22/10	  	4214460	  	09/25/12
							
	Endologix, Inc.	  	U.S.	  	ANGIOTIP	  	85/767055	  	10/30/12	  	5205176	  	05/16/17
							
	Endologix, Inc.	  	U.S.	  	DURAPLY	  	86/362822	  	08/11/14	  	5433696	  	3/27/18
							
	Endologix, Inc.	  	U.S.	  	ENDOLOGIX	  	75/323,314	  	07/11/97	  	2257799	  	06/29/99
							
	Endologix, Inc.	  	U.S.	  	EVAS FORWARD	  	86/116940	  	11/12/13	  	5306786	  	10/10/17
							
	Endologix, Inc.	  	U.S.	  	INNOVATION
TAKING SHAPE	  	85/369,728	  	07/12/11	  	4220343	  	10/09/12
							
	Endologix, Inc.	  	U.S.	  	INNOVATION
THAT EMPOWERS	  	85/514516	  	01/11/12	  	4841631	  	10/27/15
							
	Endologix, Inc.	  	U.S.	  	INTELIX	  	86/316249	  	06/20/14	  	5059968	  	10/11/16
							
	Endologix, Inc.	  	U.S.	  	INTUITRAK	  	77/494,729	  	06/09/08	  	3649757	  	07/07/09
							
	Endologix, Inc.	  	U.S.	  	INTUITRAK
DELIVERY
SYSTEM	  	77/520,529	  	07/11/08	  	3649866	  	 07/07/09

													
							
	Endologix, Inc.	  	U.S.	  	NELLIX	  	77/090544	  	01/24/07	  	3880178	  	 11/23/10

													
							
	Endologix, Inc.	  	U.S.	  	POWERLINK	  	75/658,969	  	03/12/99	  	2456038	  	 05/29/01

							
	Endologix, Inc.	  	U.S.	  	POWERLINK XL	  	78/718,728	  	09/22/05	  	3573999	  	 02/10/09

							
	Endologix, Inc.	  	U.S.	  	SUREPASS	  	78/965,443	  	08/31/06	  	3593259	  	 03/17/09

							
	Endologix, Inc.	  	U.S.	  	VELA	  	85/857988	  	02/22/13	  	5296578	  	 09/26/17

							
	Endologix, Inc.	  	U.S.	  	XPAND	  	85/126,464	  	09/09/10	  	4168563	  	 07/03/12

							
	Endologix, Inc.	  	Argentina	  	

	  	3514846	  	06/16/16	  	2888199	  	 05/19/17

							
	Endologix, Inc.	  	Argentina	  	

	  	3514844	  	06/16/16	  	2888198	  	 05/19/17

							
	Endologix, Inc.	  	Argentina	  	

	  	3514844	  	06/16/16	  		  	
							
	Endologix, Inc.	  	Argentina	  	

	  	3514842	  	06/16/16	  	2888196	  	 05/19/17

							
	Endologix, Inc.	  	Argentina	  	AFX	  	3064304	  	01/27/11	  	2496722	  	 04/04/12

							
	Endologix, Inc.	  	Argentina	  	DURAPLY	  	3386456	  	02/11/15	  	2773735	  	 12/09/15

							
	Endologix, Inc.	  	Argentina	  	INTELIX	  	3375648	  	12/19/14	  	2766285	  	 12/04/15

							
	Endologix, Inc.	  	Argentina	  	INTELIX	  	3375649	  	12/19/14	  	2766286	  	 11/04/15

													
							
	Endologix, Inc.	  	Argentina	  	INTELIX	  	3375650	  	12/19/14	  	2766287	  	11/04/15
							
	Endologix, Inc.	  	Argentina	  	NELLIX	  	3243024	  	05/02/13	  	2658594	  	06/26/14
							
	Endologix, Inc.	  	Argentina	  	VELA	  	3271551	  	08/22/13	  	2808433	  	06/03/16
							
	Endologix, Inc.	  	Argentina	  	XPAND	  	3072929	  	03/16/11	  	2506706	  	06/01/12
							
	Endologix, Inc.	  	Australia	  	

	  	1326557	  	06/14/16	  	1326557	  	04/24/17
							
	Endologix, Inc.	  	Australia	  	DURAPLY	  	1710503	  	02/10/15	  	1710503	  	11/04/15
							
	Endologix, Inc.	  	Australia	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	11/25/16
							
	Endologix, Inc.	  	Brazil	  	

	  	911.201.521	  	06/17/16	  		  	
							
	Endologix, Inc.	  	Brazil	  	

	  	911.201.572	  	06/17/16	  		  	
							
	Endologix, Inc.	  	Brazil	  	

	  	911.201.599	  	06/17/16	  		  	
							
	Endologix, Inc.	  	Brazil	  	

	  	911.201.602	  	06/17/16	  		  	

													
							
	Endologix, Inc.	  	Brazil	  	ACTIVESEAL	  	909861684	  	08/20/15	  		  	

													
							
	Endologix, Inc.	  	Brazil	  	AFX	  	830891226	  	12/21/10	  		  	
							
	Endologix, Inc.	  	Brazil	  	AFX	  	912186283	  	01/19/17	  		  	
							
	Endologix, Inc.	  	Brazil	  	DURAPLY	  	909861722	  	08/20/15	  		  	
							
	Endologix, Inc.	  	Brazil	  	INTELIX	  	909861749	  	08/20/15	  		  	
							
	Endologix, Inc.	  	Brazil	  	INTELIX	  	909861765	  	08/20/15	  		  	
							
	Endologix, Inc.	  	Brazil	  	INTELIX	  	909861773	  	08/20/15	  		  	
							
	Endologix, Inc.	  	Brazil	  	NELLIX	  	840506538	  	05/06/13	  	840506538	  	02/16/16
							
	Endologix, Inc.	  	Brazil	  	VELA	  	840618530	  	08/22/13	  		  	
							
	Endologix, Inc.	  	Canada	  	DURAPLY	  	1714718	  	02/10/15	  		  	
							
	Endologix, Inc.	  	Canada	  	INTELIX	  	1707569	  	12/17/14	  		  	
							
	Endologix, Inc.	  	Canada	  	VELA	  	1640416	  	08/21/13	  		  	
							
	Endologix, Inc.	  	Chile	  	XPAND	  	1137099	  	12/30/14	  	1187135	  	11/27/15
							
	Endologix, Inc.	  	China	  	

	  	1326551	  	06/14/16	  		  	
							
	Endologix, Inc.	  	China	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	02/10/15
							
	Endologix, Inc.	  	China	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	12/19/14
							
	Endologix, Inc.	  	Colombia	  	AFX	  	16-133051	  	05/11/26	  	582446	  	11/17/17
							
	Endologix, Inc.	  	Colombia	  	ENDOLOGIX	  	16-121402	  	05/11/16	  	582446	  	11/17/17

													
							
	Endologix, Inc.	  	Colombia	  	XPAND	  	1246435	  	12/26/14	  	1246435	  	12/26/14

													
							
	Endologix, Inc.	  	European
Community	  	AFX	  	009609884	  	12/20/10	  	009609884	  	12/01/11
							
	Endologix, Inc.	  	European
Community	  	ANGIOTIP	  	011780129	  	04/30/13	  	011780129	  	09/24/13
							
	Endologix, Inc.	  	European
Community	  	CLASSICAL
REMODELING	  	4598728	  	08/19/05	  	4598728	  	08/02/06
							
	Endologix, Inc.	  	European
Community	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	02/10/15
							
	Endologix, Inc.	  	European
Community	  	ENDOLOGIX, INC.	  	720649	  	01/12/98	  	720649	  	01/12/98
							
	Endologix, Inc.	  	European
Community	  	INTELIX	  	13361399	  	10/15/14	  		  	
							
	Endologix, Inc.	  	European
Community	  	INTUITRAK	  	7453401	  	11/28/08	  	7453401	  	09/21/09
							
	Endologix, Inc.	  	European
Community	  	INTUITRAK
DELIVERY
SYSTEM	  	7513302	  	12/23/08	  	7513302	  	07/21/09
							
	Endologix, Inc.	  	European
Community	  	NELLIX	  	011771011	  	04/26/13	  	011771011	  	09/18/13
							
	Endologix, Inc.	  	European
Community	  	POWERLINK XL	  	5002977	  	03/22/06	  	5002977	  	04/11/07
							
	Endologix, Inc.	  	European
Community	  	VISIFLEX
DELIVERY
SYSTEM	  	5075528	  	04/24/06	  	5075528	  	04/16/07

													
							
	Endologix, Inc.	  	European
Community	  	VISIFLEX SURE
PASS	  	5749338	  	02/28/07	  	5749338	  	01/31/08

													
							
	Endologix, Inc.	  	European Union	  	

	  	1326551	  	06/14/16	  	1326551	  	06/12/17
							
	Endologix, Inc.	  	France	  	POWERLINK	  	043299490	  	09/13/99	  	043299490	  	12/31/04
							
	Endologix, Inc.	  	Hong Kong	  	DURAPLY	  	303301280	  	02/15/15	  	303301280	  	10/05/15
							
	Endologix, Inc.	  	Hong Kong	  	INTELIX	  	303240954	  	12/18/14	  	303240954	  	09/07/16
							
	Endologix, Inc.	  	Italy	  	POWERLINK	  	001724	  	09/13/99	  	0001376420	  	02/27/08
							
	Endologix, Inc.	  	Japan	  	

	  	1326551	  	06/14/16	  	1326551	  	05/02/17
							
	Endologix, Inc.	  	Japan	  	ACTIVESEAL	  	2015-078597	  	08/17/15	  	5857166	  	06/10/16
							
	Endologix, Inc.	  	Japan	  	AFX	  	2015-078596	  	08/17/15	  	5824704	  	02/05/16
							
	Endologix, Inc.	  	Japan	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	01/19/16
							
	Endologix, Inc.	  	Japan	  	ENDOLOGIX, INC.	  	1155/1998	  	01/12/98	  	4352035	  	01/14/00
							
	Endologix, Inc.	  	Japan	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	10/27/15
							
	Endologix, Inc.	  	Japan	  	NELLIX	  	2013-031634	  	04/25/13	  	5613989	  	09/06/13
							
	Endologix, Inc.	  	Japan	  	VELA	  	2013-6/4901	  	08/21/13	  		  	
							
	Endologix, Inc.	  	Japan	  	VISIFLEX
DELIVERY
SYSTEM	  	2006-035170	  	04/17/06	  	4974084	  	07/28/06

													
							
	Endologix, Inc.	  	Japan	  	VISIFLEX
SUREPASS	  	2007-017236	  	02/28/07	  	5066349	  	07/27/07

													
							
	Endologix, Inc.	  	Korea	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	02/10/15
							
	Endologix, Inc.	  	Korea	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	06/13/16
							
	Endologix, Inc.	  	Malaysia	  	DURAPLY	  	2015052019	  	02/11/15	  	2015052019	  	12/29/16
							
	Endologix, Inc.	  	Malaysia	  	INTELIX	  	2014069128	  	12/18/14	  	2014069128	  	04/22/16
							
	Endologix, Inc.	  	Malaysia	  	INTELIX	  	2014069135	  	12/18/14	  	2014069135	  	05/10/16
							
	Endologix, Inc.	  	Mexico	  	XPAND	  	1246435	  	12/26/14	  	1246435	  	07/26/16
							
	Endologix, Inc.	  	New Zealand	  	DURAPLY	  	1024501	  	02/10/15	  	1024501	  	12/02/15
							
	Endologix, Inc.	  	New Zealand	  	INTELIX	  	1247823	  	12/19/14	  	1019974	  	09/27/16
							
	Endologix, Inc.	  	Peru	  	XPAND	  	601318	  	12/29/14	  	00223114	  	04/22/15
							
	Endologix, Inc.	  	Singapore	  	DURAPLY	  	40201513229	  	02/10/15	  	40201513229	  	01/06/16
							
	Endologix, Inc.	  	Singapore	  	INTELIX	  	40201508694	  	12/19/14	  	40201508694	  	11/11/15
							
	Endologix, Inc.	  	Taiwan	  	DURAPLY	  	104008448	  	02/11/15	  	1764288	  	04/16/16
							
	Endologix, Inc.	  	Taiwan	  	INTELIX	  	103072703	  	12/18/14	  	1740066	  	11/16/15
							
	Endologix, Inc.	  	Thailand	  	DURAPLY	  	973443	  	02/11/15	  	171110590	  	09/28/17
							
	Endologix, Inc.	  	Thailand	  	INTELIX	  	966979	  	12/19/14	  		  	
							
	Endologix, Inc.	  	Thailand	  	INTELIX	  	966980	  	12/19/14	  		  	
							
	Endologix, Inc.	  	United Kingdom	  	POWERLINK	  	2369587	  	09/13/99	  	2369587	  	12/09/05
							
	Endologix, Inc.	  	Venezuela	  	XPAND	  	20754-14	  	12/30/14	  	P352404	  	06/07/16
							
	Endologix, Inc.	  	Vietnam	  	DURAPLY	  	1257411	  	02/10/15	  	1257411	  	11/03/16

													
							
	Endologix, Inc.	  	Vietnam	  	INTELIX	  	1247823	  	12/19/14	  	1247823	  	05/21/15
							
	Endologix, Inc.	  	U.S.	  	ALTO	  	87/906,099	  	5/3/2018	  		  	
							
	Endologix, Inc.	  	U.S.	  	VERTA	  	87/116,482	  	7/26/2016	  		  	
							
	TriVascular, Inc.	  	U.S.	  	ALLEGRO	  	86/758,465	  	9/16/2015	  		  	
							
	TriVascular, Inc.	  	U.S.	  	CUSTOMSEAL	  	86/047,875	  	8/26/2013	  	4,732,342	  	5/5/2015
							
	TriVascular, Inc.	  	U.S.	  	OVATION	  	77/941,535	  	2/22/2010	  	4,440,468	  	11/26/2013
							
	TriVascular, Inc.	  	U.S.	  	OVATION ALTO	  	86/047,894	  	8/26/2013	  	5,195,890	  	5/2/2017
							
	TriVascular, Inc.	  	U.S.	  	OVATION PRIME	  	85/900,037	  	4/10/2013	  	4,452,625	  	12/17/2013
							
	TriVascular, Inc.	  	U.S.	  	

	  	85/832,445	  	1/25/2013	  	4,449,077	  	12/10/2013
							
	TriVascular, Inc.	  	U.S.	  	TRIVASCULAR	  	75/879,907	  	12/21/1999	  	2,867,015	  	7/27/2004
							
	TriVascular, Inc.	  	U.S.	  	

	  	85/831,355	  	1/24/2013	  	4,395,789	  	9/3/2013
							
	TriVascular, Inc.	  	Australia	  	CUSTOMSEAL	  	1608471	  	2/27/2014	  	1608471	  	1/21/2015
							
	TriVascular, Inc.	  	Australia	  	OVATION	  	1379343	  	8/20/2010	  	1379343	  	1/10/2011
							
	TriVascular, Inc.	  	Australia	  	OVATION ALTO	  	1608211	  	2/26/2014	  	1608211	  	5/28/2014
							
	TriVascular, Inc.	  	Australia	  	OVATION PRIME	  	1583683	  	10/2/2013	  	1583683	  	1/7/2014
							
	TriVascular, Inc.	  	Australia	  	

	  	1537921	  	1/29/2013	  	1537921	  	7/31/2013
							
	TriVascular, Inc.	  	Australia	  	TRIVASCULAR	  	888603	  	9/7/2001	  	888603	  	9/7/2001

													
							
	TriVascular, Inc.	  	Australia	  	

	  	983475	  	12/30/2003	  	983475	  	8/16/2004

													
							
	TriVascular, Inc.	  	Brazil	  	CUSTOMSEAL	  	840.803.346	  	2/26/2014	  	840803346	  	10/18/2016
							
	TriVascular, Inc.	  	Brazil	  	OVATION	  	830727035	  	8/20/2010	  	830727035	  	1/6/2015
							
	TriVascular, Inc.	  	Brazil	  	OVATION ALTO	  	840.803.419	  	2/26/2014	  		  	
							
	TriVascular, Inc.	  	Brazil	  	OVATION PRIME	  	840.666.152	  	10/4/2013	  	840666152	  	8/23/2016
							
	TriVascular, Inc.	  	Brazil	  	

	  	830854487	  	11/24/2010	  	830854487	  	6/3/2014
							
	TriVascular, Inc.	  	Canada	  	CUSTOMSEAL	  	1,665,277	  	2/25/2014	  		  	
							
	TriVascular, Inc.	  	Canada	  	OVATION	  	1493184	  	8/20/2010	  	TMA858,759	  	8/28/2013
							
	TriVascular, Inc.	  	Canada	  	OVATION ALTO	  	1,665,276	  	2/25/2014	  		  	
							
	TriVascular, Inc.	  	Canada	  	OVATION PRIME	  	1,645,991	  	10/2/2013	  		  	
							
	TriVascular, Inc.	  	Canada	  	

	  	1,611,335	  	1/25/2013	  	TMA934,553	  	4/12/2016
							
	TriVascular, Inc.	  	Canada	  	TRIVASCULAR	  	1,612,136	  	1/31/2013	  	TMA882,992	  	7/29/2014
							
	TriVascular, Inc.	  	Canada	  	

	  	1200748	  	12/30/2003	  	TMA825955	  	6/8/2012
							
	TriVascular, Inc.	  	China	  	CUSTOMSEAL	  	14075157	  	2/26/2014	  	14075157	  	4/28/2015
							
	TriVascular, Inc.	  	China	  	OVATION	  	8598413	  	8/23/2010	  	8598413	  	11/7/2011
							
	TriVascular, Inc.	  	China	  	OVATION ALTO	  	14075158	  	2/26/2014	  	14075158	  	4/28/2015
							
	TriVascular, Inc.	  	China	  	OVATION PRIME	  	13321289	  	10/8/2013	  	13321289	  	6/21/2015

													
							
	TriVascular, Inc.	  	China	  	

	  	8898103	  	11/30/2010	  	8898103	  	12/14/2011

													
							
	TriVascular, Inc.	  	EUTM	  	OVATION	  	009325234	  	8/20/2010	  	009325234	  	2/3/2011
							
	TriVascular, Inc.	  	EUTM	  	OVATION ALTO	  	012636908	  	2/25/2014	  	012636908	  	7/16/2014
							
	TriVascular, Inc.	  	EUTM	  	OVATION PRIME	  	012189148	  	10/2/2013	  	012189148	  	2/26/2014
							
	TriVascular, Inc.	  	EUTM	  	

	  	011523305	  	1/28/2013	  	011523305	  	6/24/2013
							
	TriVascular, Inc.	  	EUTM	  	TRIVASCULAR	  	002374593	  	9/13/2001	  	002374593	  	3/12/2003
							
	TriVascular, Inc.	  	EUTM	  	

	  	003598836	  	12/31/2003	  	003598836	  	4/29/2005
							
	TriVascular, Inc.	  	EUTM	  	TRIVASCULAR2 &
Design	  	007457344	  	11/27/2008	  	007457344	  	6/16/2009
							
	TriVascular, Inc.	  	India	  	OVATION	  	2012141	  	8/20/2010	  	2012141	  	8/23/2016
							
	TriVascular, Inc.	  	India	  	

	  	2060383	  	11/29/2010	  	2060383	  	11/29/2010
							
	TriVascular, Inc.	  	Japan	  	CUSTOMSEAL	  	2014-14237	  	2/26/2014	  	5672406	  	5/23/2014
							
	TriVascular, Inc.	  	Japan	  	OVATION	  	2010-065871	  	8/20/2010	  	5614976	  	9/13/2013
							
	TriVascular, Inc.	  	Japan	  	OVATION ALTO	  	2014-14238	  	2/26/2014	  	5672407	  	5/23/2014
							
	TriVascular, Inc.	  	Japan	  	OVATION PRIME	  	2013-024875	  	4/4/2013	  	5613251	  	9/6/2013
							
	TriVascular, Inc.	  	Japan	  	

	  	2013-5504	  	1/30/2013	  	5643434	  	1/17/2014
							
	TriVascular, Inc.	  	Japan	  	TRIVASCULAR	  	2001-115594	  	12/27/2001	  	4731627	  	12/5/2003
							
	TriVascular, Inc.	  	Japan	  	

	  	2004-030615	  	3/18/2004	  	4778040	  	6/11/2004

													
							
	TriVascular, Inc.	  	Mexico	  	OVATION	  	1113689	  	8/20/2010	  	1235645	  	8/20/2010
							
	TriVascular, Inc.	  	Mexico	  	

	  	1139285	  	12/2/2010	  	1213946	  	4/27/2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]